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Dafni Anna Glinos
Despite the high prevalence of immune-mediated diseases, the molecular mechanisms
by which they arise and the influence of genetic variation in the predisposition to
disease are not well understood. Immune susceptibility loci identified by genome wide
association studies (GWAS) overlap with active regulatory elements in CD4+ T cells,
and particularly in regulatory T cells (Tregs). CD4+ T cells are the orchestrators of the
adaptive immune response and their dysfunction has been associated with immune-
mediated disorders through uncontrolled activation and resistance to downregulation,
which is usually mediated by Tregs. T cell activation requires the combination of T
cell receptor (TCR) recognition of an antigen and CD28 co-stimulation. The role of
CD28 co-stimulation requirement in the activation of different T cell subsets has been
understudied. Here, I assessed the role of immune disease variants in modulating
pathways underlying T cell activation and Treg function. For that, I activated CD4+ T
cells using different intensities of CD28 and TCR signals, followed by genome-wide
transcriptome and chromatin profiling of naive and memory cells. I observed that CD28
plays a critical role in the expression of genes involved in effector functions, cell cycle
regulation in memory T cells and in disease susceptibility. I profiled the gene expression
regulatory landscape in Tregs using a combination of genomic assays. Due to the scarce
Treg numbers in peripheral blood I first optimised the ChIPmentation (ChM) sequencing
protocol to profile H3K4me3 and H3K27ac histone modifications in Tregs. I combined it
with chromatin accessibility and gene expression profiling in resting and stimulated
Tregs from ten donors. I observed cases of alternative transcription, such as alternative
splicing and promoter, induced by stimulation, which could be predicted by changes
in the chromatin landscape. Finally, I assessed how genetic variability impacts the
function of Tregs and how this can lead to autoimmunity. I carried a quantitative trait
locus (QTL) mapping using RNA-seq, ATAC-seq, H3K4me3 and H3K27ac ChM-seq data
from Tregs isolated from 100 individuals. Additionally, I processed publicly available
data from naive T cells to distinguish the Treg specific effects from generic CD4+ T cell
signals. I recapitulated known colocalisations between QTLs and immune GWAS loci,
and identified previously unknown Treg specific colocalisations. My findings highlight
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Parts of this chapter have been published as “Immunogenomic approaches to under-
stand the function of immune disease variants” (Glinos et al., 2017). Many sections of
the manuscript have directly been copied into this chapter.
It is estimated that around 20% of the population suffers from at least one autoimmune
disease. Autoimmunity arises when the immune system fails to distinguish self from
non-self, causing cells to respond against the antigens produced by the body. This can
happen in specific tissues, such as the pancreas, where the immune system attacks
the insulin-producing cells leading to the development of type-1 diabetes, or the lin-
ing of the joints, in the case of rheumatoid arthritis. Since the cells of the adaptive
immune system are responsible for the recognition of different antigens, their study is
of primordial importance for increasing our understanding of autoimmunity. Indeed,
despite the high prevalence of the different disorders, the molecular mechanisms which
predispose one to autoimmunity are not well understood. It is believed that, in the
majority of cases, it is a combination of genetic and non-genetic factors that contribute
to the risk of developing a disorder. Here, I will first describe the genetic architecture of
autoimmune diseases, the complexity of which has hindered a deeper understanding
of how diseases arise. I will then describe different immune cell types and pathways
that are critical for the physiological functioning of the adaptive immune response. I
will summarise the different genomic tools currently available for the study of gene
expression and its regulation thereof. Finally, I will provide an overview of different
studies that have attempted to link genetic variants associated to immune diseases
with molecular measurements.
1
1.1 The problem: The complex genetic architecture of
autoimmune diseases
1.1.1 Heritability of immune-mediated diseases
It is estimated that 1 in 5 people suffer from at least 1 of the 81 documented autoimmune
diseases in the United States (Hayter and Cook, 2012). Despite the high prevalence, the
molecular mechanisms which predispose to autoimmunity are not well understood.
The clustering of autoimmune diseases in families has indicated a strong genetic com-
ponent that underlies pathological processes driving many complex immune-mediated
diseases. Indeed, siblings of an affected individual have significantly higher risk of
developing an autoimmune disease compared to the general population. Interestingly,
this is not disease specific since co-occurrence of autoimmune diseases in families is
higher than expected by the population prevalence of the individual diseases (Eaton
et al., 2007). Therefore, the clustering also indicates that the genetic component across
different diseases is to a certain degree shared.
Most autoimmune diseases share a strong association to the major histocompatibility
complex (MHC) region (Lenz et al., 2015). The MHC is one of the most polymorphic regions
in the human genome, containing over 250 genes including the human leukocyte antigen
(HLA) genes. The HLA genes encode for receptors expressed by antigen presenting cells
(APCs). Early studies identified several loci in the MHC region with large effect sizes,
including HLA-DQB1 associated with type-1 diabetes (T1D) (Todd et al., 1987), HLA-DQ2
and HLA-DQ8 associated with coeliac disease (CEL) (Sollid et al., 1989), and HLA-DR4
associated with rheumatoid arthritis (RA) (Nepom, 1998). It is now well appreciated
that most of the autoimmune associations of the MHC region originate from these HLA
genes (Matzaraki et al., 2017). Indeed, recent research highlights the complex genetic
architecture of this locus, the non-additive effects between different HLA alleles, as
well as the interactions between the different alleles modulating the risk to common
autoimmune disorders (Hu et al., 2015a; Lenz et al., 2015).
However, the susceptible genetic background of the HLA alone is not sufficient to lead
to the development of a complex immune-mediated disease. For example, T1D, RA, CEL
and multiple sclerosis (MS), result from the combination of both the risk genotypes
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of the HLA and non-HLA genes, as well as an environmental trigger. In order to study
these effects before high-throughput genomic tools, such as whole genome genotyping
and whole genome sequencing, became available, studies focussed on a few candidate
genes within families of affected individuals. In T1D, a series of candidate gene studies
identified CTLA4, which encodes for a protein receptor expressed on the surface of T
cells, as a susceptibility gene (Nisticò et al., 1996). CTLA4 was later also associated with
patients with CEL (Djilali-Saiah et al., 1998) and RA (Plenge et al., 2007), highlighting
the key roles of this T cell receptor in autoimmunity. That same study was the first
that associated non-synonymous variants in PTPN22 with RA, which was later shown
to also contribute to the risk of T1D and systemic lupus erythematosus (SLE) (Criswell
et al., 2005). While these represent examples of successful candidate gene studies, the
majority of them resulted in non-reproducible results. This highlights the complexity
underlying the genetics of autoimmune diseases and the human bias in choosing can-
didate genes for testing.
1.1.2 GWAS of immune-mediated diseases
The previously described limitations called for the development of an unbiased and
comprehensive study approach, which emerged through genome wide association stud-
ies (GWAS). GWAS revealed that complex immune traits develop in consequence to an
interplay between hundreds to thousands of common variants (Stahl et al., 2010), all
with individually small effect sizes on the overall disease phenotype. Currently, more
than 497 susceptibility loci for autoimmune disorders have been identified (Gutierrez-
Arcelus et al., 2016). Despite the large number of mapped variants, the heritability
explained by the non-HLA loci remains moderate. Even for the most successful exam-
ples such as MS, T1D or RA, where over a hundred risk variants have been mapped, the
explained heritability varies between 20% for MS (Consortium and Others, 2013), 10%
for T1D (Hu et al., 2015a) and about 5% for RA (Okada et al., 2014).
A picture emerging from GWAS is that immune-mediated diseases, to some extent,
result from the dysregulation of the same biological pathways. For example, the initial
T cell dysregulation observed in individuals with CTLA4-mutations was found to extend
to an entire locus harbouring genes for receptors that control T cell activation, CD28,
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ICOS and CTLA4, which is associated to CEL, RA and T1D. The sharing of genetic regions
associated with immune diseases is widespread; of the 90 risk loci associated to T1D, RA,
CEL and MS, 37% overlap between two or more diseases (Fortune et al., 2015). Despite
the success in finding disease susceptibility loci, the molecular mechanisms by which
these genetic variants hinder control of immune system and lead to autoimmunity have
only been determined for a small number of variants. For example, missense mutations
in the exon of CTLA4, induce severe immunodeficiency and a spectrum of autoimmune
and autoinflammatory diseases (Schubert et al., 2014). These rare monogenic disorders
have provided insights into the control of the immune system in the presence of the
dysfunctional genes. However, the same genotype-to-function logic cannot be easily
applied to all associations.
The challenges of understanding GWAS results for complex traits are both statistical and
biological (Spain and Barrett, 2015). Among the statistical problems is that associated
loci map to regions of the genome with extended linkage disequilibrium (LD). The LD
blocks often comprise tens to hundreds of highly correlated single nucleotide polymor-
phisms (SNPs) that are co-inherited. Therefore, in a statistical test, the high correlation
between SNPs results in equivalent strength of the association signal spread throughout
all of the variants in LD. Practically, this renders the variants indistinguishable from one
another and hinders the prioritisation of the causal variant based on the association
statistics alone. Another problem is linking the associated SNPs to effector genes, as
the causal variants may not necessarily affect the closest gene but instead act through
long range genomic interactions. Finally, the majority of the associated variants localise
to the non-coding regions of the genome, implicating that the disease variants are
likely to act through dysregulation of gene expression. This poses a challenge because
gene expression regulation can be highly cell type specific and therefore functional
follow up studies have to be carried out in the cell types most relevant to the disease.
However, for many immune diseases the exact pathological cell type is unknown.
4 1 Introduction
1.2 The system: Immune cell types and their role in
autoimmunity
1.2.1 CD4+ T cells within the adaptive immune system
Adaptive immunity is a branch of the immune system that is characterised by immuno-
logical memory and changes across an individual’s lifespan depending on the pathogens
to which they have been exposed. The adaptive immune system has two main players,
B cells, which mature in the bone marrow, and T cells, which mature in the thymus. B
cells and T cells sense their environment and communicate with each other via the
expression of cytokines and chemokines, along with their receptors. These are small
proteins whose concentrations within a cellular environment can determine the fate of
the immune response.
T cells constitute the backbone of adaptive immunity and can be broadly divided into
cytotoxic, which express CD8, and helper, which express CD4. Mature T cells that express
T cell receptors (TCR+) are generated in the thymus, from where they are released into
secondary lymphoid organs. Once in the secondary organs, the primary role of T cells
is to recognise antigens derived from micro-organisms and orchestrate an immune
response to fight them.
T cell maturation is a highly regulated process, in which the cells are screened for
TCR reactivity to self-peptides bound to the MHC, and removed in case of high affinity.
Cells with low affinity receive a weak TCR stimulation which contributes towards their
maturation. The cells then undergo rounds of double positive selection through contact
with MHC class I and II, and at the end of the process a cell only expresses either CD4+
(helper T cells (Th)) or CD8+ (cytotoxic T cells (Tc)) along with CD3 (Klein et al., 2014).
Both CD4+ and CD8+ cells are characterised by the expression of CD3, which forms a
complex with the TCR, and allows the cells to successfully establish contact with MHC
presenting cells. When CD8+ T cells recognise an antigen and become activated they
are able to induce apoptosis.
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1.2.2 Signal transduction in T cells in response to stimulation
CD4+ T cell stimulation occurs in secondary lymphoid tissues where T cells interact
with professional APCs, like dendritic cells, B cells and macrophages. Upon interaction,
two coordinated signals are delivered to the T cell; the first is delivered via the TCR,
which recognises antigen bound to MHC molecules, and the second is delivered via
a co-stimulatory receptor. CD28 is the main co-stimulatory receptor expressed by T
cells, and it interacts with CD80 and CD86 ligands on the APCs. The coordination of TCR
and CD28 signals is important for T cell activation, proliferation, differentiation and
survival (Figure 1.1 ). CD80 and CD86 can also be bound by CTLA-4 with higher affinity,
as a means to dampen the immune response. CTLA-4 is expressed on the surface of
all T cells upon stimulation and is the main pathway employed to downregulate the
immune response upon completion. There are other co-stimulatory pathways, such as
those mediated via ICOS, 4-1BB (encoded by TNFRSF9) and OX40 (encoded by TNFRSF4)
receptors, all of which tend to be upregulated on the T cell surface upon stimulation.
The combination of these signals critically affects the magnitude and fate of the T cell
response. Therefore, co-stimulatory pathways provide a key checkpoint for controlling
T cell responses, which is increasingly relevant therapeutically (Ford et al., 2014).
T cell activation promotes a number of signalling cascades that determine the fate of a
cell. Activation is initiated via the phosphorylation of immunoreceptor tyrosine-based
activation motifs (ITAMs) on the cytosolic side of CD3 by lymphocyte protein tyrosine
kinase (Lck). Lck also interacts with CD28 C-terminal chain, and represents an important
integration point for the two signals (Dobbins et al., 2016). Zeta-chain associated protein
kinase (Zap-70) is then recruited to the TCR-CD3 complex where it becomes activated,
promoting a series of phosphorylation events of adaptor and scaffold proteins. These
result in the production of the second messengers diacylglycerol (DAG) and inositol
trisphosphate (IP3). DAG activates protein kinase C (PKC) and the MAPK/Erk pathways,
both promoting transcription factor (TF) NF-κB activation. IP3 indirectly promotes the
entry of extracellular Ca2+ inside the cells, which in turn encourages IL2 transcription by
the NFAT and AP-1 TFs. IL-2 is a growth factor that initiates cell proliferation upon binding
to the IL-2 receptor, which itself is composed of three chains, including the α chain,
CD25, which is expressed on the surface of activated T cells. It is CD28 co-stimulation
















Figure 1.1: T cell activation requires two signals to engage in cell proliferation and differentia-
tion into effector functions. In order to become activated, a CD4+ T cell needs an
antigen presented by the major histocompatibility complex (MHC) to be recognised
by the T cell receptor (TCR) and a B7 molecule (CD80 or CD86) to be recognised by
the co-stimulatory receptor CD28. In the absence of a CD28 signal, T cells undergo
apoptosis or become anergic. In the absence of the antigen a cell will not undergo
any response.
the levels of IL-2 (Fraser et al., 1991; Shapiro et al., 1997). The Weiss laboratory identified
a region in the IL2 promoter that binds TFs in a CD28-dependent manner, therefore
called CD28-response element (CD28RE).
Early investigations into TCR signalling relied on cloning techniques to identify the
receptor responsible for the T cell identity (Hedrick et al., 1984; Yanagi et al., 1984).
Subsequent signalling studies used cell line knock-outs and discovered they could
stimulate T cells pharmacologically using phorbol esters, such as phorbol 12-myristate
13-acetate (PMA), and calcium ionophores, such as ionomycin (Weiss and Imboden,
1987). PMA is a small molecule that can diffuse through the cell membrane into the
cytoplasm, where it can directly activate PKC and initiate the MAPK pathways, omitting
the requirements for a surface receptor. Ionomycin complements PMA by triggering a
calcium release which is necessary for NFAT signalling. This paved the way for a number
of in vitro cell stimulation assays using PMA and ionomycin and antibodies against CD3.
Once the important role of the CD28 co-stimulatory receptor in preventing cell anergy
was identified (Figure 1.1 ; Jenkins et al., 1988), the most common stimulation method
became a combination of anti-CD3 and anti-CD28 antibodies. These are commonly
bound to magnetic beads in order to make their distribution and removal easier.
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1.2.3 Helper T cell classification
Upon stimulation Th cells usually differentiate from the naive, that is a mature CD4+
T cell that has not encountered an antigen, into an effector state. Effector helper T
cells are classified into Th1, Th2, Th17 and Tfh depending on the antigens present in the
environment. Each subpopulation produces a different set of cytokines and promotes a
different branch of the immune response (Zhu et al., 2010a). Th1 responses are criti-
cal for the defence against intracellular pathogens such as viruses and bacteria, and
are characterised by the secretion of interferon-γ (IFN-γ). Th2 cells are important for
controlling helminthic parasites and secrete interleukin-4 (IL-4), IL-5, and IL-13. Th17
cells regulate the host response against extracellular bacteria and fungi, and produce
IL-17 (Zhu et al., 2010a). Tfh cells (follicular helper T cells) assist the B cells in the
production of antibodies and express high levels of CD40 ligand (CD40L), IL-21 and IL-4.
Another pathway is for CD4+ T cells to become T-regulatory (Treg) cells, which function
in immune response homeostasis and downregulate the induction of effector T cells to
avoid and reduce ongoing inflammation. CD4+ T cells can acquire a regulatory function
either in the thymus, in which case they are referred to as natural Tregs (nTregs) or
after activation in the periphery, referred to as induced Tregs (iTregs). Tregs exert their
actions by producing the anti-inflammatory cytokines IL-10 and transforming growth
factor-β (TGF-β) and uptaking the T cell growth factor IL-2 via high expression of its
receptor, CD25, in order to limit its supply (Fontenot et al., 2005b). Tregs also express
high levels of CTLA-4, which outstrips activating ligands from the surface of APCs, and is
also necessary for the generation of Tregs (Read et al., 2000; Zheng et al., 2006).
Upon completion of the immune response, a small proportion of the responding effector
cells survives to form antigen-specific memory T cells. Memory T cells retain elements
of the previously induced state and are available to recreate a rapid defence in case of
further antigenic challenge. Memory cells are characterised by the high expression of
CD44 and CD45RO markers, while some of the cells are CD62Lhigh and CCR7high (central
memory T cells) and others are CD62Llow CCR7low (effector memory T cells). Central mem-
ory T cells are found in the lymph nodes and the peripheral circulation and are capable
of self-renewal, while effector memory T cells are found in the peripheral circulation
and in the tissues and have a more specialised function. The molecular processes that
define which cells will commit to become memory cells remain unknown. It has been
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reported that increasing the strength of the TCR signal promotes an activated naive cell
to become a memory cell (Williams et al., 2008). This is in contrast with other theories
that support an asymmetric cell division model of naive cells while differentiating into
memory and effector cells (Chang et al., 2007).
Given the importance of the CD28 pathway, a still largely unresolved question is the dif-
ferential impact of CD28 co-stimulation at the transcriptional level in naive and memory
T cells. Previous studies have suggested that memory T cells have lower co-stimulation
thresholds or conversely, that naive cells have a greater requirement for co-stimulatory
signals (Croft et al., 1994; Dubey et al., 1995; London et al., 2000). This has given rise
to a widely perceived notion that, in contrast to naive, memory T cells do not require
CD28 co-stimulation. However, there is evidence that this may not be the case in some
settings, and that CD28 co-stimulation is important to numerous aspects of functional
competence for previously primed T cells (Borowski et al., 2007; Linterman et al., 2014;
Ndlovu et al., 2014; Fröhlich et al., 2016). These contrasting conclusions are likely influ-
enced by the experimental systems used, as well as the nature and intensity of the TCR
signal. Finally, different T cell processes may vary in their degree of dependence on
CD28 co-stimulation, for example the requirement for CD28 to induce T cell proliferation
appears lower than that for T follicular helper cell differentiation (Wang et al., 2015)
which is strongly CD28-dependent.
1.2.4 T cell role in immune-mediated disease progression
The primary role of the immune system is to protect the host from infection by a variety
of pathogens constantly present in the environment. As such, genetic defects that
cause loss of the immune system’s activity result in recurrent infections and severe
immunodeficiency that is often life threatening. However, uncontrolled activation of
immune cells may result in the response being targeted towards healthy cells causing
chronic inflammation, tissue destruction, and eventually inflammatory diseases. Un-
controlled activation of the immune system can also occur when cells respond against
the self-antigens and ultimately against the auto-antibodies, which would lead to au-
toimmunity. T cell related autoimmune and inflammatory diseases are characterised by
an imbalance between effector T cells and functional Treg cells. Inadequate number of
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Treg cells, defective Treg function, suppression resistant effector T cells or deficient T
cell stimulation have all been associated with autoimmunity (Buckner, 2010).
The strongest evidence of the contribution of decreased Treg numbers to autoimmunity
comes from patients with IPEX, who completely lack Treg cells due to different mutations
in the FOXP3 gene (Bennett et al., 2001). Furthermore, mice with Foxp3 mutations (scrufy)
display systemic autoimmunity (Fontenot et al., 2005a). FoxP3 is the hallmark TF of Tregs
and acts mostly as a repressor to downregulate genes involved in Treg cell activation
(Fontenot et al., 2005b). However, in patients with common autoimmune diseases the
number of circulating Tregs are more variable compared to IPEX patients, which makes
them complex to study. This is exacerbated by the difficulty in isolating tissue specific
Tregs, since FoxP3 is an intracellular protein. High levels of CD25 and low levels of CD127,
the α receptor for IL-7, are typically used to isolate Tregs from a CD4+ cell population,
to achieve a pure Treg cell population, where more than 95% will express FOXP3 (Liu
et al., 2006). For the same reasons, as well as the absence of a reliable assay, Treg
cell function is also complicated to study. Even when enough cells are obtained, the
functional assays are set up in vitro, which might not accurately represent the pro-
cesses in vivo, since Treg cells show decreased proliferation in vitro compared to in vivo.
Treg function is usually assessed through suppression assays, first described 20 years
ago (Takahashi et al., 1998), where the authors observed that co-culturing Tregs with
CD4+CD25- conventional T cells (Tcons), led to the decreased proliferation of activated
Tcons, measured through flow cytometry. Since then, numerous slight variations of
the protocol have been proposed, such as measuring the cytokine milieu using ELISA
(Nakamura et al., 2001) and changing the stimulation from anti-CD3 and anti-CD28 to
different antibodies, such as glucocortoid induced TNF receptor (GITR) (Shimizu et al.,
2002; McHugh et al., 2002). Using such assays a recently published study by the Todd
group demonstrated that Tregs from SLE patients have lower levels of CD25, which
affects their suppressive phenotype and decreases their survival (Ferreira et al., 2017b).
The functional defect at the source of an immune attack could also lie within the re-
maining T cell populations; naive, memory and effector. Different mechanisms by which
T cells can become resistant to Treg suppression have been described. These vary
between diseases and include modifications of intracellular signalling pathways, which
can result in changes in the T cell activation threshold, and exposure to extracellular
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signals such as a specific cytokine milieu or an activation signal. Early studies that pro-
vided strong co-stimulatory signals via the anti-CD28 antibody led to Tcon cells resisting
Treg suppression (Takahashi et al., 1998) and highlighted co-stimulatory pathways as an
important component of acquired resistance. Another co-stimulatory receptor, OX40,
has also been associated with many immune-mediated diseases, including SLE, where
its levels in memory cells were elevated and the cells were resistant to Treg suppression
(Kshirsagar et al., 2013). Interestingly, polymorphisms in the gene encoding for its ligand
(TNFSF4 or OX40L) led to abnormal levels of its transcripts (Graham et al., 2007), which
have been suggested to promote a Tfh profile (Jacquemin et al., 2015). The role of
activated memory cells in immune diseases has also been observed in patients with
juvenile idiopathic arthritis (JIA), where their synovial fluid had significantly elevated
numbers of memory cells that were fully differentiated and active, which made them
resistant to downregulation by Tregs (Haufe et al., 2011). Finally, autoimmune diseases
are characterised by the overproduction of inflammatory cytokines, and a number of
interleukins have been found to lead to Tcon resistance. The most notable example is
IL6, which has elevated levels in JIA, RA, SLE, inflammatory bowel disease (IBD) and MS.
Tcons from the peripheral blood of MS patients were observed to be highly prolifera-
tive and characterised by increased IL6 signalling through pSTAT3. Blocking of STAT3
phosphorylation led to increased suppression of these cells by Tregs (Schneider et al.,
2013). Resistance acquirement can also be studied via suppression assays, and the
development of carboxyfluorescein succinimidyl ester (CFSE) and CellTrace proliferation
dyes marked an important step to be able to separately stain Tregs and Tcons within a
co-culture to distinguish between the two proliferative profiles. In these assays it is
difficult to distinguish between acquired resistance and loss of Treg function, which
makes the establishment of appropriate controls crucial.
T cells continue to play a role in autoimmunity as the initial immune response escalates.
After the self-antigen has initiated a reaction it is difficult to eradicate it since it leads
to increased tissue damage and the emergence of new antigens. As cells are recruited
to the affected site, they secrete cytokines inducing an inflammatory environment.
In fact, targeting specific cytokines consists of one of the main strategies to control
inflammation in immune-mediated diseases (Ishihara and Hirano, 2002; Taylor et al.,
2009; Papoutsaki and Costanzo, 2013). Inflamed tissue is characterised by abnormal
proportions of different immune cells when compared to ratios in their healthy coun-
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terparts. For example, the inflamed skin of patients with psoriasis (PSO) has increased
numbers of Tregs which however produce the pro-inflammatory cytokine IL-17 leading to
increased inflammation (Bovenschen et al., 2011). In contrast, in lesions of SLE patients,
Treg cells display increased sensitivity to cell death mediated by the death receptor
CD95. This sensitivity leads to a decrease in their numbers the extent of which correlates
with increased clinical severity of the flare (Miyara et al., 2005).
Tregs have the potential to resolve an autoimmune reaction. Effector cells produce IL-2
which leads to the activation and expansion of tissue resident Tregs and the formation
of new Tregs (Knoechel et al., 2005). Depending on the reason for the development of
the disease, the generation or maintenance of these Tregs might be defective, in which
case there will be no disease resolution.
1.3 The tools: Genome wide assays for functional profiling of
immune-disease loci
1.3.1 RNA sequencing
RNA sequencing (RNA-seq) is a widely used method to quantify the dynamic transcrip-
tome of a cell in a genome wide manner. There are three steps involved in preparing
a sample for RNA-seq. Firstly, RNA has to be isolated from the cells. In the case of T
cells, this can be difficult as they are characterised by a small diameter and therefore
reduced input material. Secondly, to obtain messenger RNA (mRNA) as the measure for
the transcriptomic state of the cells isolated, the RNA has to be filtered. This step is
necessary since the majority of all cellular RNA is ribosomal. In eukaryotes, filtering
for mRNA is usually achieved either using a depletion method or poly-A selection. If
this step is performed using poly-A selection, it can result in variation in read coverage
across the gene body and introduce 3’ bias (Lahens et al., 2014). Finally, the filtered
mRNA is reverse transcribed to yield cDNA libraries. cDNA is amplified using polymerase
chain reaction (PCR) to enrich for specific fragments and attain a desirable concentra-
tion necessary for loading onto the sequencing machine. PCR can also result in biases,
since it preferentially amplifies sequences with high content of G and C nucleotids
(Benjamini and Speed, 2012). In order to address different biases in RNA-seq, multiple
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experimental and computational approaches have been developed to ensure that the
generated libraries are of high complexity.
Conventionally, once the RNA-seq libraries have been sequenced, the individual reads
are aligned to a reference genome using a splice aware algorithm, such as STAR (Dobin
et al., 2013). The genomic coordinates of transcripts and different transcript isoforms
are maintained in public databases such as GENCODE (Harrow et al., 2012). Mapped
reads that overlap annotated genes are counted using tools such as featureCounts
(Liao et al., 2014). More recently, pseudoalignment methods for gene quantification,
such as Salmon (Patro et al., 2017), were developed. They bypass the requirement of a
reference genome alignment step by quantifying expression levels directly based on
the transcriptomic sequences, leading to a dramatic reduction in the computational
time required. Furthermore, since these methods directly quantify reads, they can be
used to assess the ratios of different transcripts present in a cell.
The majority of human genes express more than one transcript per gene, which in-
creases their potential pool of proteins by 10-fold on average (Nilsen and Graveley,
2010). Transcripts can differ in their functionality and subcellular localisation, with
the most notable example being the PTPRC gene encoding for the CD45 protein, a cell
surface tyrosine phosphatase (Michie et al., 1992). Naive T cells express CD45RA while
memory T cells express CD45RO, an isoform which lacks three exons.
Despite large efforts by databases such as Ensembl (Aken et al., 2017), a lot of tran-
scripts remain unannotated along with the mechanisms by which they arise. Alternative
transcripts can arise from alternative promoters, alternative splicing and alternative
polyadenylation. To address this, one can use methods such as LeafCutter, which fo-
cuses on alternative transcription events directly, looking at the reads that span two
exons, commonly referred to as exon-exon junctions (Li et al., 2018).
1.3.2 Chromatin state profiling
Gene expression regulation results from the interplay between gene enhancers and pro-
moters. Chromatin immunoprecipitation followed by sequencing (ChIP-seq) assesses
DNA-protein interactions by pulling down DNA regions of the genome that are bound
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by a protein of interest. ChIP-seq has been used to annotate the activity of non-coding
regions of the genome through the presence of different post-translational histone
modifications. Four core histones are used to pack the DNA of a cell within a structure
called the nucleosome. Post-translational modifications of histones reflect changes in
chromatin structure that is often coupled with accessibility of different proteins, such
as TFs, and thus regulate gene expression. Histone H3 is the most modified histone.
The fourth lysine of H3 can be mono- or tri-methylated (H3K4me1 or H3K4me3) denot-
ing enhancers and promoters, accordingly. The 9th lysine, when trimethylated marks
constitutively repressed genes while when acetylated it denotes actively transcribed
promoters. The 27th lysine of H3 can be trimethylated (K27me3), which is a signal tagging
inactivate enhancers and promoters, or acetylated (K27ac), which is a signal for active
regulatory elements. Finally, H3K36me3 locates in the bodies of actively transcribed
genes (ENCODE Project Consortium, 2012).
There have been large efforts led by international consortia to comprehensively an-
notate the non-coding sequences of the genome across a wide range of cell lines and
primary cell types (ENCODE Project Consortium, 2012; Roadmap Epigenomics Consortium
et al., 2015; Stunnenberg et al., 2016). Currently, more than 150 different cell types have
been annotated using the above marks for the presence of promoters, enhancers and
repressive sequences, and often are also complemented by the annotation of binding
sites for specific TFs.
Similarly to RNA-seq data, ChIP-seq data is typically aligned to a reference genome
using a standard aligner, such as bwa (Li and Durbin, 2009). The next step consists
of identifying regions that show a higher pile-up of reads which would correspond
to more protein binding or chromatin accessibility than the background. These are
typically referred to as “peaks” and are identified using peak calling algorithms such
as MACS2 (Zhang et al., 2008). Depending on the protein being assayed, the resulting
peaks can be characterised as narrow, when spanning a few hundred base-pairs (e.g.
a TF ChIP-seq), or broad, when spanning up to tens of thousands of base-pairs (e.g.
H3K27me3 ChIP-seq), and a different algorithm has to be used when dealing with each.
However, ChIP-seq typically requires material in the order of millions of cells, an amount
prohibitive for rare cell type population studies. These requirements can be overcome by
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a recent modification of the standard ChIP-seq protocol, Chipmentation-seq (ChM-seq).
In ChM a series of adapter ligation and purification steps during the library preparation
stage is replaced by the more straight-forward transposase (Tn5) mediated sequencing
adapters addition during the immunoprecipitation step (Schmidl et al., 2015). This new
protocol results in reduced overall time, costs and input requirements and has been
shown to yield reliable results with low cell numbers, as few as 10,000 cells for some
histone modifications. Such low inputs have been shown to work in the cell line K562
(Schmidl et al., 2015) and innate lymphoid cells (Lim et al., 2017).
Tn5 has in fact already been used in the assay for transposable-accessible chromatin
followed by sequencing (ATAC-seq) protocol, which identifies open chromatin regions
(Buenrostro et al., 2013). Chromatin accessible regions determined by ATAC-seq repli-
cated regions identified by a more established method, the DNAse-seq-Hypersensitivity
(DHS) assay (Boyle et al., 2008). DHS is a challenging assay and for this reason it hasn’t
been applied at a large population scale. However, ATAC-seq has been successfully
used in human population studies due to its easy implementation and low cell num-
ber requirement (Alasoo et al., 2018; Gate et al., 2018). The only initial limitation of
ATAC-seq was the sheer number of resulting mitochondrial reads. A recent optimisation
of the protocol led to decreased percentage of the mitochondrial reads captured in
a sample, which has allowed to decrease the sequencing depth required (Sos et al., 2016).
1.4 The goal: Functional fine-mapping of disease variants
1.4.1 Importance of context specificity for the study of autoimmunity
The annotation of regulatory chromatin for enhancers and promoters has provided
an opportunity to interpret the role of non-coding disease variants. The development
of statistical approaches that integrate GWAS SNPs with histone marks allowed the
prioritisation of disease relevant cell types (Trynka et al., 2013; Farh et al., 2015; Pick-
rell, 2014) (Figure 1.2 ). Enrichment of GWAS variants in cell-type-specific promoters
marked by H3K4me3, confirmed the importance of CD4+ T cell subsets in a number of
autoimmune disorders. CD4+ memory T cells and regulatory T (Treg) cells showed high
enrichment for variants associated with a number of diseases, including RA, IBD and
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CEL (Trynka et al., 2013). This observation converges with the previous immune studies










variants associated with disease
Figure 1.2: Causal disease variants overlap cell type specific chromatin marks. Chromatin
marks from tissues of interest (left) can be obtained by chromatin immunopre-
cipitation followed by sequencing (ChIP-seq) and chromatin accessibility assays.
These assays yield reads which are mapped against the reference genome to find the
genomic location of the chromatin marks. Regions enriched in reads for the assayed
chromatin marks can be recognised as ‘peaks’ in the genomic position plot of reads
(right). Such genomic annotations generated from different tissues [lymph nodes
(green), lungs (blue), femur (pink)] provide a valuable roadmap of cell type specific
genome activity. The genome annotations can be overlapped with genetic variants
associated with a phenotype of interest, such as an autoimmune disease, represented
as grey circles. If a statistically significant proportion of associated variants overlaps
with peaks specific to a cell type it can point towards disease-relevant tissue and
prioritize causal variants. Here, we illustrate a single-associated locus where only
one single nucleotide polymorphism (SNP; red circle) overlaps with a peak specific to
the lymph nodes and absent from the other two tissues.
Since active histone marks tend to localise near the genes whose expression they
control, gene expression measurements themselves can also be used to prioritise a
specific cell type or condition (Slowikowski et al., 2014; Calderon et al., 2017). Using gene
expression measurements across different conditions also allows the identification of
potential key genes driving the enrichment in that cell type and could play a role in
disease pathogenesis. Using this statistical approach, Hu and colleagues identified the
critical cell types for different autoimmune diseases: transitional B cells for SLE, ep-
ithelial associated stimulated dendritic cells for Crohn’s disease (CD) and CD4+ effector
memory T cells for RA (Hu et al., 2011). Following this observation, they isolated high
purity CD4+ T effector cells and measured relative cell abundance, as well as the gene
expression of 215 genes located in RA loci, and cell proliferation capacity upon in vitro
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stimulation with anti-CD28/anti-CD3 beads (Hu et al., 2014). They identified a group
of genes whose basal level could predict the proliferative potential of CD4+ effector
memory cells, along with a non-coding genetic variant that increased cell division
capacity. Although, this study did not link RA risk loci with the modulation of CD4+
memory cell proliferation, it exemplifies how to link genotype to immune cell function.
1.4.2 Correlating disease variants with gene expression
Having identified the most relevant cell types, the effects of genetic variants on gene
expression are often assessed through genotype correlation with gene expression levels
measured across tens to thousands of individuals (expression quantitative trait loci,
eQTL; Figure 1.3 ). Disease associated variants are enriched for eQTLs (Dimas et al., 2009;
Nicolae et al., 2010). A relevant and easily accessible tissue for immune diseases is blood.
As such, early studies that integrated GWAS SNPs with gene expression identified an
enrichment of immune disease SNPs in whole blood or peripheral blood mononuclear
cells (PBMCs) expression variants. For example, over 50% of CEL variants also had an
eQTL effect (Dubois et al., 2010). Disease associated variants affecting gene expression
can point towards a dysregulated specific pathway. For instance, five of the IBD risk
variants were also eQTLs which had an increasing effect on the expression levels of
the ITGA, ITGAL, ICAM and ITGB8 genes, encoding for integrins, the proinflammatory cell
surface proteins (Lange et al., 2017).
As the gene expression studies increased in sample size (Westra et al., 2013), and ex-
panded across tissue types (GTEx Consortium, 2015) and cell states (Fairfax et al., 2014),
it became evident that the eQTL effects are widespread. For instance, a study of whole
blood gene expression from over 8,000 individuals identified that nearly 6,500 genes
(44% of all tested genes) were under a genetic control (Westra et al., 2013).
Recent studies that have incorporated of disease associated loci defined by GWAS with
eQTLs have highlighted that the initially observed enrichment of GWAS SNPs among
eQTLs may have been overestimated. This is because of the confounding effects of the
LD and cell type specific gene expression. The LD results in long distance correlations
between tens to hundreds of variants. The GWAS and eQTL signals can overlap in a
genetic location, however it is critical to determine whether the overlap is coincidental
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or driven by the same functional variants. For that, simple overlap between the eQTL
and the GWAS SNPs is not sufficient and more stringent methods that colocalise the LD
variants between the two signals need to be applied instead (Guo et al., 2015; Chun et al.,
2017). Guo et al. (Guo et al., 2015) assessed the colocalisation of 595 variants from 154
non-overlapping regions associated to ten different immune-mediated diseases with
gene expression variants from primary resting and stimulated monocytes and resting B
cells. Of the 1,414 genes mapping to these regions, 125 showed an eQTL effect that also
overlapped with a disease SNP. However, there was only strong support of colocalising
signals for six genes.
The early eQTL mapping studies had already recognised the importance of cell type
specific gene regulation. Dimas et al. used lymphoblastoid cell lines (LCLs), primary
fibroblasts and T cells from umbilical cords and reported that 69-80% of regulatory
variants affected gene expression in a cell type specific context (Dimas et al., 2009).
Another recent study found that only a small proportion of IBD variants overlapped with
whole blood eQTL SNPs (8 of 76 IBD loci) (Huang et al., 2017). The lack of enrichment
could be due to the presence of heterogeneous populations of immune cells in the
whole blood. In fact, higher enrichment was observed with eQTLs from CD4+, ilium
and CD14+ monocytes (an essential cell of the innate immune response), underscoring
the importance of the cell type specific context when analysing the function of GWAS
variants (Figure 1.3 ).
Regulatory variants can exhibit opposite effects across different cell types (Solovieff
et al., 2013). For example, of over 7,000 eQTLs that were shared between monocytes and
T cells, Raj et al. identified 42 to have inverse effects between the two cell types (Raj
et al., 2014). One of these eQTLs affected the expression of CD52, a target for antibody
therapy used in MS treatment (CAMMS223 Trial Investigators et al., 2008). Furthermore,
even closely related cell types, such as CD4+ and CD8+ T cells showed a limited overlap
between eQTLs and GWAS SNPs (21 SNPs affecting the expression of 133 genes) based
on a cohort of 313 healthy individuals (Kasela et al., 2017). Improving our understanding
of disease associated variants in a cell type specific context can therefore inform future
drug development strategies by ensuring that a drug is targeting a protein in a specific
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Figure 1.3: Cell type specific and cell-state-specific expression quantitative trait loci. Cellular
phenotypes, such as gene expression, cytokine secretion or chromatin accessibility,
might be affected by a genetic variant only in a specific cell type and under specific
conditions, e.g. at a specific time-point following a stimulation. Here, a bulk of cell
types (upper panel), as well as each cell type individually, were stimulated for 2 and
24 hr. In all scenarios, the measured phenotype, e.g. gene expression, increased upon
stimulation, but the effect was only correlated with the genotypes in the green cell
type (middle panel). The effect was missed when measured in the sample containing
the mixed cell population (upper panel). The blue cell type (bottom panel) shows
the strongest up-regulation in expression upon stimulation and largely drives the
observed increase in expression in the bulk sample.
However, even if the relevant cell type is identified, the functional effect of a variant may
not be detected unless the cell is challenged in an appropriate environment. Fairfax et
al., (Fairfax et al., 2014) stimulated monocytes with lipopolysaccharide (LPS) and IFN-γ
and demonstrated that 467 eQTLs overlapped with disease associated GWAS SNPs, 53%
of which were stimulation specific. One of the eQTL-GWAS SNPs was an MS variant that
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affected IRF8 expression following two hours stimulation with LPS. Earlier studies that
investigated the expression levels of IRF8 in PBMCs using microarrays failed to identify
a variant controlling the expression of this gene (De Jager et al., 2009), likely due to
the cell type specific effect. The same locus is also associated with SLE but with an
opposite effect. IRF8 is a regulatory factor of type-1 interferons, which are elevated
in SLE patients while MS patients present low interferon levels (Chrabot et al., 2013).
Importantly, the authors observed eQTL effects that differed between early and late
stimulatory responses. The dynamic nature of gene expression regulation was also
observed in dendritic cells stimulated with IFN–γ (Lee et al., 2014) and in CD4+ T cells
stimulated with anti-CD3/anti-CD28 beads (Ye et al., 2014). Ye et al. identified 157 GWAS
SNPs that overlapped with genetic variants that affected gene expression in CD4+ T
cells in a cohort of 348 healthy individuals (Ye et al., 2014). Notably, an ulcerative colitis
(UC) variant nearby IL23R and a variant nearby IL2RA associated to T1D, MS and vitiligo,
only presented an effect on gene expression 48 hours following stimulation. Given
that most effector functions of immune cells are performed following stimulation, it is
not surprising that the majority of immune disease variants would only be functional
in activated cells. Further studies are necessary to investigate different stimulation
contexts in more detail.
1.4.3 Correlating disease variants with epigenetic marks
The correlation between histone marks and genotypes can also be directly analysed
(Kumasaka et al., 2016). ChIP-seq assays result in pile-ups of sequence reads at ge-
nomic regions that map the interaction with proteins. In that respect, they produce
a quantitative measurement and, just like gene expression, can be analysed in light
of correlations with different alleles, as QTLs. Regulatory annotations are not only a
good predictor of gene activity but can also suggest a mechanism of action, e.g. by
implicating a specific TF binding site (McVicker et al., 2013), or when overlapping with
eQTLs (Rosario et al., 2015). For example, H3K27ac QTLs in human lymphoblastoid cell
lines are highly enriched for immune disease GWAS variants, particularly from MS. In a
study of three major immune cell types; neutrophils, monocytes and CD4+ T cells, from
200 individuals, Chen et al. mapped coordinated genetic effects on the epigenome and
transcriptome (Chen et al., 2016).
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In addition to ChIP-seq, genome activity can also be measured through chromatin acces-
sibility. Analysis of 349 tissues and cell types generated using DHS-seq found that over
75% of non-coding GWAS associated variants lie within a DHS. The localisation of SNPs
in DHS was quantitative and cell specific, e.g. Th1 and Th17 CD4+ T cells were enriched
for CD variants, indicating its potential future use for QTL mapping for mechanistic
understanding of the disease. For example, around 25% of GWAS SNPs associated with
autoimmune diseases within DHSs in immune cells (n=262) altered a TF binding motif
for the IRF9 pathway (Maurano et al., 2012). The IRF9 network along with the Jak/Stat
cascade are initiated in the presence of IFN-γ, indicating that this pathway might play
an important role in autoimmunity.
Despite the observed enrichment of disease variants in regulatory non-coding se-
quences it is estimated that only 10-20% of 823 disease variants lay within TF binding
motifs. This suggests that there are other mechanisms of gene expression regulation
(Farh et al., 2015) such as mechanisms that affect spatial genomic interactions. To test
this hypothesis, a promising approach is the integration of GWAS variants with Hi-C
assays (Belton et al., 2012) that infer chromosome conformation by mapping interactions
between genomic regions located nearby in the 3D space. The technique allows for
both the high level mapping of chromatin loops as well as identification of precise
interactions between enhancers and gene promoters. The latter can be directly used
in mapping non-coding disease variants to target genes. For example, a recent study
using Hi-C demonstrated that the non-coding region on chromosome 6 containing a
variant that has been associated with RA and PSO, interacts not only with the promoter
of TNFAIP3, the closest gene, but also with IL20RA, which is 680kbp upstream from the
variant (McGovern et al., 2016). A comprehensive examination of the promoter Hi-C
interactions in 17 human primary blood cell types found an enrichment of autoimmune
disease SNPs in lymphoid cells compared to myeloid cells (Javierre et al., 2016). The
authors found that 76% of the identified genes had not been previously linked with
immune-mediated diseases, since they were outside of the immune associated loci.
Five of the newly identified genes, associated with RA and SLE, were under the control of
an eQTL, e.g. RASGRP1, a gene that activates the Erk/MAP kinase cascade and regulates
T and B cell development and differentiation.
Gene expression regulation is also reflected through DNA methylation. By combining
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DNA methylation with RNA sequencing from 3,841 Dutch individuals Bonder and co-
workers observed that trans methylation QTLs (meQTLs), where genetic variants affect
distant rather than local methylation status, were enriched for immune associated
GWAS traits (Bonder et al., 2017). While methylation has typically been linked to re-
pressed regions, the authors found two distinct functions for methylation depending
on its location. To investigate these findings further, they carried out TF ChIP-seq and
identified 13 trans-meQTLs that influenced the TF binding site, including two SNPs on
chromosome 4 associated with UC. They prioritised one of them as the causal SNP based
on its association with lower methylation and the higher gene expression of NFKB1, the
TF which controlled this binding motif. In addition, by incorporating the Hi-C assay with
DNA methylation and RNA sequencing, Bonder et al., identified that interchromosomal
contacts provide a mechanism by which some trans-meQTLs act. The 402 identified CpG
islands overlapped with CTCF, RAD21 and SMC3 TF binding sites.
1.4.4 Correlating genetic variation with immunological readouts
To gain comprehensive insights into the effects of genetic variants on the immune sys-
tem, genomic assays have to be complemented with traditional immunological methods.
The network of cellular interactions can be assessed at both a global scale, for instance
by looking at mechanisms that control cell frequency and cell proliferation, and at the
cellular level, by measuring protein expression and identifying genes that drive the
phenotype of interest. To accurately infer the causal relationships between genetic
variants and cellular traits it is important to carry out the experiments in cells isolated
from healthy individuals, limiting the effects of active disease or ongoing treatment.
The ratio between different immune cell subsets is heritable and could partly be a
pathobiological disease mechanism (Hall et al., 2000; Brodin et al., 2015). Through an
association study of genome wide SNPs with cell counts, two independent genetic
signals were identified to control the CD4+ to CD8+ T cell ratio. Both signals mapped
to MHC region, explaining 8% of the observed variance. Interestingly, one of these
associations overlapped with a T1D protective variant where the T1D risk allele increases
the number of CD4+ cells by decreasing their apoptosis rate (Ferreira et al., 2010). Past
years have seen many systematic, large scale efforts aiming to associate genetic variants
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with cell counts. Astle et al. identified over 2,500 variants associated with 36 different
hematopoietic traits (Astle et al., 2016). They observed an overlap between asthma
associated variants and the eosinophil counts, highlighting that the established positive
association between eosinophil counts and asthma is genetically controlled. Addition-
ally, variants associated within the MHC locus and nearby COG6, SPRED2, RUNX1 and
ATXN2/SH2B3/BRAP genes pointed towards a novel link between eosinophil function
and RA. A study of immune cell frequencies and surface protein expression levels of
170 dizygotic and 75 monozygotic pairs of twins using seven distinct 14-plex antibody
panels identified 151 independent heritable immune traits (Roederer et al., 2015). This
study reported that one of the most heritable traits is the frequency of CD39+ Tregs.
They identified a SNP that increases the level of CD39, and thus alters the proportion
of CD39+ Tregs. CD39 along with CD73 are enzymes that degrade the proinflammatory
ATP molecule to an anti-inflammatory adenosine (Antonioli et al., 2013). Dysregulation
of this machinery has been observed in MS, RA and IBD patients, with multiple drugs
targeting these two proteins. Additionally, the same variant had previously been identi-
fied in a study that measured counts of 95 different cell types from a cohort of 1,629
individuals from Sardinia (Orrù et al., 2013).
Immune cells exert their effector function by communicating with each other through
the expression of receptors and receptor ligands, combined with the secretion of spe-
cific molecules, such as cytokines. Alteration of these cellular functions results in
impaired immune response. The cytokine levels in the blood have been shown to be
highly heritable (Brodin et al., 2015). Systematic characterisation of the cell response
to different bacterial and fungal infections identified six cytokine QTLs (cQTLs) that
explained the IL-6, IL-8, IL-10 and TNF-α levels (Li et al., 2016b). The genetic control
of cytokine secretion in response to pathogens is relevant, as some of the identified
cytokines have also been associated with autoimmune diseases and are being targeted
by drugs, e.g. IL-6 with RA and PSO (Ishihara and Hirano, 2002). IL-6 pathways, along
with IL-1β were identified as being mostly driven by genetics, compared to environ-
mental factors and the microbiome. A larger study by the same group assessed five
cytokine production responses of PBMCs, whole blood and macrophages from 500
individuals to a pathogenic stimulus compared to no stimulus. They identified cell
type specific cQTLs, with monocyte specific cQTLs being associated with susceptibility
to infectious diseases and T cell specific cQTLs being associated with autoimmune
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diseases (Li et al., 2016a). In addition, colocalisation of genetic variants that control
cytokine levels with those that contribute to susceptibility to autoimmune diseases
linked the VEGF cascade with IBD and expression of the α subunit of the IL-2 receptor
with CD and MS (Ahola-Olli et al., 2017). Together these data demonstrated that the
levels of a number of pro- and anti- inflammatory cytokines are under genetic con-
trol. In the future, a large scale characterisation of molecular mechanisms that control
cytokine levels in health and disease will provide further insights into disease pathology.
1.5 The product: Outline of the thesis
Over the last decade, hundreds of immune disease loci have been successfully mapped.
Recent advances in genomics have enabled functional follow up studies that are starting
to provide insights into the molecular mechanisms by which disease variants drive
disease pathology. The aim of my thesis is to better understand the influence of genetic
variation associated with common immune diseases on the function of human immune
cells and identify pathways that are potentially perturbed. I focus on CD4+ T cells
because GWAS variants are enriched in the active regulatory elements of these cells
and they have an established role in autoimmune disorders.
Given the importance of studying the role of immune variants in the most relevant
cellular context, I first investigate in Chapter 2 if the two major subsets of CD4+ T cells,
naive and memory, operate the same gene expression programmes upon stimulation.
I disentangle the differential requirement of CD28 in naive and memory CD4+ T cells
using functional genomic assays. I show evidence that T helper differentiation cytokines
and chemokines expression increases in response to CD28 signal intensity in both naive
and memory cells. I observe that cell cycle and division are sensitive to CD28 in memory
cells in contrast to the paradigm that memory cells are CD28-independent. Lastly, I
show that CD28-sensitive genes, that is genes whose expression increases alongside
the increase in the intensity of the CD28 stimulus, are enriched in autoimmune disease
loci, pointing towards the role of memory cells and the regulation of T cell activation
through CD28 in autoimmune disease development.
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In Chapter 3 I optimise a newly published genomic protocol to investigate the regulatory
landscape of resting and stimulated regulatory T cells, a critical cell type which has
not been thoroughly studied due to its low abundance. I use ChM-seq assays to assess
the promoter and enhancer landscape of resting and activated Tregs and link identi-
fied elements to putative changes in gene expression. I find that the majority of gene
expression regulation changes are controlled by changing the levels of H3K27ac and
not by altering the levels of H3K4me3. Furthermore, I identify differences in transcript
ratio, which are indicative of differential transcript usage upon stimulation, including
for key CD4+ T cell TFs, such as NFATC1 and YY1. Since I observe that many peaks remain
unannotated from the target genes, I delve deeper into understanding other gene
expression regulatory mechanisms and perform correlation between changes in the
histone landscape and splicing patterns in this cell type.
Finally, in Chapter 4 I investigate the role of immune-mediated disease variants in Treg
function. Using freshly isolated Tregs from 100 donors, I identify over 5,000 eQTLs and
2,000 transcript ratio (tr) QTLs, of which around 40% were not observed in naïve CD4+ T
cells. I observe 117 genes colocalising with immune-mediated disease signals, many of
which were not observed in naive T cells. Finally, I integrate this data with chromatin
accessibility QTLs (caQTLs), promoter regions QTLs (promQTLs) and active regions QTLs
(actQTL). This allows me to fine-map the association signal at 33 loci. For two of the
immune associated genes I identify as being Treg specific, in relation to naive CD4+ T
cells, but also the GTEx consortium, MAP3K8 and TNFRSF9, I suggest one causal variant.
In summary, my thesis aims at addressing the role of immune disease variants in the
context of three important components of the immune response: 1) differential require-
ment of stimulus for the activation of naive and memory T cells, 2) effect of activation
on gene expression regulation in regulatory T cells, and 3) genetic variation on gene
expression regulation in regulatory T cells.
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2The role of co-stimulation in naive
and memory T cells
Collaboration note
The work described in this chapter is awaiting publication and is currently on biorxiv as
“CD28 control of memory T cell proliferation, effector function and autoimmune suscep-
tibility” (Glinos and Soskic et al. pending). Many sections of the manuscript have been
directly copied into this chapter. I processed the samples to cell isolation, generated
the RNA-seq, H3K27ac ChM-seq and ATAC-seq data, performed the flow cytometry and
analysed all the data. Blagoje Soskic performed the cell stimulation, the proliferation
assays and analysed the flow cytometry data, contributed to the ATAC-seq and H3K27ac
ChM-seq data generation and the flow cytometry acquisition. Blagoje Soskic and Dave
Sansom were involved in the experimental design and interpretation of the results.
RNA-seq library construction and sequencing of all materials was done by DNA Pipelines
core facility at Sanger.
2.1 Introduction
The ability of T cells to respond to pathogens whilst remaining tolerant to host antigens
is critical for human health. T cell stimulation generally occurs in secondary lymphoid
tissues where T cells interact with professional antigen presenting cells (APCs). Here, two
coordinated signals are delivered: the first via T cell receptor (TCR) recognising antigen
bound to MHC molecules and the second provided by APCs via upregulation of co-
stimulatory ligands. In this regard, CD28 is the main co-stimulatory receptor expressed
by T cells which interacts with CD80 and CD86 ligands on APCs. The coordination of
TCR and CD28 signals is essential for T cell activation, proliferation, differentiation and
survival. Therefore, the CD28 pathway provides a key checkpoint for controlling T cell
responses (Rowshanravan et al., 2017), which is increasingly relevant therapeutically.
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Early studies demonstrated that memory T cells have higher affinity for their antigen
and consequently need lower concentrations of it in order to respond (Savage et al.,
1999; Richer et al., 2013). Given that memory T cells have a lower activation threshold
than naive cells it has been suggested that they can respond in the absence of CD28
triggering (Luqman and Bottomly, 1992; London et al., 2000). The concept that memory
cells are CD28 independent has been challenged recently using in vivo mouse models
and different methods to knock-out or block CD28 (Ndejembi et al., 2006, Borowski
et al., 2007; Garidou et al., 2009; Teijaro et al., 2009; Ndlovu et al., 2014; Fröhlich et al.,
2016). Experiments using CD28 deficient mice and mice with a Cre/lox induced deletion
of CD28 prior to a secondary challenge demonstrated that CD28 is crucial for efficient
defense against worms in both primary and memory responses (Ndlovu et al., 2014).
Furthermore, Teijaro et al. demonstrated that treatment of mice with a co-stimulation
blocker reduced both the expansion and accumulation of memory T cells in spleen
and lungs following influenza infection (Teijaro et al., 2009). Finally, while it may be
possible to trigger memory T cell activation without CD28 engagement, the long term
survival of the cells and their abilities to assume effector functions are likely to be more
demanding on CD28 involvement (Jenkins et al., 1991).
The level of CD28 co-stimulation is likely to vary considerably in different immunological
settings. For example, the presence of regulatory T cells (Tregs) expressing CTLA-4, which
degrades CD80 and CD86 ligands (Qureshi et al., 2011) will influence CD28 co-stimulation.
Indeed, deficiency in CTLA-4 expression is associated with the development of profound
autoimmune diseases (Tivol et al., 1995; Kuehn et al., 2014; Schubert et al., 2014; Lo
et al., 2015) due to increased CD28 signalling (Tivol et al., 1997; Tai et al., 2007). In a
pharmacological setting, severe adverse reactions were observed in reaction to a CD28
agonistic antibody, TGN1412, due to stimulation of a cytokine storm from effectormemory
T cells (Eastwood et al., 2010; Hünig, 2012). Furthermore, excessive activation of memory
T cells is a hallmark of many common complex immune diseases, such as autoimmune
arthritis and systemic lupus erythematosus (SLE) (Haufe et al., 2011; Kshirsagar et al.,
2013). Genome-wide association studies (GWAS) have mapped numerous risk variants
to loci encoding genes in T cell stimulatory pathways, including CD28, CTLA4 and ICOS
located at 2q33.2 (Fortune et al., 2015; Dubois et al., 2010; Okada et al., 2014; Onengut-
Gumuscu et al., 2015). While the exact effects of the associated variants are unknown,
their mapping to the non-coding regions of the genome suggests effects on regulation
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of gene expression (Fairfax et al., 2014; Westra et al., 2013). Therefore, understanding
how varying levels of TCR and CD28 co-stimulation impacts gene expression and the
ensuing T cell response, has significant implications in understanding susceptibility to
diseases, in particular autoimmunity and cancer.
The fact that T cell activation can be measured in different systems and using different
assays, highlights the need for a new unbiased approach that would encompass more
than one aspect of activation. Here, I designed an approach to address the requirement
of TCR and CD28 in the activation of naive and memory human CD4+ T cells by profiling
the transcriptome and epigenome of these cells in response to varying intensities of
TCR and CD28 stimulation. I show that the major effector functions, such as T helper
(Th) differentiation, expression of chemokine receptors and cytokines, are all strongly
influenced by CD28 in both naive and memory T cells. Strikingly, cell division is markedly
differently controlled between the two cells, which we find to be controlled by CD28 in
memory cells whilst predominantly driven by TCR in naive cells. I identify genes that
were sensitive to TCR or CD28 levels and map the promoter and enhancer landscape
associated with gene expression regulation. Finally, I show that a proportion of loci
associated to common immune diseases is enriched in CD28-sensitive genes, pointing
towards the important role of this co-stimulatory pathway in disease pathogenesis.
2.2 Materials and Methods
2.2.1 Sample collection and DNA isolation
Blood samples were obtained from eight healthy adults, aged from 22 to 46 years.
Peripheral blood mononuclear cells (PBMCs) were isolated using Ficoll-Paque PLUS (GE
healthcare, Buckingham, UK) density gradient centrifugation. CD4+ T cells were isolated
from PBMCs using EasySep® CD4+ enrichment kit (StemCell Technologies, Meylan, France)
according to the manufacturer’s instructions. DNA was isolated from live PBMCs using
Qiagen DNeasy blood and tissue kit. All samples were obtained in accordance with
commercial vendor’s approved institutional review board protocols and their research
use was approved by the Research Ethics Committee (reference number: 15/NW/0282).
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2.2.2 Flow cytometry and cell sorting
CD4+ enriched cells were stained with the following antibodies for sorting: CD4+ (OKT4)-
APC (Biolegend); CD25 (M-A251)-PE (Biolegend); CD127 (eBioRDR5)-FITC (eBioscience) and
Live/Dead fixable blue dead cell stain. Live conventional T cells (Tcons, CD4+ CD25low
CD127high) were isolated and cultured for 16 hours. Stimulated naive and memory cells
were sorted based on the expression of CD25-PE, CD45RA- Alexa700 (Biolegend) and
DAPI. Resting naive and memory cells I sorted for low expression of CD25 (proportion of
CD25+ cells < 1%).
2.2.3 Cell culture and stimulation
Chinese hamster ovary (CHO) cells expressing CD86 or FcR (FcRγII, CD32) were cultured in
DMEM (Life Technologies, Paisley, UK) supplemented with 10% v/v FBS (Sigma, Gillingham,
UK), 50 U/ml penicillin and streptomycin (Life Technologies), and 200 µM l-glutamine
(Life Technologies) and incubated at 37°C in a humidified atmosphere of 5% CO2. CHO
cells expressing CD86 and FcR were generated as previously described (Qureshi et al.,
2011). T cells were co-cultured with glutaraldehyde fixed CHO-CD86 to provide CD28
signal or CHO-FcR for 16 hours in RPMI 1640 supplemented with 10% v/v FBS, 50 U/ml
penicillin and streptomycin, and 200 µM l-glutamine. Cultures stimulatedwith CHO-CD86
were treated with various concentrations of anti-CD3 (OKT3) while cultures stimulated
with CHO-FcR were treated with 1 µg/ml of anti-CD3 (OKT3) or 1 µg/ml of anti-CD28 (9.3).
For the full information of the samples and simulations used refer to Table 2.1 .
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Table 2.1: Metadataof blooddonorsprocessedand sample specifications. Ind. ID: Identification
number of blood donor; Coll. time: Time of the day the blood was collected; Process
Date: Month and year the blood was processed; Age: Age of individuals at the time
of the blood draw; Sex: Sex of the blood donors, F(emale) or M(ale); Stimulation:
Stimulation used on this sample, l refers to low and h refers to high. When the
two stimuli were combined lCD28 corresponds to 1 CHO cell for 25 T cells, hCD28
corresponds to 1 CHO cell to 2.5 T cells, lTCR corresponds to 0.01ng/µl and hTCR
corresponds to 1ng/µl. When the stimuli are used alone hCD28 corresponds to 1ng/µl
and hTCR corresponds to 1ng/µl; Cell type: Memory cells (M) are defined as CD4+CD25-
CD127+CD45RA- and Naive (N) cells are defined as CD4+CD25-CD127+CD45RA+. Upon
stimulation assayed cell are CD25+; Cell num. (x1000): Number of cells used for RNA
extraction; Activated cells (%): Percentage of naive or memory T cells subpopulation













25 1045 Feb-16 26 F hCD28 M 301 65.98
25 1045 Feb-16 26 F hTCR M 309 55.98
25 1045 Feb-16 26 F hTCR hCD28 M 300 55.41
25 1045 Feb-16 26 F hTCR lCD28 M 250 25.12
25 1045 Feb-16 26 F lTCR hCD28 M 250 25.78
25 1045 Feb-16 26 F lTCR lCD28 M 150 12.46
25 1045 Feb-16 26 F resting M 248 0
25 1045 Feb-16 26 F hCD28 N 750 60.05
25 1045 Feb-16 26 F hTCR N 1150 96.05
25 1045 Feb-16 26 F hTCR hCD28 N 1550 88.65
25 1045 Feb-16 26 F hTCR lCD28 N 886 35.78
25 1045 Feb-16 26 F lTCR hCD28 N 1456 65.66
25 1045 Feb-16 26 F lTCR lCD28 N 653 25.61
25 1045 Feb-16 26 F resting N 718 0
26 1205 Feb-16 22 M hCD28 M 138 53.9
26 1205 Feb-16 22 M hTCR M 119 58.48
26 1205 Feb-16 22 M resting M 152 0
26 1205 Feb-16 22 M hCD28 N 351 36.25
26 1205 Feb-16 22 M hTCR N 545 77.43
26 1205 Feb-16 22 M resting N 577 0
27 1300 Feb-16 31 M hCD28 M 491 73.54
Continued on next page
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27 1300 Feb-16 31 M hTCR M 382 64.78
27 1300 Feb-16 31 M hTCR hCD28 M 756 58.51
27 1300 Feb-16 31 M hTCR lCD28 M 456 30.81
27 1300 Feb-16 31 M lTCR hCD28 M 483 33.82
27 1300 Feb-16 31 M lTCR lCD28 M 287 19.02
27 1300 Feb-16 31 M resting M 336 0
27 1300 Feb-16 31 M hCD28 N 374 59.81
27 1300 Feb-16 31 M hTCR N 386 77.7
27 1300 Feb-16 31 M hTCR hCD28 N 1200 90.73
27 1300 Feb-16 31 M hTCR lCD28 N 679 49.75
27 1300 Feb-16 31 M lTCR hCD28 N 969 66.24
27 1300 Feb-16 31 M lTCR lCD28 N 434 29.9
27 1300 Feb-16 31 M resting N 354 0
29 1210 Feb-16 36 F hCD28 M 248 59.67
29 1210 Feb-16 36 F hTCR M 104 31.6
29 1210 Feb-16 36 F hCD28 N 75 47.03
29 1210 Feb-16 36 F hTCR N 63 53.36
30 1130 Feb-16 39 M hCD28 M 212 NA
30 1130 Feb-16 39 M hTCR M 182 NA
31 1045 Feb-16 25 F hCD28 M 355 NA
31 1045 Feb-16 25 F hTCR M 463 NA
31 1045 Feb-16 25 F resting M 500 NA
31 1045 Feb-16 25 F hCD28 N 151 NA
31 1045 Feb-16 25 F hTCR N 366 NA
31 1045 Feb-16 25 F resting N 460 NA
42 1400 Apr-16 26 F hCD28 M 210 37.59
42 1400 Apr-16 26 F hTCR M 300 47.09
42 1400 Apr-16 26 F hTCR hCD28 M 315 19.57
42 1400 Apr-16 26 F hTCR lCD28 M 220 11.97
Continued on next page
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42 1400 Apr-16 26 F lTCR hCD28 M 187 13.03
42 1400 Apr-16 26 F lTCR lCD28 M 146 7.2
42 1400 Apr-16 26 F resting M 250 0
42 1400 Apr-16 26 F hCD28 N 124 15.76
42 1400 Apr-16 26 F hTCR N 757 100
42 1400 Apr-16 26 F hTCR hCD28 N 2000 87.41
42 1400 Apr-16 26 F hTCR lCD28 N 1300 52.24
42 1400 Apr-16 26 F lTCR hCD28 N 1360 58.8
42 1400 Apr-16 26 F lTCR lCD28 N 790 31.06
42 1400 Apr-16 26 F resting N 340 0
43 1235 Apr-16 46 M hCD28 M 547 51.71
43 1235 Apr-16 46 M hTCR M 845 82.64
43 1235 Apr-16 46 M hTCR hCD28 M 530 28.84
43 1235 Apr-16 46 M hTCR lCD28 M 254 13.05
43 1235 Apr-16 46 M lTCR hCD28 M 236 13.97
43 1235 Apr-16 46 M lTCR lCD28 M 237 9.38
43 1235 Apr-16 46 M resting M 658 0
43 1235 Apr-16 46 M hCD28 N 225 38.65
43 1235 Apr-16 46 M hTCR N 487 87.71
43 1235 Apr-16 46 M hTCR hCD28 N 650 64.21
43 1235 Apr-16 46 M hTCR lCD28 N 285 26.09
43 1235 Apr-16 46 M lTCR hCD28 N 351 31.44
43 1235 Apr-16 46 M lTCR lCD28 N 180 17.49
43 1235 Apr-16 46 M resting N 401 0
2.2.4 T cell proliferation assay
Prior to stimulation with CHO-FcR cells and anti-CD3 or anti-CD28, naive and memory
T cells were labeled with CellTrace Violet dye (Life Technologies) according to the
manufacturer’s instructions. Five days following stimulation, T cell proliferation was
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analyzed by flow cytometry and proliferation was modeled using the Flowjo proliferation
platform. Total T cell numbers per sample were established relative to AccuCheck
counting beads (Invitrogen).
2.2.5 FACS markers validation
PBMCs were isolated from whole blood, as described above. Naive and memory CD4+
T cells were isolated by negative selection using human CD4+ T Cell Enrichment Kits
(EasySep™, STEMCELL Technologies). After six days of stimulation, as described above,
cells were observed by flow cytometry using two directly conjugated antibody panels
listed in Table 2.2 . Intracellular staining was done using the eBioscience FOXP3 staining
buffers.
Table 2.2: Panel of antibodies used in the validation of genes that were TCR or CD28 sensitive.
Panel 1 Panel 2
Epitope Fluorophore Epitope Fluorophore
CD25 (2A3) BV605 (BD) CD25 (2A3) BV605 (BD)
CD45RA (HI100) PerCP-Cy5.5 (eBioscienc) CD45RA (HI100) PerCP-Cy5.5 (eBioscienc)
CD69 (FN50) PE-Cy7 (BD) ICOS (DX29) BV711 (BD)
CD71 (M-A712) AF700 (BD) CD71 (M-A712) AF700 (BD)
CD40L (24-31) e450 (eBioscienc) OX40 (ACT35) PeCy7 (BD)
CTLA4 (BNI3) PE (BD) CD80 (L307.4) PE (BD)
CD28 (CD28.2) APC (eBioscienc) PDL1 (MIH1) FITC (BD)
CD27 (L128) BUV395 (BD)
2.2.6 RNA-seq
Naive and memory T cells were placed in 0.5 ml of Trizol (Invitrogen) and stored at
-80°C. Samples were thawed at 37°C before adding 100 µl chloroform. After reaching
equilibrium, samples were centrifuged for 15 minutes at 4°C at 10,000g. The collected
aqueous phase wasmixed 1:1 with 70% ethanol before proceeding withminElute columns
(Qiagen) for purification, according to the manufacturer’s protocol. RNA was quantified
using Bioanalyzer (Agilent Technologies, USA). The RNA was sequenced in two separate
batches. Libraries were prepared using Illumina TruSeq index tags and sequenced on
the Illumina HiSeq 2500 platform using V4 chemistry and standard 75 bp paired-end. The
first batch consisted of 56 samples that were multiplexed at equimolar concentrations
and sequenced across 14 lanes, to yield on average 71.3 million reads per sample. The
34 2 The role of co-stimulation in naive and memory T cells
second batch consisted of 18 samples that weremultiplexed at equimolar concentrations
and sequenced across 3 lanes to yield on average 61 million reads per sample.
2.2.7 RNA-seq data processing
Sequence reads were aligned to the GRCh38 human reference genome using STAR
(v2.5.0c) (Dobin et al., 2013) and the Ensembl reference transcriptome (v83). Gene counts
were estimated using featureCounts (v1.5.1) tools (Liao et al., 2014) from the subread
package and only reads assigned to the transcripts were used for further processing
(84-90% of reads were assigned).
To find genes that were upregulated upon stimulation, I first defined differentially
expressed genes using DESeq2 (v1.14.1) (Love et al., 2014) by performing pairwise compar-
ison of all conditions to the resting state, in a cell type specific manner, using Benjamini-
Hochberg controlled false detection range (FDR) ≤ 5% (Benjamini and Hochberg, 1995)
and an absolute fold-change ≥ 2. I then build a linear and a switch model of gene
expression using a likelihood ratio test (LRT) separately for naive and memory cells. In
the linear model, I assumed a linear increase of gene expression along with stimulus
intensity (incremental fold-change ≥ 1.5). Genes that did not follow the linear model
were tested for the switch model. Here, I assumed an “on-and-off” mode of expression,
where a gene is significantly upregulated (fold-change ≥ 2) in response to the presence
of either CD28 or TCR. In both of these models, I used all seven conditions, e.g. when
testing for CD28-sensitive genes I grouped the TCR alone stimulation with the resting,
since neither received CD28 signal. A gene was classified in one of the two categories
without overlap and prioritised for the linear model.
To control for the different batches in which I processed the blood, which accounted
for 12% of the observed variability, I performed batch correction prior to PCA using the
Combat algorithm from the sva package (Leek et al., 2012). To estimate the percentage
of the variance explained separately by each of the recorded variables, such as the
stimulus, the cell type, the gender of the donors, I fitted a linear model with only the
stimulus or the cell type as variables (method adapted from McCarthy et al., 2017).
I performed pathway enrichment analysis by testing whether different gene-sets were
over-represented in particular hallmark pathways (Liberzon et al., 2015). I used the
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Jaccard index to quantify the proportion of stimuli-specific genes present in a tested
pathway and assessed the statistical significance of the over-representation using a
permutation strategy. For that, within each cell type and condition, I randomly sampled
10,000 gene-sets of the same size as in the observed dataset, matching for the gene
length and expression levels.
2.2.8 ChIPmentation-seq (ChM-seq)
The ChM protocol was performed according to the protocol presented in Schmidl et al.,
2015 and adapted to work with the iDeal ChIP-seq Kit for Histones. After sorting the
cells were resuspended in pre-warmed full medium (IMDM, 10% FCS) at 1-2 million cells
per ml and allowed to recover in the incubator (37ºC, 5% CO2) for at least 30 minutes
The cells were then fixed by addition of formaldehyde to the medium to reach a final
concentration of 1% and were incubated for 5 minutes at 37ºC, followed by quenching
at room temperature with glycine for 5 minutes at a final concentration of 125 mM. The
cross-linked cells were subsequently washed twice with ice-cold PBS and snap-frozen
by immersion in liquid nitrogen.
Five hundred thousand crosslinked cells were washed using 250 µl IL1 buffer and resus-
pended in 250 µl IL2 lysis buffer, both of which contained 1X protease inhibitor cocktail
(PIC). Cells were left to lyse for 5 minutes at 4°C on a rotator and then centrifuged at 4°C
(3000g) for 5 minutes. The pellets were resuspended in 250 µl IS1 buffer and sonicated
using the Bioruptor®Pico (Diagenode) for 5 minutes for resting cells or 4 minutes for
stimulated cells (Diagenode). We kept a portion of the chromatin from two samples
aside, one naive and one memory stimulated with hTCR and hCD28, and used them as a
ChM-seq input.
The chromatin was immunoprecipitated using protein-A coated IP beads. Twenty mi-
croliters of beads were washed four times using 40 µl IC1 buffer on the magnetic rack
before being resuspended in 20 µl of IC1. The beads were mixed with 56 µl 5X IC1 buffer,
6 µl 50X BSA, 1.5 µl 200X PIC and 1 µg of H3K27ac (Cat. no. C15410196, Diagenode). We
added to the mix 100 µl of chromatin (equivalent to 200,000 cells) and incubated the
samples overnight at 4ºC at 10 rpm.
The beads were then washed on the magnet with 350 µl of iW1, iW2 and iW3 buffers and
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a final wash with 2X 1000 µl 10 mM Tris pH 8. The beads with the chromatin, as well as
the two input samples, were then resuspended in 29 µl ChM buffer (Tris pH 8 1M, MgCl2
1M, ChIP grade water) with 1 µl Tn5 and incubated for 10 minutes at 37ºC at 1500 rpm.
The tagmentation was stopped with the addition of 2X 350 µl iW3. Finally, the beads
were washed with 350 µl iW4. The chromatin from the beads was eluted using 96µl iE1
and incubated for 30 minutes at room temperature at 1500 rpm. The chromatin was
reverse cross-linked overnight using 4 µl of iE2 buffer. The DNA was then eluted in 30 µl
of water using the MinElute PCR CLeanup kit (QIAGEN). The DNA was the purified twice
using SPRI beads at 1.6x ratio using a Zephyr G3 SPE Workstation. The libraries were
amplified following the ATAC-seq library amplification protocol (Buenrostro et al., 2013),
but using NEBNext® High-Fidelity 2X PCR Master Mix (New England Biolabs). Eighteen
libraries were indexed and pooled in equimolar concentration and sequenced on three
lanes using the Illumina HiSeq 2500 platform and V4 chemistry using standard 75 bp
paired-end reads to yield on average 80 million reads per sample.
2.2.9 ATAC-seq
ATAC-seq was performed according to published protocol (Buenrostro et al., 2013), with
the following modifications. Fifty thousand cells were washed with 1 ml of ice-cold PBS.
The cells were then resuspended in the tagmentation buffer containing Tn5 transposase
(Illumina Nextera) and 0.01% digitonin and incubated for 30 minutes at 37ºC before
purifying the DNA using the MinElute PCR purification kit (QIAGEN). Sequencing libraries
were prepared using Nextera primers as described in the ATAC-seq protocol (Buenrostro
et al., 2013). Sixteen libraries were indexed and pooled in equimolar concentration and
sequenced on three lanes using the Illumina HiSeq 2500 platform and V4 chemistry using
standard 75 bp paired-end reads to yield on average 65 million reads per sample.
2.2.10 ChM and ATAC data processing
The quality of the sequence reads was assessed using the fastx toolkit and the adaptors
were trimmed using skewer (v0.2.2) (Jiang et al., 2014). Reads were mapped to the human
genome reference GRCh38 using the bwa mem algorithm (v0.7.9a) (Li and Durbin, 2009).
I only kept uniquely mapped reads, removed PCR duplicated reads and for the ATAC I
excluded mitochondrial reads using samtools (v0.1.9) (Li et al., 2009). I retained 83.3%
of ATAC and 73.8% of ChM reads. Genome browser tracks were created using BEDTools
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(v2.22.0) (Quinlan and Hall, 2010) and the UCSC binary utilities. Furthermore, I generated
insert size distributions using PICARD tools (v2.6.0) CollectInsertSizeMetrics function
which can be indicative of over-sonicated chromatin and excess of adapters in the data.
The mapped reads were converted into bed files and chimeras were removed. Peaks
were called using MACS2 (v2.1.1) (Zhang et al., 2008) setting the parameters to -q 0.05
–nomodel –extsize 200 –shift -100 for ATAC, and –broad –broad-cutoff 0.1 –nomodel
–extsize 146 for H3K27ac ChM. For ChM, all samples were downsampled to to the same
read number (21.6 million reads) prior to peak calling against the input.
I used the fraction of reads in peaks (FRiP), the proportion of peaks with signal value
(fold-change compared to the background or the input) greater than 10, the insert size
distribution and the genome tracks to investigate the quality of the data. The median
FRiP score was 59.2% for ATAC and 73.5% for H3K27ac ChM. The proportion of peaks with
fold-change > 10 was 22.9% for ATAC and 4.8% for H3K27ac ChM. I concluded that the
quality of the data was high. I merged all the ATAC samples and called peaks again
using the parameters described above. For the H3K27ac ChM samples, I first merged
the donors within each cell type and condition and then randomly sampled 17 million
reads from each into one sample to reach the same read number as in the input. Since
I merged already QCed samples I used the –keep-dup flag when calling peaks with
MACS2, as the PCR duplicated reads for individual samples were already removed and
I expected to observe a small proportion of the same reads present in independent
samples by chance. I also increased the -q value threshold to 0.1 for both assays. The
resulting peak files were used as a reference to count the number of reads falling into
peak regions using featureCounts (Liao et al., 2014), therefore generating a quantitative
table of read counts specifically present across the different conditions and cell types.
To ensure the analysis focused on high confidence peaks I removed the bottom 10th
percentile of peaks with the lowest read counts in each dataset and obtained a final
count of 142,306 and 49,638 peaks for ATAC and ChM, accordingly. To define differentially
accessible regions (DARs) and differentially modified histone regions (DMHRs) the
dataset was processed using DESeq2. To find regions that were upregulated upon
stimulation, I compared all conditions to the resting state and used Benjamini-Hochberg
controlled FDR of 5% and an absolute fold-change ≥ 2.
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2.2.11 Binding expression target analysis
To identify regions of the genome that changed upon stimulation, which could subse-
quently regulate gene expression, I used Binding Expression Target Analysis (BETA) in
the plus mode (Wang et al., 2013b). I performed the analysis using both DMHRs and DARs,
as well as the list of regions that required one or the other stimulus. For example, TCR
specific DMHRs or DARs were defined as the regions that are present in TCR stimulation
but not in CD28 stimulation. I used the differential gene expression output from the
pairwise comparison between stimulated and resting states. The median distance of
interaction between an enhancer and gene promoter is estimated at 150 kbp (Mumbach
et al., 2017). I therefore used the same window size around the transcription start site
(TSS) of the differentially expressed genes to define boundaries for the analysis, along
with the transcription activation domains (TADs) identified in CD4+ T cells (Javierre et al.,
2016). That is, if the extended 150 kbp region fell beyond the TAD boundary I consid-
ered the TAD coordinates as the boundary for testing predictive effects of DMHRs and
DARs on gene expression. I relied on the ATAC-seq output for the transcription factor
enrichment analysis (p-value ≤ 0.01) as it generates narrow peaks allowing for a more
accurate estimation of the transcription factor binding sites (TFBS). I used the JASPAR
database of transcription factors and the Cistrome method to calculate transcription
factor enrichment (p-value ≤ 0.05).
2.2.12 Disease SNP enrichment for stimulus-sensitive genes
I collected the GWAS data for Crohn’s disease (CD), ulcerative colitis (UC; Jostins et al.,
2012), coeliac disease (CEL; Trynka et al., 2011), multiple sclerosis (MS; International Mul-
tiple Sclerosis Genetics Consortium (IMSGC) et al., 2013), rheumatoid arthritis (RA; Okada
et al., 2014), psoriasis (PSO; Tsoi et al., 2012), systemic sclerosis (SSc; Bossini-Castillo
et al., 2015) and type-1 diabetes (T1D; Onengut-Gumuscu et al., 2015). Additionally, I
used Bone mineral density (BMD) as a control trait by searching in the GWAS catalog for
"Bone Mineral Density". I excluded all variants that fell within the MHC locus and using
a genome wide p-value threshold of < 5x10-8. I defined the disease loci by mapping
all the single nucleotide polymorphisms (SNPs) in linkage disequilibrium (LD) with the
reported index SNP, using R2 > 0.8 calculated across the European populations present
in the 1000 Genomes Project data, and extending the LD boundaries by 150 kbp on
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each side, to account for the possibility of distant gene expression regulation between
enhancers and gene promoters. This resulted in 234 unique regions associated to one
of the 8 tested traits.
I tested whether the stimulus sensitive genes fell within the SNP loci boundaries more
often than expected by chance using a permutation strategy. To build the null distribu-
tion I selected the same number of genes, matching for gene size and mean expression
level. I repeated the process 10,000 times.
Finally, I examined whether any of the SNPs used to define the LD boundaries over-
lapped with an H3K27ac or an ATAC peak identified in the specific stimulatory condition;
CD28 alone stimulation for CD28 sensitive genes and TCR alone stimulation for TCR
sensitive genes. The disruption of TFBS by SNPs was assessed using the SNP2TFBS
database (Kumar et al., 2017).
2.3 Results
2.3.1 Experimental approach
To study the influence of varying TCR and CD28 signals I sorted human blood CD4+
CD25- T cells and stimulated them with high (referred to as h) or low (referred to as l)
concentrations of soluble anti-CD3 (referred to as TCR) and cells expressing the CD28
ligand, CD86 (referred to as CD28) (Figure 2.1 A). As previously described (Manzotti
et al., 2006), Chinese hamster ovary (CHO)-CD86 cells provide a source of natural CD28
ligand in an otherwise irrelevant cell background. In this way CD28 engagement was
mediated via the the CD86 ligand, which has been documented to be the main ligand
driving T cell responses (Borriello et al., 1997). In order to deconvolute gene expression
programmes controlled individually by TCR and CD28, I also stimulated T cells with
either anti-CD3 (an antibody against the signalling component of the TCR complex) or
anti-CD28 antibodies alone, in the presence of CHO cells expressing Fc-gamma Receptor
II (CHO-FcR) to provide crosslinking. Since I used CHO cells expressing CD86 to provide
CD28 signal, individual antibodies were also crosslinked on CHO cells to account for
any CHO cell effects. Following a 16 hours stimulation, I sorted activated CD25+ cells
into naive (CD45RA+) and memory (CD45RA-) subsets. I used CD25 as an early marker of
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T cell activation, since cells had been depleted of regulatory T cells. To understand the
differences in naive and memory sensitivity to TCR and CD28, I profiled gene expression
with RNA-seq, chromatin accessibility with ATAC-seq and active enhancers and promoters
with H3K27ac ChIPmentation-seq. As expected, across different stimulatory conditions
I observed a variable proportion of activated T cells (11-78% of all cells) (Table 2.1 ).
However, by sorting only activated T cells I ensured that the measured gene expression
reflected cell activation state induced by different signal intensities, while not being
confounded by the variable percentage of cells that had undergone activation. As a
control, cells were cultured in the presence of fixed CHO cells expressing FcR in the
absence of stimulating antibodies. In this condition cells were not activated and were
sorted for low CD25 expression, henceforth they are referred to as resting T cells.
2.3.2 Naive and memory cells have cell type specific signatures
I first applied principal component analysis (PCA) to the RNA-seq data and observed
that PC1 reflected cell stimulation while PC2 corresponded to cell type (Figure 2.1 B).
Indeed, the majority of the gene expression variance was explained by the stimulation
(47%) and by the cell type (10%) (Figure 2.1 C). The separation of naive and memory
T cells by PC2 indicated clear differences in transcriptional responses between them.
Furthermore, the different conditions clustered together, capturing the gradient of
stimulation intensity in both cell types, with high levels of the combination of TCR with
CD28 (hTCR hCD28) stimuli being the furthest separated from unstimulated cells on
PC1 and intermediate intensity of stimuli mapping in between. Surprisingly, strong
CD28 alone (hCD28) was amongst the lower responding conditions in naive cells yet it
clustered with the more highly stimulated conditions in memory cells. Furthermore,
naive cells stimulated with strong CD28 alone clustered towards the memory cells along
PC2. Thus, the transcriptional program of cell activation is modulated by the intensity of
TCR and CD28 signals, and CD28 stimulation enriches for the characteristics of memory
T cells.
To confirm that I had successfully sorted naive andmemory cells I performed differential
gene expression analysis in the resting cells (fold-change ≥ 2 and false discovery rate
(FDR) ≤ 0.05) (Figure 2.2 A). The 289 genes upregulated in memory cells included genes








































































































































Figure 2.1: Overview of study design and RNA-seq data. A. Overview of the study design. CD4+
T cells were isolated from eight healthy individuals and cultured in six different
stimulatory conditions, which included variable concentrations of anti-CD3 and anti-
CD28 stimuli. In parallel, resting cells were cultured as a control. To ensure I mea-
sured cellular response to successful stimulation, I generated sequencing data from
sorted activated naive and memory cells identified as CD4+CD25+CD45RAhigh and
CD4+CD25+CD45RAlow, respectively. B. Principal component analysis using the ex-
pression of all genes. The first two components explain collectively 53.7% of the
observed variability and correlate with stimulation strength and cell type. Each dot
corresponds to an individual sample, colored by stimulation and shaped according
to the cell type. C. The percentage of the total variance that can be explained by
stimulation and cell type.
GPR1, cell adhesion molecules such as CD58 (LFA-3) and B1 integrins), intracellular
signalling (phosphatases, calcium signalling molecules, e.g. SYT11, ITPRIPL1, and kinases,
e.g. CDKN1A), memory T cell survival and homeostasis (cytokine receptors (e.g. IL1R1,
IL2RB, IL12RB2 and IL18RAP), lectins and FAS) and transcription factors affecting T cell
differentiation (e.g. MAF, TBX21, RORC, BHLHE40 and PRDM1). PECAM1 (CD31), a well known
marker of a subset of naive T cells (Kimmig et al., 2002), was among the 33 observed
genes upregulated in naive cells. Thus, the differential gene expression profile validated
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my initial cell selection approach revealing clear and expected differences between
naive and memory populations. The majority of the identified genes have already been
documented to be differentially expressed between naive and memory cells, however, I
also observed several genes that have not been reported before, including STOM, AIM2
and THBS1 in memory cells, and FLT1 (VEGFR1) and GNAI1 expressed at a higher level in
naive cells. Recently, it has been suggested that THBS1 interaction with CD47 receptors
determines regulatory T cells and long-lived memory T cells (Grimbert et al., 2006; Van
et al., 2012). Importantly, I did not observe significant differences in gene expression
variance between naive and memory cells across the eight donors (Wilcoxon rank
sum test p-value = 0.48), indicating that the identified differentially expressed genes
were not driven by individual samples and reflected consistent biological differences
(Figure 2.2 B).
2.3.3 Naive and memory T cells operate different gene expression
programmes upon activation
To understand cell type specific responses induced by the different stimuli, I compared
gene expression profiles between resting and stimulated naive and memory T cells
(false discovery rate (FDR) ≤ 0.05 and fold-change ≥ 2; Figure 2.3 A). As expected, the
majority of upregulated genes was shared between the two cell types, however, naive
cells displayed a larger number of differentially upregulated genes (DEGs) (mean: 1,240
genes) than memory cells (mean: 840 genes), with the exception of CD28 stimulation
alone, where more genes were upregulated in memory cells. This likely reflects the
greater changes in gene expression levels resulting from transitioning to activation
from a deeper quiescent state in naive cells. Indeed, differential expression analysis
between naive and memory cells in the resting state revealed a larger number of genes
expressed highly in memory cells compared to naive.
When looking globally at the whole genome maps of H3K27ac and chromatin accessible
regions (ATAC-seq), memory cells were characterised by more peaks in the resting state
in both ATAC-seq (17.5% more peaks) and H3K27ac ChM-seq (10.6% more peaks). In
order to gain a better understanding of the dynamic responses upon stimulation, I
performed the same comparisons as with the RNA-seq data. At the mRNA level I ob-
served 35% of the genes to be differentially expressed upon stimulation, however the
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Figure 2.2: Differential gene expression analysis between resting naive and memory CD4+ T
cells. A. Volcano plot of differential gene expression test between resting naive
cells and resting memory cells. Genes colored in blue correspond to differentially
expressed genes with log2 fold-change ≥ 1 and FDR ≤ 5%. Labelled are DEG with
the lowest p-values. B. Wilcoxon rank sum test between the variance observed in
memory and naive cells in the resting state.
chromatin regulatory landscape showed far fewer changes; only 8% of the chromatin
changed in accessibility and 9% of the regions changed in histone acetylation. This
is probably due to the fact that the majority of these genes are already expressed at
low levels, which would be reflected by chromatin being already open and enhancers
being marked by H3K27ac acetylation. Furthermore, similarly to the differential gene
expression, the majority of differential histone modified regions (DMHRs; 54%) and
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differentially accessible regions (DARs; 58%) were shared across responses to TCR, CD28,
or both. However, as with the gene expression analysis, I observed a larger proportion of
acetylation changes driven by CD28 alone in memory compared to naive cells (Fisher’s
exact test p-value RNA = 4.9x10-11; H3K27ac < 2.2x10-16), indicating that CD28, in line with
my observations for the RNA, is also more potent in inducing chromatin changes in
memory T cells. Conversely, in response to strong TCR stimulation alone, I detected a
larger proportion of differentially acetylated H3K27 regions and chromatin accessible
sites in naive cells compared to memory cells (Fisher’s exact test p-value RNA < 2.2x10-16;
H3K27ac < 2.2x10-16; ATAC < 2.2x10-16; Figure 2.3 B). As such, the observed high number of
stimulus-specific differentially regulated regions suggests that there are unique chro-
matin remodelling changes acquired in both a cell type and stimulus-specific context.
Given the observation that TCR and CD28 induced a different number of changes in chro-
matin accessibility and histone modifications, I next assessed if there was a difference
in the proportion of these chromatin activity changes that were also predictive of the
observed differential gene expression (Wang et al., 2013b). I found that DARs and DMHRs
were predictive of a large proportion of upregulated genes (mean 46.5%; Figure 2.4 A).
Although, globally, TCR induced more changes in chromatin activity, the percentage of
gene upregulation predicted by DMHRs and DARs was similar between TCR and CD28
(Figure 2.4 B). I observed that the majority of genes for which I had assigned predictive
differentially regulated regions included peaks differentially regulated upon a specific
stimulus (naive TCR 82.3%; memory TCR 70.6%; naive CD28 62.23%; memory CD28 50.2%).
This indicates that each stimulus uniquely contributes to the gene regulatory landscape
of a cell.
Whilst the majority of the genes were assigned a single differentially regulated re-
gion, a set of 69 genes displayed dramatic alterations in multiple regions of chromatin
accessibility and histone modifications in response to one stimulus, indicating that
they are highly sensitive to a particular signal (Figure 2.4 C). Among the genes with the
highest number of differentially regulated regions (>10 regions) were IRF4, DUSP5, IRF8,
TNIP3 and CD28, all strongly modified by TCR alone. IRF4 protein abundance increases
alongside TCR signal intensity increase, as it does at the RNA level, and programs the
expansion of high-affinity T cell clones (Man et al., 2013). Other genes are known to be
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Figure 2.3: Pairwise comparison between resting and stimulated states. A. Number of upreg-
ulated genes upon stimulation defined from differential expression test between
stimulated and resting cells (pairwise), with fold-change≥ 2 and FDR≤ 5%. B. Percent-
age barplot of differentially expressed genes (DEG), differentially accessible regions
(DARs) and differentially histone modified regions (DHMRs) upon stimulation with
both stimuli, strong TCR alone or strong CD28 alone. The percentage was calculated
based on the total number of DEGs, DARs and DHMRs. Written inside the barplot is
the corresponding number. The coloring corresponds to the overlap between the
three stimulatory conditions.
occurs are unknown. For example it has been demonstrated that DUSP5-transgenic mice
have impaired thymocyte positive selection by inhibiting ERK activation (Kovanen et al.,
2008). Finally, for some of these genes it is the first time that a relationship between
their levels and TCR has been suggested, such as IRF8. In comparison, the genes induced
by strong CD28 alone revealed a smaller number of differentially regulated regions (>5
regions) but included interferon inducible chemokines CXCL9/CXCL10/CXCL11 as well as
the IL13/IL5 locus, which encodes for classical Th2 cytokines. While hyperacetylation of
the IL5 locus in response to co-stimulation, and the overall effect of CD28 in Th2 cell fate
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had been documented (Avni et al., 2002), it is the first time that a similar effect has been
observed in the CXCL locus. Therefore, despite the small percentage of regions changing
upon activation, there is a subset of loci that undergo large chromatin configuration
























































































































Figure 2.4: Integration across assays of pairwise comparison between resting and stimulated
states. A. Proportion of differentially expressed genes that have at least one differ-
entially regulated region nearby (< 150 kbp) as detected by ATAC-seq and ChM-seq
on H3K27ac. The analysis was repeated using only the stimulus specific peaks. B.
Proportion of differential accessible regions (DARs) and differentially modified his-
tone regions (DMHRs) that regulate at least one differentially expressed gene (< 150
kbp away from TSS). C. Number or predictive DARs and DHMRs discovered per genes.
Marked are the genes with the highest number of predictive regulatory elements.
Among the genes with predictive chromatin changes I identified a 26.4 kbp region that
overlapped with the transcription start site (TSS) of TBX21, the gene that encodes for
T-bet transcription factor. The acetylation changes were specific to naive cells and
shared across all three stimuli (Figure 2.5 A). This revealed an increase in H3K27ac that
was driven by both TCR and CD28 while memory cells already displayed some acetylated
regions even in the resting state. In contrast, an example of a DAR detected in naive cells
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Figure 2.5: Examples of a gene expression predictive DHMRs and DARs. For the purposes of
plotting the two donors for each assay were combined and averaged A. A predictive
DHMR in naive cells that is a stimulation shared response (shared between hTCR
hCD28, hTCR alone and hCD28 alone) in the transcription start site (TSS) of TBX21,
the gene that encodes for T-bet. B. A DAR in naive cells that requires both hTCR and
hCD28 in proximity to the promoter of CD86. C. Four DARs in naive cells that require
TCR around the CD28 gene. D. A DAR in naive cells that requires CD28 in the promoters
of CXCL10 gene. E. Gene expression profiles for the four genes examined above in
four of the seven conditions.
that required both TCR and CD28 signals spanned 1 kbp and was located in proximity to
the promoter of the CD86 co-stimulatory molecule (Figure 2.5 B). Notably, this region
was strongly co-stimulation dependent in naïve cells, but had a more relaxed response
to stimulation in memory cells, where TCR, CD28 or both could trigger an opening in
chromatin. The CD28 gene had four DARs around its TSS and within its introns, and the
chromatin accessibility change appeared contingent on the presence of TCR specifically
in naïve cells (Figure 2.5 C). Lastly, an example of a DAR that required CD28 spanned
560 bp and localised on the TSS of CXCL10 gene (Figure 2.5 D). Here, CD28 alone in
memory cells and CD28 alone or as a co-stimulus in naive cells induced chromatin
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changes, whereas TCR alone did not have an effect. All of these genes (Figure 2.5 E) are
examples that showcase the stimulus-specific predictability of histone modifications
and chromatin accessibility.
Finally, I investigated the expression and regulation of IL2, a gene that has been widely
demonstrated to be co-stimulation dependent in memory cells (Ndejembi et al., 2006).
IL2 gene expression was upregulated in all but memory cells stimulated with low doses
of CD28 and TCR (Figure 2.6 A). The biggest upregulation was observed in response to
a combination of the two stimuli in high dose in both cell types, and in response to
hCD28 only in memory cells. There were four chromatin accessible regions detected
by ATAC-seq near the IL2 gene, all of which were more open in memory compared to
naive cells (Figure 2.6 B). Similarly, the H3K27ac profile around the gene highlighted
greater activity levels in memory compared to naive cells. Interestingly, in memory cells
both the chromatin activity and the accessibility decrease upon stimulation, despite
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Figure 2.6: Gene expression and chromatin regulation of IL2. A. IL2 gene expression per condi-
tion. B. ATAC-seq and H3K27ac ChM-seq profiles in the chr4:122448000-122461000
region surrounding the IL2 gene. The read counts of two donors for each assay were
combined and averaged for plotting purposes.
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2.3.4 T cell effector functions are predominantly controlled by CD28
Based on the above observations I sought to better understand the role of each stim-
ulatory signal in gene upregulation in the two cell types. To classify genes as either
CD28 or TCR-sensitive, I used two models (linear and switch modes) of gene expression
where the linear model reflects changes in stimulation intensity whereas the switch
model reflects a digital on/off state (Figure 2.7 A). In both cell types together, I was able
to assign a unique stimulus sensitivity to 1,567 genes, meaning that the expression of
these genes was either sensitive to TCR or CD28 intensity. I observed that the majority
of stimulus-sensitive genes (88%) followed the linear model (Figure 2.7 B).
I next assessed if naive and memory cells differed in sensitivity to the two stimuli. I
observed that most of the stimulus-sensitive genes in naive T cells were TCR-sensitive
(1,057; Figure 2.7 C), whereas a smaller number of genes was CD28-sensitive (n=363).
However, a larger number of genes was CD28-sensitive (n=351) than TCR-sensitive (n=299)
in memory cells. As such, a both TCR and CD28 sensitive genes were unevenly distributed
between the two cell types, with a shift towards naive cells for TCR genes (Fisher’s exact
test p-value < 2.2x10-16) and a shift towards memory cells for CD28 genes (Fisher’s exact
test p-value < 2.14x10-5). Based on the pairwise comparisons across the six conditions
against the resting state, I defined a group of genes that was upregulated upon stimula-
tion. Of these, I observed that the expression of 1,228 genes in naive cells (55%) and only
490 genes in memory cells (29%) was sensitive to a single stimulus (Figure 2.7 D). This
indicated that the majority of the upregulated genes in memory cells either responded
to both stimuli (i.e. TCR or CD28 were both capable of driving the response) or they
were truly CD28 co-stimulation dependent, requiring TCR and CD28 together.
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Figure 2.7: Models of gene expression upregulation alongside stimulus intensity increase. A.
Classification of genes as CD28- or TCR-sensitive using different models of gene
expression. In the linear model, I required a linear increase of gene expression along
with stimulus intensity (incremental gene expression fold-change ≥ 1.5), separately
evaluating naive and memory cells. Genes that did not follow the linear model were
tested for the switch model. Here, I assumed an “on-and-off” mode of expression
where a gene is significantly upregulated (fold-change ≥ 2) in response to the pres-
ence of either CD28 or TCR. In both of these models, I used all seven conditions, e.g.
when testing for CD28-sensitive genes I grouped the TCR alone stimulation with the
resting, since neither received a CD28 signal. A gene was classified in one of the two
categories without overlap and prioritised for the linear model. B. Number of TCR
and CD28 sensitive genes identified by the linear and the switch model in the two
cell types. C. Comparison of the number of genes in naive and in memory cells under
TCR or CD28 control. D. Number of upregulated genes upon stimulation. The colour
represents different stimulatory dependencies. Grey indicates a small number of
peaks that were only shared between hTCR alone and hCD28 alone stimulations.
Since the majority of human T cell stimulation experiments use both TCR and CD28 to
activate cells, it is unclear which cell functions are controlled by TCR and which by CD28,
and how they differ between naive and memory cells. Using this approach, I found
that many classical T cell activation markers such as EGR2, EGR3 and CTLA4 were TCR-
sensitive in both cell types, while TNFRSF8 and CD69 were TCR-sensitive in naive cells
only (Figure 2.8 A), possibly explained by the fact that they were already expressed at
high levels in resting memory cells (resting memory and naive cells TNFRSF8 log2FC = 1.19
and CD69 log2FC = 1) and thus not detected as differentially expressed upon stimulation
of memory cells. In contrast, I found that the majority of cytokines and chemokines
were CD28-sensitive (Figure 2.8 B and C). Among the chemokines, I observed that CXCL9,
CXCL10, CXCL11 and the CCL25 CC chemokine were CD28-sensitive in both cell types. The
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expression of cytokines essential for the differentiation of the major Th subsets were
also under CD28 control, including IFNG (Th1), IL4 and IL13 (Th2) and IL17A, IL17F and IL22
(Th17). In addition, I observed that the expression of the Treg transcription factor, FOXP3,
was also CD28-sensitive. Taken together, these results demonstrate that a number
of pathways associated with the effector functions of CD4+ T cells are predominantly
controlled by the CD28 pathway in both naive and memory cells.
Different co-stimulatory and co-inhibitory receptors along with their ligands function
at different stages of the T cell activation timeline, which might explain a different
requirement on TCR or CD28 for their expression (Chen and Flies, 2013). I therefore
investigated the control of expression of co-stimulatory ligands and receptors, since
they play a key role in T cell activation (Figure 2.8 D). The expression of CD28 itself was
only upregulated upon strong TCR stimulation alone, suggesting that TCR signalling
makes cells more receptive to CD28 engagement. However, the presence of CD28
stimulus impeded an increase in its expression, highlighting that this is not a self-
reinforcing process. Other co-stimulatory receptors involved in the co-regulation of T
cells were CD28-sensitive, in both naive and memory T cells. These included, CD27-CD70
co-stimulatory pair and CD274 (PD-L1). On the other hand, CD80 and ICOS were CD28-
sensitive specifically in memory cells. Thus, I was able to detect different modes of
regulation for CD28, CTLA4 and ICOS, despite the fact that they are all encoded within the
same 260 kbp locus. This implies complex mechanisms of gene expression regulation
in the two cell types and a fine-tuned control highlighting that co-located genes can be
regulated by different modes of stimulation.
In order to confirm whether the observed linear changes at the RNA level were also
observed at the protein level, I stimulated naive and memory cells using the same
stimulation conditions and carried out flow cytometry analysis six days post-stimulation.
I used two antibody panels; one containing selected antibodies for genes that had been
determined to be TCR sensitive (CD25, CD28, CD40L, CD69 and CTLA4), and one with
antibodies for genes that were found to be CD28 sensitive (CD25, CD27, CD80, ICOS, OX40
and PD-L1). I was able to replicate the linear relationship for all of the TCR sensitive
genes in both cell types (Figure 2.8 E). On the other hand, I was not able to demonstrate
a linear relationship at the protein level between any of the selected CD28 sensitive
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genes. This suggested that CD28 sensitive genes might be subject to more complex
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Figure 2.8: Examples of TCR and CD28 sensitive genes in naive andmemory cells. A+B. Selected
examples of TCR- or CD28-sensitive genes. The x-axis corresponds (A) to the level of
TCR (anti-CD3 antibody in µg/ml) or (B) to the level of CD28 (proportion of T cells to
CHO-CD86 cells) and the y-axis corresponds to the log2 counts of gene expression.
Labels next to the gene name indicate the cell type in which stimulus sensitivity is
observed. C. Cytokines and chemokines, and D. co-stimulatory ligands and receptors
that are expressed in the dataset. Colouring represents the log2 fold change of gene
expression E. Selected examples of protein levels for genes that were found to be
TCR or CD28 sensitive by flow cytometry.
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2.3.5 DNA replication and proliferation are driven by different stimuli in naive
and memory T cells
To characterise whether genes sensitive to CD28 or TCR regulate the same cellular
processes in naive and memory T cells I tested if these genes were over-represented
in hallmark functional pathways (Liberzon et al., 2015) (Figure 2.9 A). I observed seven
shared pathways enriched in both cell types. For example, IL2 signalling through STAT5
and TNF-α signalling via NF-κB was significantly enriched in both naive and memory
cells and sensitive to both TCR and CD28. However, the expression of the majority of
genes broadly classified as immune cell pathways, such as IL6 signalling through the
Jak/Stat3 and interferon α and γ response, were CD28-sensitive in both cell types. In
contrast, genes that are targets of Myc and E2F transcription factors were controlled by
TCR in naive cells, which is concordant with MYC and E2F6 genes being TCR-sensitive as
well as with previous studies in mice (Allison et al., 2016).
Interestingly, I observed that some pathways were differentially sensitive to TCR and
CD28 in the two cell types. Most notably, the G2M checkpoint, which marks DNA replica-
tion and cell division, was CD28-sensitive in memory cells but TCR-sensitive in naive
cells, suggesting that commitment to cell division is more dependent on TCR in naive
cells but driven by CD28 in memory cells. To functionally test this observation I stimu-
lated CellTrace Violet (CTV) labelled naive and memory T cells with either anti-CD3 or
anti-CD28 crosslinked by CHO cells expressing FcR (Figure 2.9 B). Five days following stim-
ulation, T cell division was measured by flow cytometry. In accordance with the results
from gene expression, naive T cells proliferated extensively following TCR crosslinking
but mounted poor responses to CD28. In contrast, cross-linking CD28 was sufficient to
induce division in memory cells whereas TCR stimulation was clearly much less effective.
Thus, although combined TCR and CD28 co-stimulation is generally utilised to trigger T
cell proliferation, this data indicates a division of labour between these stimuli where
control of cell cycle in naive cells is generally TCR-sensitive, whilst in memory cells it is
more dependent on CD28.
I noticed three genes (CDC6, CDC20 and CHEK1) driving the enrichment of the G2M path-
way, which were TCR sensitive in naive cells but switched to CD28 sensitivity in memory
cells. I therefore sought to identify if there were more “switching” genes present in
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the dataset, i.e. genes sensitive to the different stimuli between the two cell types.
I identified a group of 18 genes that were TCR-sensitive in naive cells and changed
to CD28 sensitivity in memory cells. Among others, I identified transferrin receptor
TFRC (CD71) and DNA replication initiation factor MCM10 (Figure 2.9 C and Table 2.3 ).
Together these data highlight the enrichment of cell cycle/DNA replication pathway as
targets for CD28 in memory T cells which, in contrast, are controlled by TCR in naive cells.
Table 2.3: List of switcher genes. N: Naive cell; M: Memory cell
Gene LOG2FC M CD28 FDR M CD28 LOG2FC N TCR FDR N TCR
TRNP1 0.635 9.08x10-5 0.627 2.06x10-3
CDC20 0.636 1.56x10-4 0.88 2.03x10-9
AK4 0.756 0.0351 1.407 7.36x10-6
DTL 1.153 8.09x10-8 0.807 1.32x10-3
MTHFD2 1.149 0.0134 0.923 1.04x10-4
CCL20 1.075 3.34x10-4 0.971 1.87x10-3
TFRC 0.691 2.47x10-4 0.91 5.16x10-8
STC2 3.051 2.85x10-3 1.534 4.81x10-4
EPB41L4B 0.771 7.18x10-4 0.968 3.82x10-4
TXN 0.68 2.69x10-4 0.683 1.86x10-4
MCM10 1.173 1.62x10-8 1.107 2.83x10-5
DNAJC12 1.011 2.18x10-3 1.015 3.72x10-5
DGAT2 1.07 5.53x10-3 0.75 2.99x10-6
CHEK1 0.727 2.31x10-9 0.603 1.57x10-8
NETO2 0.807 1.45x10-4 1.355 1.59x10-5
NLN 0.635 6.08x10-3 0.919 5.06x10-6
CDC6 0.658 1.74x10-4 0.734 4.65x10-7

































































































Figure 2.9: TCR and CD28 sensitive genes enrichment across hallmark gene pathways high-
lights different stimulus sensitivity in naive and memory cells. A. Measure of simi-
larity between the genes that are TCR-sensitive or CD28-sensitive and a selection
of the 50 hallmark gene-sets. The similarity coefficient was calculated using the
Jaccard index and I used a permutation strategy to assess the likelihood of this being
observed by chance (p-value < 0.05). B. Number of proliferating cells and mean
division cycle upon TCR or CD28 stimulation separately for naive and memory cells.
C. Switcher genes examples that play a role in cell cycle.
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2.3.6 AP1 initiated transcriptional cascade is co-stimulation dependent in
memory cells
To understand how TCR and CD28 stimuli exert effects on gene expression I tested for
enrichment of transcription factor binding sites (TFBSs) in DARs identified by ATAC-seq
that were concordant with gene expression (Figure 2.10 A). I tested 242 transcription
factors with detectable levels of gene expression in the dataset.
I identified 5 different motifs enriched in naive cells and 20 motifs in memory cells
(p-value ≤ 0.01). In naive T cells I observed an enrichment for Blimp-1, a transcrip-
tional repressor that maintains T cell homeostasis (Martins et al., 2006), combined with
interferon response elements, IRF2, IRF3 and IRF8. Increases in TCR signalling have
been shown to induce the IRF4 transcription factor, which mediates Blimp-1 abundance
in mice (Man et al., 2013). As expected, the enrichment was driven by TCR, with little
enhancement in response to CD28 co-stimulation. Blimp-1 and the identified IRFs recog-
nize a similar motif (Figure 2.10 B), and antagonize each others binding in vitro (Doody
et al., 2010).
In memory T cells I observed that the profile driven by TCR was similar to naive cells,
consisting of a combination of Blimp-1 with interferon response elements. However,
in marked contrast, a more robust response was observed in the presence of CD28
co-stimulation. Notably, this was characterised by the enrichment of AP1 transcrip-
tion factors (Figure 2.10 A). Specifically, only IRF4, JunD and BATF transcription factor
binding sites co-occurred in regions that changed in response to strong TCR alone,
whereas c-Fos, FOSL1, c-jun, jun-B and JDP2 all required the presence of CD28. C-jun
and c-Fos constitute the backbone of AP1, a transcription factor that plays an important
role in the induction of the immune response. Thus my observations are consistent
with previous work which suggested that CD28 regulates the expression and activity
of AP1 transcription factors (Shapiro et al., 1997; Fraser et al., 1991; Edmead et al., 1996).
Interestingly, BATF and c-jun transcription factors can also form a heterodimer and
cooperate with IRF4 and recognise AP1–IRF composite elements (AICEs) in pre-activated
CD4+ T cells (Figure 2.10 B) (Li et al., 2012). These transcription factors play a crucial role











































































































Figure 2.10: Transcription factor enrichment in TCR, CD28 and TCR+CD28 induced peaks. A. Tran-
scription factor binding sites (TFBS) enriched in the differentially regulated ATAC-seq
peaks that were assigned to predict gene expression changes. B. Position weight
matrices (PWMs) for the enriched TFBS motifs.
2.3.7 Immune GWAS loci are enriched for CD28 sensitive genes
The role of T cell activation in the development of immune-mediated diseases is well
established and single nucleotide polymorphisms (SNPs) nearby genes relevant to T cell
activation, differentiation and trafficking have been implicated in autoimmune diseases
through GWAS (Trynka et al., 2013; Farh et al., 2015; Hu et al., 2014; Okada et al., 2014).
Therefore, I sought to investigate if immune disease associated loci were enriched for
the genes identified as TCR or CD28-sensitive, thereby implicating the involvement of
these stimulatory pathways in disease pathogenesis.
In the enrichment analysis I tested eight immune-mediated conditions, Crohn’s disease
(CD), ulcerative colitis (UC), celiac disease (CEL), rheumatoid arthritis (RA), type-1 dia-
betes (T1D), systemic sclerosis (SSc), multiple sclerosis (MS) and psoriasis (PSO). I used
bone mineral density (BMD) as a negative control as I would not expect to observe sig-
nificant enrichment among BMD loci. The majority of the tested immune diseases were
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more strongly enriched (permuted p-value < 0.01) for CD28-sensitive than TCR-sensitive
genes. An exception was T1D where genes sensitive to TCR showed a higher enrichment
(Figure 2.11 A). In addition, I observed that TCR-sensitive genes were enriched in CEL loci
in both cell types (permuted p-value < 0.0097) and in RA (permuted p-value = 0.0096)
and MS (permuted p-value = 0.0054) specifically in memory cells. Taken together, this
suggests that the variants associated with common immune-mediated diseases could
regulate the expression of genes sensitive to CD28 and through this pathway modulate
the outcome of T cell activation.
The majority of immune disease associated genetic variants fall in the non-coding
regions of the genome and previous studies showed that disease associated variants
are enriched in regions highlighting active enhancers (Trynka et al., 2013; Trynka et al.,
2015). I therefore investigated if disease SNPs map within active or open chromatin
regions as defined by H3K27ac or ATAC peaks near the genes driving the enrichment.
Given that the majority of peaks were shared between the cell types and stimuli, these
chromatin marks were uninformative in discriminating if disease SNPs were more sig-
nificantly enriched in specific conditions. However, I observed that, on average across
traits, 73% of the genes driving the enrichment also had at least one disease associated
variant overlapping an active promoter or enhancer, identified based on the presence
of H3K27ac. Among the GWAS loci with the highest number of SNPs falling in regulatory
regions I identified a single locus that contributed to the enrichment observed for CD28
sensitive genes in both cell types for CEL, CD, UC and RA. The locus overlaps with STAT1
and MYO1B. STAT1 encodes for a transcription factor that responds to IFN-γ signalling
and plays an important role in cell survival upon a pathogenic attack (Krause et al.,
2006). In contrast, the TCR-sensitive CTLA4 gene fell within a GWAS locus with the highest
number of SNPs falling in regulatory regions in both cell types, and contributing to the
enrichment observed in CEl, T1D and RA.
I then tested whether any of these SNPs disrupted a TFBS, limiting the analysis to the TFs
that had previously been identified as enriched. I found 13 unique SNPs that disrupted a
binding motif (Table 2.4 ). Two SNPs, associated with MS and in high LD with the reported
index variant rs1021156 (R2>0.8), disrupted the IRF TFBS within the ZC2HC1A/IL7 locus
(Figure 2.11 B). The first one, rs3808619 localised in the promoter of ZC2HC1A and the
risk allele led to decreased binding by IRF family of transcription factors (Figure 2.11 B).
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The second variant, rs60486739, located in intron 3 of IL7, and the minor allele also
led to increased binding by IRF transcription factors (Figure 2.11 B). Both genes were
sensitive to CD28 stimulation in memory cells and the H3K27ac peak that contained the
rs60486739 variant was only present in stimulated memory cells, suggesting a potential
functional role of the variant in modulating TF binding in this enhancer and affecting
the expression levels of the gene.
Table 2.4: Transcription factor binding sites in open chromatin or H3K27ac peaks that are dis-
rupted by immune-disease associated variants. SNP: Disease SNP residing within an
ATAC peak and disrupting TFBS; All: SNP alleles; Gene: Gene that is stimulus-sensitive
and maps to the disease locus; Stim.: Stimulus to which the gene is sensitive; Cell: Cell
type in which disease gene shows stimulus sensitivity, M corresponds to memory and
N to naive; TF: Transcription factor recognising the binding site; ∆PWM: Difference in
PWM score between the reference and the alternative allele; Trait: Disease for which
the association was reported (T1D - type-1 diabetes, CEL - celiac disease, CD - Crohn’s
disease, UC - ulcerative colitis, RA - rheumatoid arthritis, MS - multiple sclerosis, PSO -
psoriasis, SSc - systemic sclerosis).
SNP All Gene Stim. Cell TF ∆PWM Trait
rs2852151 G/A SEH1L TCR N RELA -132 T1D, CEL
rs3181365 A/T TNFSF15 CD28 M BLIMP1 -249 CD, UC
rs6715826 T/G MYO1B, STAT1 CD28 M BLIMP1 -55 CEL, RA,
CD, UC,
MS
rs2548530 T/C ERAP2 CD28 N IRFs -159 CD, UC
rs10061936 T/C ERAP2 CD28 N IRFs -50 CD, UC
rs9392504 G/A IRF4 TCR N, M IRFs 93 CEL, RA
rs4679081 T/C TRIM71 TCR M MEF2C, IRFs -32, -14 CEL, MS
rs2115592 T/C REL TCR M IRFs, BLIMP1 382, 14 CEL, RA,
MS
186498:20:00 C/CT SOCS1 CD28 N, M IRFs -24 MS
rs60486739 G/A IL7, ZC2HC1A CD28 M IRFs 311 MS
rs3808619 A/C IL7, ZC2HC1A CD28 M IRFs -71 MS
rs11249219 C/T CLIC4 CD28 M IRFs -24 CEL, PSO
rs3784789 C/G CYP1A1,
CYP1A2
CD28 N SPI1 -172 CEL, SSc
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Figure 2.11: TCR and CD28 sensitive genes enrichment in immune GWAS loci. A. Enrichment of
TCR- and CD28-sensitive genes in immune-mediated disease loci. Bone mineral
density (BMD) is used as a negative control. (Crohn’s disease - CD, ulcerative colitis -
UC, celiac disease - CeD, type-1 diabetes - T1D, rheumatoid arthritis - RA, systemic
sclerosis - SSc, multiple sclerosis - MS, psoriasis - PSO). B. MS associated locus
containing two genes, ZC2HC1A and IL7, that are CD28-sensitive. In the upper panel
in red are indicated all the SNPs in LD with previously reported GWAS index variant,
rs1021156. Of these, the two highlighted variants, rs3808619 and rs60486739, overlap
CD28-upregulated H3K27ac peaks and are predicted to disrupt and IRF binding site.
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2.4 Discussion
Productive T cell activation is thought to involve recognition of antigen by the TCR in
association with co-stimulatory signals via receptors such as CD28 (Chen and Flies,
2013). However, the relative quantities of both signals are likely to be highly variable
depending on the setting of T cell activation. There is evidence to suggest that naive and
memory cells have different requirements for CD28 co-stimulation, and a widely held
view is that CD28 co-stimulation is less required for activation of memory than naive
T cells (Dubey et al., 1995; London et al., 2000; Croft et al., 1994; Luqman and Bottomly,
1992). Understanding the requirements for CD28 co-stimulation during immune re-
sponses is important for many therapeutic approaches including immune suppression
in autoimmunity and transplantation, as well as cancer immunotherapy.
Previous genomic studies have solely focussed on the additional effects of CD28 as a
co-stimulus, and not on varying the levels of CD28 itself, and were carried out in popu-
lations of mixed cells which includes cells that have successfully undergone activation
as well as the resting cells (Diehn et al., 2002; Wakamatsu et al., 2013; Allison et al., 2016).
The data presented here reveal that CD28 has an important impact on memory T cells,
particularly their proliferation. I was able to reach this conclusion thanks to three key
components in the experimental design: (i) I specifically isolated and profiled only
stimulated cells, therefore reducing the confounding effect of variable cell activation
across different cell cultures, (ii) I separately assessed naive and memory cells, and (iii)
I provided the first genome-wide perspective of gene expression regulation through
mapping RNA and chromatin changes induced by strong CD28 stimulation in the absence
of TCR. Thus, although providing CD28 on its own might not be physiological, this system
allowed me for the first time to disentangle genes that are TCR or CD28 sensitive. I did
not assay the CD25- cells within each experimental condition as I expected those to
mostly represent resting cells. However, future time-course RNA-seq experiments could
provide further insights into the dynamic nature of CD28 stimulus on memory cells and
determine whether the totality of cells eventually gets activated. Recent research in
CD8 naive T cells suggests that a weaker stimulus would indeed not affect the type of
the response, but the time it takes to be initiated (Mehlhop-Williams and Bevan, 2014;
Richard et al., 2018).
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I observed a significant upregulation of genes in memory T cells in response to stim-
ulation with CD28 alone that were related to cell cycle, suggesting a role for CD28 in
memory cell proliferation. Indeed, I validated this directly by stimulating T cells in
vitro and demonstrating proliferation in memory T cells following activation with CD28
alone. Furthermore, I observed a significant upregulation of effector cytokines and
chemokines in response to CD28, indicating that CD28 is also key to cell effector func-
tions. However, the experiment was performed on a mixed memory cell population of
effector and central Th cells, which differ in their levels of expression of CD28 (Koch
et al., 2008). The differences in the expression levels of CD28 might have an impact in
the immune response initiated, given that influenza infected mice treated with CTLA4Ig
shift their memory T cell pool to one predominantly composed of central memory cells,
while influenza specific memory cells in untreated mice were predominantly effector
cells (Ndejembi et al., 2006). This could explain why activated effector memory T cells
produce cytokines more efficiently than central memory T cells (Barski et al., 2017).
Finally, the variability in expression of the CD28 receptor between young and old is only
significant in effector memory T cells (Koch et al., 2008), suggesting that the ability of
memory T cells to get activated is directly concordant with their ability to sense CD28,
and as I have here demonstrated, initiate proliferation. Therefore, the lack of CD28
signal might contribute towards immunosenescence.
The data presented here provide a new context for the interpretation of several previ-
ous observations on CD28 function. Firstly, the ill-fated CD28 superagonist antibody
(TGN1412) trial for B-cell chronic lymphocytic leukemia and RA, which tested the ability
of CD28 co-stimulation to specifically expand and activate Tregs, revealed a powerful
effector response to CD28 stimulation driven by effector memory T cells (Hünig, 2012).
Secondly, recent data indicated that human Treg cells can be expanded by utilising
CD28 antibodies alone (He et al., 2017). This is in line with my observations, given that
Tregs predominantly consist of memory cells and that CD28 stimulation upregulates
FOXP3. Thirdly, there is now increasing evidence using conditional deletion of CD28
in mice that memory T cell responses are dependent on CD28 stimulation (Linterman
et al., 2014; Ndlovu et al., 2014; Fröhlich et al., 2016). Finally, I showed that a strong TCR
signal alone is sufficient to induce the expression of key drivers of cell division and
consequently trigger proliferation of naive T cells, but surprisingly had smaller effect
on the proliferation of memory T cells. As such, I conclude that memory cells are not
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simply more sensitive to activation signals, but that there is a true difference in the TCR
and CD28 requirement between the two cell types. This is further supported by a recent
study which demonstrated that naive CD8 T cells proliferate in response to low antigen
concentrations, in contrast to memory T cells, which while detect the antigen, fail to
engage the TCR signalling cascade (Mehlhop-Williams and Bevan, 2014). Taken together,
this data provides a genomic explanation for the requirement of CD28 in the activation
and effector functions of memory T cell.
My findings have further implications for understanding susceptibility to complex
immune-mediated diseases, where T cell activation is one of the hallmark pathobiolog-
ical processes. GWAS of immune diseases have mapped hundreds of associated risk
loci, many of which harbour genes of immune function. However, the specific role of
the identified genes in T cell activation processes is unclear. By examining T cell gene
expression sensitivity in response to specific stimuli I demonstrated that GWAS loci are
enriched for CD28-sensitive genes, rather than TCR-sensitive genes, thereby increas-
ing support for the role of T cell activation via CD28 co-stimulation in susceptibility
of immune-mediated diseases. For example, a recent study identified that cytokine
oncostatin M (OSM) is expressed at higher levels in inflamed intestinal tissues from IBD
patients compared to healthy controls (West et al., 2017). In the dataset presented here
OSM is CD28-sensitive and is among the genes driving the enrichment of CD28-sensitive
genes in IBD. The importance of CD28 co-stimulation in immune-mediated diseases is
further supported by data from the CTLA-4 field (Kuehn et al., 2014; Lo et al., 2015). Loss
of CTLA-4 in mice and heterozygous mutations in humans reveal profound autoimmunity
where enteropathy is a consistent feature (Tivol et al., 1995; Schubert et al., 2014; Kuehn
et al., 2014). The fact that the CTLA-4 pathway directly regulates CD28 stimulation by
competing for the same ligands strongly suggests that CD28 plays a key role in suscep-
tibility to immune-mediated diseases and that increased CD28 co-stimulation may be
sufficient for effector T cells to support their survival, proliferation and secretion of
proinflammatory cytokines (Khattri et al., 1999; Qureshi et al., 2011). The data shows that
memory T cells are highly sensitive to CD28 stimulation, which is consistent with these
cells being under the control of CTLA-4.
Lastly, the concept that CD28 is involved in the proliferation of memory T cells is in-
triguing in the light of recent data related to checkpoint blockade for cancer treatment.
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It has been suggested that PD-1 blockade, which is important to the reinvigoration of
exhausted effector T cells, requires CD28 signalling (Hui et al., 2017; Kamphorst et al.,
2017). Again, this aligns well with the data presented here and supports the concept
that differentiated memory T cells in tumours utilise CD28 and that CTLA-4 and the PD1
blockade are known to trigger autoimmunity (Nasr et al., 2017; Bertrand et al., 2015).
Taken together, this chapter provides new insights into the role of TCR and CD28 co-
stimulation in the activation and proliferation of human naive and memory CD4+ T cells,
and the influence of these stimuli on immune disease susceptibility.
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3Regulation of gene expression in
regulatory T cells in response to cell
stimulation
Collaboration note
The data acquisition described in this chapter was performed in collaboration with
Natalia Kunowska, who was a Senior Research Assistant in Gosia Trynka’s lab at the
time. Natalia also optimised the ChM-seq protocol. I performed the flow cytometry
validation and Blagoje Soskic analysed the flow cytometry data. I did all the genomic
data analysis. RNA-seq library construction and sequencing of all materials was done
by DNA Pipelines core facility at Sanger.
3.1 Introduction
Regulatory T cells (Tregs) play an essential role in the homeostasis of the immune
system and the downregulation of inflammation by suppressing the proliferation and
effector function of other T cells. Therefore, Treg cells constitute an essential component
in the prevention of autoimmunity and the maintenance of self-tolerance. Tregs are
characterised by high expression of the forkhead box transcription factor (TF) FoxP3,
which is essential for their development and function (Fontenot et al., 2005b). Mutations
of the FOXP3 gene in humans leads to immune dysregulation polyendocrinopathy,
enteropathy, X-linked syndrome (IPEX), an autoimmune disease characterised by very
low Treg cell numbers (Bennett et al., 2001).
This has established FoxP3 as the master regulator of Treg cell fate. However, genetic
and epigenetic studies have highlighted that the complex regulation of Treg cell identity
does not depend on FoxP3 alone. Differential gene expression analysis between Tregs
and CD4+ T helper cells in resting and activated states have shown that the Treg gene
signature is one distinct from other T cells. A number of molecules form the Treg
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gene signature, including the phosphatase DUSP4, the membrane protein LRRC32, the
receptor CTLA4 and the TFs IKZF2 and IKZF4 (Pfoertner et al., 2006; Birzele et al., 2011). It
has been shown that the development of Treg cells is contingent on the establishment
of a Treg specific DNA hypomethylation pattern which gets established in the thymus
(Ohkura et al., 2012). Hypomethylation of CTLA4, IL2RA and IKZF4 therefore precedes
FoxP3 expression, but requires TCR stimulation and is necessary for lineage stability
and suppressive capacity. Furthermore, the enhancers of CTLA4, IL2RA and IKZF2 are
active, as assessed by H3K27 acetylation from a pre-Treg stage (Kitagawa et al., 2017).
This places a number of different genes at the epicentre of Treg identity, not all of which
have been thoroughly studied in different cellular settings.
Given the importance of regulatory T cells (Tregs) in the downregulation of the immune
system and the implications of their role in the pathogenesis of autoimmune diseases
(Buckner, 2010), a more comprehensive understanding of Treg cell regulatory processes
is necessary. Specifically, it is unclear how Tregs gene expression regulation profile
changes upon activation. T cells are typically activated using a combination of anti-CD3
and anti-CD28 antibodies or PMA combined with ionomycin, which mimics a strong
TCR signal. PMA diffuses into the cell and directly stimulates protein kinase C which
initiates the MAPK cascade, while ionomycin triggers a Ca2+ influx into the cell (Weiss
and Imboden, 1987). Combined, they can activate the three TF pathways, NFAT, NF-κB and
AP1. Since Treg cells constitute a small percentage of CD4+ T cells, the implementation
of high-throughput assays has been difficult due to limitations in obtaining sufficient
amount of cellular material. For this reason, there are scarce resources of data available
and the majority of the work has been carried out in mice.
In this study, I adapted the Chipmentation (ChM)-seq protocol, a recently published
modification to the widely used ChIP-seq assay, to generate high quality data. For
the optimisations I used the Jurkat cell line followed by primary human Treg cells.
Comparison with the traditional ChIP-seq assay showed high correlation between the
two methods, both in the cell line and in primary cells. ChM-seq was then used to study
the gene regulatory landscape of Treg cells upon stimulation. I performed ChM-seq
of H3K4me3 to assess promoters and of H3K27ac to assess active elements on ten
human donors in resting and stimulated state. I also acquired open chromatin profiles
using ATAC-seq and gene expression profiles using RNA-seq. Using this multi-layer
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dataset, I identified gene regulatory programs initiated upon Treg cell stimulation at
the chromatin level. Furthermore, I investigated the dynamics of gene transcription in
Treg activation by assessing gene expression levels globally, as well as the alternative
splicing and the impact on the usage of different gene isoforms by comparing transcript
ratios.
3.2 Materials and Methods
3.2.1 Sample collection
Whole blood samples were obtained from healthy adults and CD4+ cells were isolated
as described in Chapter 2. CD4+ enriched cells were stained with the following anti-
bodies for sorting: CD4+ (OKT4)-APC (Biolegend); CD25 (M-A251)-PE (Biolegend); CD127
(eBioRDR5)-FITC (eBioscience) and Live/Dead fixable blue dead cell stain. Live regula-
tory T cells (CD4+ CD25high CD127low) were sorted. Treg cells used for the optimisation
of ChIP and ChM assays were obtained from the NHS Blood and Transfusion in Cam-
bridgeshire. The ten samples used for the comparison between resting and stimulated
Tregs were obtained from a commercial vendor with commercial vendor’s approved
institutional review board protocols. Research use was approved by the Research Ethics
Committee (reference number: 15/NW/0282).
3.2.2 Cell culture
Human Tregs and Jurkat human T-lymphoblast cells were grown in Iscove’s Modified
Dulbecco’s Media (IMDM) (Life Technologies, Paisley, UK), supplemented with 10% human
serum (HS), 50 U/ml penicillin and streptomycin (Life Technologies) and 100 U/ml
recombinant human IL-2 and incubated at 37°C in a humidified atmosphere of 5% CO2.
Cells were activated using PMA (5-10 ng/µl) with ionomycin (200 ng/µl) (Sigma-Aldrich)
overnight (18 hours). See Table 3.1 for full specifications.
3.2.3 ChIP-seq and ChIPmentation-seq
In order to reliably compare the ChIP with the ChM protocol, I sonicated 500,000 Jurkat
cells, and equally divided the samples to continue with the ChIP and ChM protocols.
Cells were sonicated for 40 minutes (T regulatory cells) or 30 minutes (Jurkat cells) in
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250 µl using the Bioruptor®Pico (Diagenode, Belgium) sonicator and DNA LoBind tubes
(Eppendorf, Germany) to obtain 200 to 3000 bp fragments. Resting and stimulated
Tregs were sonicated for 6 minutes and 5 minutes, accordingly, using Diagenode tubes.
I tested sonicated chromatin fragment sizes using gel electrophoresis. I used 100,000
cells of each for qPCR confirmation and proceeded with sequencing the remaining
100,000 cells. Once the protocol was deemed reliable I repeated the same steps using
isolated T regulatory cells.
Both ChIP-seq and Chipmentation were performed using the Low SDS iDeal histone
ChIP kit (Diagenode), as described in Chapter 2. The immunoprecipitation was done
using 1µg of each antibody; H3K27ac (Cat. no. C15410196, Diagenode), H3K27me3(Abcam),
H3K4me1(Active Motif) and H3K4me3 (Catalog No: 39915, Active Motif). The only differ-
ence to the protocol described in Chapter 2 was that all the washes with iW1, iW2, iW3
(iDeal ChIP-seq Kit for Histones, Diagenode) were performed using an Agilent Bravo
Automated Liquid Handling Platform (Agilent, Santa Clara, U.S.). ChIP-seq libraries were
performed using Illumina TruSeq index tags, while ChM-seq libraries were performed
using the Nextera dual index tags.
The samples used for protocol optimisation were indexed and polled in equimolar
concentration and sequenced on the MiSeq 2500 platform as such: 7 ChIP samples
and 7 ChM samples produced from Jurkat cells (5 antibodies, ATAC-seq and input) were
sequenced across 3 lanes to generate 62 million reads per sample; 5 ChIP samples
and 5 ChM samples from 2 donors (4 antibodies and input) were sequenced across
two lanes each to generate 27 million reads per sample; 13 samples, including five
ChM samples from one donor were sequenced across two lanes to generate 32 million
reads per sample. Thirty-one (because it was combined with different experiments)
ChM libraries were indexed and pooled in equimolar concentration and sequenced on
eight lanes using the Illumina HiSeq 2500 platform and V4 chemistry using standard 75
bp paired-end reads. Sequencing yielded on average for the samples in this study 62
million reads per sample.
3.2.4 ATAC-seq
ATAC-seq was performed according to protocol (Buenrostro et al., 2013), with the follow-
ing modifications. After sorting, T cells were washed with ice-cold PBS and resuspended
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in sucrose buffer (10 mM Tris pH 8, 3 mM CaCl2, 2 mM MgOAc, 1 mM DTT, 0.32 M sucrose,
0.5 mM EDTA, 0.25% TritonX-100), followed by 5 minutes incubation on ice to isolate
the nuclei. Isolated nuclei were washed once with 1x TD buffer (Tagment DNA Buffer,
Nextera DNA Library Prep Kit, Illumina, U.S) and resuspended in 50 µl 1x TD buffer
containing 2.5 µl of Tn5 enzyme (TDE1, Nextera). The reaction was carried out at 37ºC,
mixing and then stopped by addition of 250 µl of buffer PB (MinElute PCR Purification Kit,
QIAgen, Hilden, Germany). The DNA was then purified on MinElute columns according to
the manufacturer’s instructions and eluted in 10 µl sterile double distilled water. The
libraries were amplified using the Nextera PCR Master Mix from Nextera DNA Library
Prep Kit and Index adapters i7 and i5 (Nextera Index Kit, Illumina, U.S), according to the
manufacturer’s instructions. The number of amplification PCR cycles for each sample
was determined individually by performing a qPRC reaction of 7.5 µl aliquot of the mix
with an addition of the EvaGreen dye (Biotium, Fremont, U.S.). The amplified libraries
were SPRI purified (upper cut 0.5x, lower cut 1.8 x) on a Zephyr G3 SPE Workstation
(PerkinElmer, Waltham, U.S.), multiplexed the libraries and did 75 bp sequencing using
an Illumina HiSeq V4 to yield on average 147 million reads per sample.
Table 3.1: Donors specifications and culture conditions.
Ind.
ID




RNA ATAC H3K27ac H3K4me3
20 1 NA M 10 1 83.5 Yes Yes No No
21 1 NA F 10 1 78 Yes Yes No No
22 1 NA F 10 1 68.6 Yes Yes No No
25 2 26 F 5 1 NA Yes Yes Yes Yes
26 2 22 M 5 1 NA Yes Yes Yes Yes
27 2 31 M 5 1 NA Yes Yes Rest. Yes
28 3 22 M 5 2 NA Yes Yes Yes Yes
29 3 36 F 5 2 NA Yes Yes Yes Yes
30 4 39 M 5 2 80.7 Yes Yes Yes Yes
31 4 25 F 5 2 78.5 Yes Yes Yes Yes
3.2.5 ChM and ATAC data processing
The quality of the sequence reads was assessed using the fastx toolkit and the adap-
tors were trimmed using skewer (Jiang et al., 2014). Reads were mapped to the human
genome reference GRCh38 using the bwa mem algorithm (Li and Durbin, 2009). I only
kept uniquely mapped reads, removed PCR duplicated reads and for the ATAC I excluded
mitochondrial reads using samtools (Li et al., 2009). Genome browser tracks were cre-
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ated using BEDTools (Quinlan and Hall, 2010) and the UCSC binary utilities. Furthermore,
I generated insert size distributions using PICARD tools CollectInsertSizeMetrics func-
tion, since these can be indicative of over-sonicated chromatin and excess of adapters
in the data.
The ATAC mapped reads were converted into bed files and chimeras were removed.
Peaks were called using MACS2 (Zhang et al., 2008) setting the parameters to -f BED -q
0.05 –nomodel –extsize 50 –shift -25 for ATAC. Peaks were called directly from the bam
files for the ChM samples, using the parameters -q 0.01 for H3K4me3 and H3K4me1 and
–broad –broad-cutoff 0.1 –nomodel –extsize 146 for H3K27ac and –extsize 73 H3K27me3.
For ChM, all samples were downsampled to to the same read number prior to peak
calling against the input. I used the fraction of reads in peaks (FRiP), the insert size
distribution and the genome tracks to investigate the quality of our data. I excluded
one H3K27me3 ChIP-seq sample from Tregs and one Treg ATAC sample in the stimulated
state for having FRiP < 5%.
For the comparison between ChIP and ChM, I merged all samples from the same cell
type, antibody and method, and downsampled to the smallest read number, which was
19 million reads for ChIP and 41 million reads for ChM. I called peaks in H3K4me1 and
H3K4me3 using a -q value threshold of 0.001, of 0.1 for H3K27ac and a p-value of 0.001
for H3K27me3.
For the comparison between resting and stimulated Tregs, I merged all ATAC samples
and called peaks again using the parameters described above. For the H3K27ac and
H3K4me3 ChM samples, I first merged the donors within each condition (resting and
stimulated) and then randomly sampled 17 million reads from each into one sample
to reach the same read number as in the input. Since I merged QCed samples I used
the –keep-dup flag when calling peaks with MACS2, as the PCR duplicated reads for
individual samples were already removed and I expected to observe a small proportion
of the same reads present in independent samples by chance. I also increased the -q
value threshold to 0.1 for both assays. The resulting peak files were used as a reference
to count the number of reads falling into peak regions using featureCounts (Liao et al.,
2014). I only kept regions that had at least 20 reads in at least 3 samples to get a final
count of 54,811 in ATAC, 20,363 in H3K4me3 ChM and 44,820 in H3K27ac ChM.
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3.2.6 Global ChIP, ChM and ATAC data overview
To correlate the samples I divided the genome into 10 kbp windows and counted the
number of reads that fell within each, normalised by the total number of reads. I then
calculated the Pearson correlation coefficient. The overlap among different samples,
the distance from the transcription start site (TSS) of a gene and the permutations
for the enrichment of the different chromatin marks in promoter capture Hi-C regions
mapped in CD4+ T cells (Javierre et al., 2016) was calculated using BEDtools (Quinlan
and Hall, 2010).
3.2.7 Differential regulatory regions analysis
To carry out differential regulation analysis between the resting and stimulated sam-
ples I used DESeq2 (v1.14.1) (Love et al., 2014). To find regions that were changed upon
stimulation, I compared the stimulated samples to the resting state, using the blood
processing batch as a covariate, and used Benjamini-Hochberg controlled false detec-
tion range (FDR) of 10% (Benjamini and Hochberg, 1995) and an absolute fold-change ≥
2. I overlapped the differentially defined regions of one assay with the total regions of
another assay using ChIPpeakAnno’s findOverlapsOfPeaks and plotted their distribution
around the TSS using the function binOverFeature from the same package (Zhu et al.,
2010b).
3.2.8 RNA-seq and initial processing
Sorted regulatory T cells were placed in 0.7ml of QIAzol Lysis Reagent (Qiagen) and stored
at -80°C. RNA was isolated following the Qiagen miRNeasy Micro kit manufacturer’s
protocol. RNA was quantitated using Bioanalyzer (Agilent Technologies, USA). Libraries
were prepared using Illumina TruSeq index tags and sequenced on the Illumina HiSeq
2500 platform using V4 chemistry and standard 75 bp paired-end. Twenty samples were
multiplexed at equimolar concentrations and sequenced across five lanes, to yield on
average 72.5 million reads per sample.
Reads were aligned to the GRCh38 human reference genome using STAR (Dobin et al.,
2013) and the Ensembl reference transcriptome (version 87). Gene counts was performed
using featureCounts tools from the subread package v1.5.1 (Liao et al., 2014) and only
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assigned reads were used for further processing (58.5-70.3% of reads were assigned).
Sequence reads were also aligned using Salmon (Patro et al., 2017). I used the options
–seqBias –gcBias to adjust for sample specific fragment bias and GC bias accordingly.
3.2.9 Differential gene expression analysis
To identify differentially expressed genes (DEGs), I used DESeq2 (R version 3.3.3, DESeq2
version 1.14.1) (Love et al., 2014). For downstream analysis I only considered 17,225 genes
that had at least 20 copies in at least 3 samples. I compared resting to stimulated cells
using Benjamini-Hochberg controlled FDR (Benjamini and Hochberg, 1995) of 5% and
an absolute fold-change ≥ 2 to find activation induced genes.
For the clustering of DEGs, raw counts were normalised using DESeq2 rlog function. To
control for the different batches in which we processed the blood, which accounted
for 14.6% of the observed variability, I performed batch correction using the combat
algorithm as implemented by the sva package (Leek et al., 2012). Finally, the values
were quantile normalised. I did hierarchical clustering on all DEGs using the euclidean
distance between samples and the optimal number of clusters was defined using
dynamicTreeCut (Langfelder et al., 2008) (minimum cluster size was set to 50). I used
g:Profiler (Reimand et al., 2016) R package to identify the top three Reactome pathways
(Croft et al., 2014) enriched in each cluster.
3.2.10 Primary transcript usage
I used tximport to obtain the transcript level abundances, and only used the transcripts
that had at least one transcript per million (TPM) in at least four samples and whose
gene expression passed the filtering threshold used with the STAR output. I calcu-
lated transcript ratios (tr) based on the total expression per gene. The final table was
composed of 67,239 transcripts, which corresponded to 12,100 genes. I calculated the
difference in ratios for each transcript between the resting and stimulated state and
derived the mean across the ten donors. Finally, I extracted the extreme 1% tail of each
side of the distribution and required a gene to have a transcript in both tails in order
to be included.
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3.2.11 Binding expression target analysis
I identified regions of the genome that changed upon stimulation as described in
Chapter 2. Based on the distribution of the peaks around the TSS, I used a window of 3
kbp around the TSS for active promoters and 100 kbp for active enhancers. If active
enhancers were less than 3 kbp apart they were considered to be a single enhancer.
3.2.12 LRRC32 flow cytometry validation
The level of expression of LRRC32 was quantified in ten donors in resting cells and cells
stimulated with anti-CD3/anti-CD28 beads (1 bead:4 cells). CD4+ cells were isolated
and cultured for 18 hours with or without stimulant. After 18 hours of stimulation cells
were observed by flow cytometry using a directly conjugated antibodies CD4+ (RP4-T4)-
Alexa700 (eBioscience), GARP (G14D4)-PE (eBioscience), CD25 (B96C)-PeCy7 (eBioscience),
CD69 (FN50)-FITC (Biolegend), CD28 (CD28.2)-APC (eBiosience), CD45RA (HI100)-BV785
(Biolegend). Intracellular staining for FOXP3 (206D)-BV421 (Biolegend) was done using
the eBioscience FOXP3 staining buffers.
3.2.13 Differential intron excision analysis
I used LeafCutter’s annotation free approach (Li et al., 2018) to identify 26,342 clusters
of intron excision events corresponding to 96,809 alternatively excised introns. I limited
the analysis to the genes that had been detected by gene counts. In each sample, I
counted the number of reads supporting each intron excision event in a cluster as well
as the total number of reads in a cluster. I removed clusters with less than 2 samples with
coverage > 20, clusters that had more than 10 introns, clusters with less than 2 introns
used in more than 4 samples. I identified a total of 6,861 clusters corresponding to 4,307
genes that were differentially spliced upon stimulation (using Benjamini-Hochberg
controlled FDR (Benjamini and Hochberg, 1995) of 1% and an absolute fold-change ≥ 2).
To calculate the conservation score across the junctions I used the conservation scoring
PhyloP phylogenetic values obtained for multiple alignments of 99 vertebrate genomes
to the human genome (Pollard et al., 2010). I used both junction ends for the novel
annotated pairs and the unanchored junction, but only the 3’ end for the cryptic 3’ sites
and the 5’ end for the cryptic 5’ sites. I compared the result to a randomly sampled
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distribution of base pairs of the same size.
To provide functional support for some of the novel annotated pairs and cryptic 5’
junctions, I overlapped the 5’ of these clusters with differentially active promoters using
bedtools. I only kept promoters that had a peaks value ≥ 100 and did not overlap an
annotated TSS.
3.3 Results
3.3.1 Optimising ChIPmentation-seq in Tregs
To compare the performance of ChIP and ChM I assayed in parallel four different marks
(H3K4me3, H3K4me1, H3K27ac and H3K27me3) using material from the same cell cul-
ture for Jurkat cells and the same donors for Tregs. I observed a higher percentage of
mapped reads and non-PCR duplicates across all ChM experiments. After calling ChIP
and ChM-seq peaks, i.e. genomic regions enriched for read pile-ups compared to the
background read distribution, I observed that ChM displayed more peaks regardless of
the antibody used and showed a higher fraction of reads in peaks (FRiP), which resulted
in a higher fold-change enrichment across the called peaks (Figure 3.1 A and B). This
suggested that ChM-seq is more sensitive than ChIP-seq.
In order to assess how the different histone marks and cell types related to each other,
I calculated the Pearson correlation coefficient (PCC) between all the assays performed.
In this analysis I included ATAC assays to identify potential Tn5 biases in the ChM-seq
assay. I observed a high PCC between assays performed with the same antibody and
between ATAC-seq from different donors (Figure 3.1 C). Hierarchical clustering of the
samples showed two distinct clusters, the first one was composed of H3K27me3, a
repressive mark, while the second one encompassed the rest of the assays, which are
all active marks. Within the active marks I identified some substructure depending on
the assay performed. Therefore, samples separate according to chromatin activity.
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Figure 3.1: Qualitative control shows that ChM-seq is a more sensitive method than ChIP-seq.
A. Percentage of uniquely mapped reads (left panel) and non-PCR duplicate fragments
(right panel) for ChIP and ChM quantified for the input and the four antibodies against
histone modifications assayed in the Jurkat cell line and in T regulatory cells. B.
Fraction of reads in peaks (FRiP) and number of peaks called from ChIP and ChM
data for all sequenced libraries. C. Genome-wide Pearson correlation heatmap for all
histone marks and cell types. Correlation was derived based on reads in 10,000 bp
bins across the whole genome.
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In order to increase the sensitivity of peak calling, I recalled peaks for each histone
mark by merging the files from the different T regulatory cells donors. This was possible
because of the high correlation observed between the same histone marks within an
individual method (ChM or ChIP-seq) across all replicates. For H3K27ac, H3K4me1 and
H3K4me3 antibodies, ChM-seq captured over 95% of the peaks called using ChIP-seq
(Figure 3.2 A). The overlap was smaller for H3K27me3 (70%), which marks broader regions
of the genome. The mean peak length for this mark was 3.85 kbp, compared to 2.57 kbp
for H3K27ac, 1.39 kbp for H3K4me1 and 1.55 kbp for H3K4me3. Since ChM-seq resulted
in a higher number of method specific peaks, I examined the characteristics of these
regions in relation to all peaks. Method specific peaks, that is peaks called using only
one method, had similar p-value and peak length distribution as the total peak-set.
However, the largest peaks with the smallest q-values were shared between the two
methods (Figure 3.2 B). Therefore the peaks identified by ChM-seq are very similar to
the ones found by ChIP-seq.
I annotated the peaks based on the nearest transcription start site (TSS) of a gene across
the genome. As expected, H3K4me3 and H3K27ac were enriched in gene promoters,
H3K4me1 and H3K27ac in enhancers and unannotated regions of the genome were
marked by H3K27me3 (Figure 3.2 C). Because ChM-seq resulted on average in an increased
number of peaks compared to ChIP-seq, I further assessed if the distribution of method
specific peaks was skewed towards specific genomic regions. For H3K4me3, ChIP-seq
specific peaks (37 in total) were mostly located away from the gene body, while ChM-seq
specific peaks (15,798 in total) localised to promoter regions (up to 10 kbp upstream from
the TSS) and introns. To further validate that ChM specific peaks mapped to biologically
relevant gene regulatory regions, I tested if the peaks colocalised with chromatin
contacts mapped with promoter capture Hi-C (PCHi-C) in CD4+ cells (Javierre et al., 2016).
Both ChIP-seq and ChM-seq active marks were enriched in PCHi-C chromatin contacts,
while the H3K27me3 silencing mark was depleted from those regions (Figure 3.2 D).
However, when repeating this on method specific peaks, only ChM-seq peaks remained
significantly colocalised with PCHi-C mapped regions. This suggested that ChM-seq is a
more sensitive and specific method than ChIP-seq since it identified a higher number
of peaks in relevant regulatory regions.
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Figure 3.2: Global comparison of ChIP-seq and ChM-seq in Tregs highlights increased sensitiv-
ity of ChM-seq. A. Overlap between ChIP-seq and ChM-seq peak-sets. B. Peak length
and significance (darker colors correspond to the results of the analysis using method
specific peaks). C. Peak annotation for ChIP and ChM-seq peaks based on the dis-
tance to the transcription start site of the closest gene. D. Significance of enrichment
of ChIP and ChM-seq peaks in PCHi-C regions mapped in CD4+ T cells (black dots
correspond to the results of the analysis using method specific peaks).
3.3.2 Identification of the optimal conditions for Treg stimulation
Having validated the applicability of ChM in producing robust and reproducible results
in primary Tregs, I applied the protocol to profile the chromatin landscape of this rare
cell population upon stimulation. I used ChM-seq for the H3K27ac and the H3K4me3
antibodies, as well as ATAC-seq and RNA-seq to generate the first comprehensive map
of stimulation induced changes in Tregs isolated from ten individuals.
I isolated Tregs by fluorescently activated cell sorting (FACS), selecting for CD4+CD25high
CD127low. Cells were cultured for 18 hours with or without PMA and ionomycin to
provide the stimulation. I initially stimulated Tregs with beads coated with antibodies
against CD3 and CD28. However, I found that the interaction between cells and beads
was extremely strong and washing cells off the beads resulted in a significant loss of
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cellular material. I reasoned this loss could be reduced by substituting beads with
PMA/ionomycin. Therefore, I tested how different the gene expression changes induced
by PMA/ionomycin and anti-CD3/anti-CD28 beads were. To assess this, I used CD4+
conventional T cells (CD4+CD25lowCD127high) isolated from two donors. I observed
93% correlation of log2 fold change in gene expression between resting and stimulated
cells in each of the two conditions (Figure 3.3 A). This indicated that the differences
between the two stimuli were negligible and that PMA/ionomycin could be reliably
used as a relevant stimulus for T cell activation. To ensure that a large proportion
of Tregs was successfully stimulated in culture, I quantified cell activation through
CD69 staining, a cell surface marker of early activation (Figure 3.3 B). On average,
100% of cells responded to activation. Additionally, to measure the purity of the Treg
isolation protocol I performed intracellular staining for FoxP3 (mean FoxP3+ cells =
83.5%) (Figure 3.3 C). In conclusion, using flow cytometry I confirmed both the successful
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Figure 3.3: Optimisation of Treg isolation and stimulation by PMA/ionomycin. A. Correlation of
log2 fold changes in gene expression between resting and anti-CD3/CD28 beads
stimulated (x-axis) and resting and PMA stimulated conventional T cells (y-axis).
The Spearman correlation was calculated using all genes. B. Percentage of Treg
cells expressing CD69 activation marker after 18 hours of cell culture either with
PMA/ionomycin or without, as measured by flow cytometry. C. Percentage of cells
expressing FoxP3 as measured by flow cytometry.
3.3.3 Stimulation induces specific changes in promoter and enhancer activity
I firstly looked at the epigenetic data from ten donors to quantify stimulation induced
changes. I used MACS2 to call peaks per donor for each of the three assays individu-
ally. Globally, upon stimulation Tregs displayed a higher number of ATAC and H3K27ac
peaks (paired t-test p-value < 0.05), while no difference was observed for H3K4me3
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(Figure 3.4 A). This suggested that stimulation increased chromatin accessibility and
upregulated active regulatory elements, but did not result in the formation of new
promoters. Next, I defined a union set of peaks in each assay from stimulated and
resting cells by merging the peaks across different samples. I counted the number
of reads that fell within these genomic coordinates per sample. Using these tables, I
calculated the Euclidean distance between different samples per assay and created
a heatmap (Figure 3.4 B). I observed that resting and stimulated samples clustered
separately. To further understand if the observed chromatin remodelling was driven
by increased promoter or enhancer activity, I overlapped the peaks marked by the
three assays and defined four groups of regulatory elements: active promoters (AP;
H3K4me3+H3K27ac), non-active promoters (NAP; H3K4me3-H3K27ac), active enhancers
(AE; H3K27ac-H3K4me3) and open chromatin (OC; ATAC-H3K27ac-H3K4me3) (Figure 3.4 C).
In order to uncover the genetic mechanisms of Treg activation, I used the three assays
to compare the gene regulatory landscape of resting and stimulated cells to define the
differential peaks (FDR ≤ 0.1 and fold-change ≥ 2). For each assay, I then overlapped
the set of differential regulatory regions with the full peak-sets from the remaining two
assays to define stimulation induced changes in active promoters, non-active promoters,
active enhancers and open chromatin. I considered a regulatory element to undergo a
stimulation induced change if at least one chromatin mark peak showed a significant
differential change (Figure 3.5 A). The greatest number of changes occurred in active
regions of the genome, where more than 10,000 regions were altered upon stimulation
(Figure 3.5 B). The open chromatin and the non-active promoters changed very little
with stimulation (less than 2,000 regions). A comparable number of active enhancers
and promoters were upregulated (approx. 3,200). I examined the distribution of the
differentially up and down regulated regions with respect to the TSS and compared it
with the global distribution of H3K27ac ChM-seq for active enhancers, H3K4me3 ChM-
seq for active and non-active promoters, and ATAC-seq of open chromatin. I observed
a depletion of differentially active enhancers near the TSS, while the distribution of
differentially active promoters remained largely unchanged and concentrated around
the TSS. Therefore stimulation induced changes in gene expression via the regulation
of distal enhancers. Interestingly, there was a slight shift towards the gene body in
upregulated, but not downregulated, active promoters compared to the background







































































































































































































Figure 3.4: Stimulation induces changes in H3K4 tri-methylation, H3K27 acetylation and chro-
matin accessibility in Tregs. A. Distribution of the peak number detected across
samples in resting and stimulated regulatory T cells for the three assayed chromatin
marks. Asterisk indicates significantly different numbers of peaks detected between
the two cell states, ATAC (p-value = 2.95x10-3), H3K27ac ChM (p-value = 4.82x10-2)
and H3K4me3 ChM (p-value = 0.83). B. Heatmap of Euclidean distance between the
samples acquired from each assay. C. Overlap of peaks between the ATAC, H3K27ac
and H3K4me3 assays. A peak from an individual assay can overlap more than one
peak from another assay, I have written in the Venn diagram the smallest number
to not inflate the values. For example, if one H3K27ac ChM-seq peak overlaps two
H3K4me3 ChM-seq peaks and three ATAC-seq peak, I would only count this as a single
overlap.
body in active promoters could suggest an additional gene regulation by promoter
switching, and the induction of expression of other isoforms.
3.3.4 Gene expression signatures of activated regulatory T cells
In order to better understand the association between changes in chromatin marks and
gene expression regulation I integrated RNA-seq data from the same ten individuals
with the chromatin modification and accessibility results. I first assessed global gene
expression changes triggered by stimulation, before combining the RNA-seq differential
expression results with the changes in chromatin marks and accessibility. I performed
differential gene expression analysis (fold-change ≥ 2 and a false discovery rate (FDR)
≤ 0.05) between resting and activated Treg cells and detected over 2,300 upregulated
and 3,000 downregulated genes upon stimulation. Among the upregulated genes I
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Figure 3.5: Differential epigenetic regulation upon stimulation in Tregs occurs primarily in ac-
tive regions of the genome. A. Number of peaks with significant stimulation induced
changes in individual assays profiling chromatin activity (H3K27ac, H3K4me and ATAC).
The Venn diagrams illustrate the overlap between the differential peaks of each assay
and the total number of peaks of the other two assays. B. Number of differentially
regulated peaks per defined region (active promoters (AP), non-active promoters
(NAP), active enhancers (AE) and open chromatin (OC)) across the three assays. C.
Distribution of the peaks relative to the TSS. Differentially upregulated (blue) and
downregulated (grey) regions are plotted against the distribution of all peaks (black)
using H3K27ac ChM-seq (for active enhancers), H3K4me3 ChM-seq (for active and
non-active promoters) and ATAC-seq (for open chromatin).
found multiple classical T cell activation markers (e.g. CD69, CD200, CTLA4, IL2RA and
TNFRSF9), transcription factors (TFs) related to the immune response (e.g. EGR1, EGR2,
EGR3, NR4A2, FOSL1, IRF4, IRF8 and TBX21) and cytokines (IL1A, IL2, IL3, IL6, IL10, IL17A,
IL21, IL23A, EBI3 and IFNG) (Figure 3.6 A). Among the down regulated genes I found genes
important for Treg cell identity, such as IKZF4 (Figure 3.6 A).
To identify clusters of co-regulated genes, I grouped genes that followed similar expres-
sion trajectories in response to stimulation. I identified four clusters of co-upregulated
genes and nine clusters of co-downregulated genes (Figure 3.6 B). Interestingly, clus-
ter 1, which contained the majority of upregulated genes (72%) and cluster 2, which
contained the majority of downregulated genes (40%), were characterised by limited
variability compared to the remaining clusters. This meant that the majority of up and
downregulated genes were not variable across donors, and there is a uniform response
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to stimulus. On the other hand, the median gene dispersion in clusters 4, 9, 10, 12 and
13 was more than five times greater than the gene dispersion of non-differentially ex-
pressed genes (Figure 3.6 C). These clusters contain genes whose expression in response
to stimulation varies across donors and might be influenced by the genetic background
or are artifacts, in the case of the smallest clusters 12 and 13.
To assess if the co-regulated genes were enriched for specific pathways I used the
Reactome database (Croft et al., 2014). While all upregulated clusters were significantly
enriched for relevant pathways, only three of the nine downregulated clusters showed
significant enrichments. This suggests that downregulated genes are more randomly
distributed across different pathways. Cluster 1 was highly enriched for processes
related to G2M progression (p-value = 9.8x10-20), RNA metabolism (p-value = 7.7x10-30)
and NF-κB signaling (p-value=5x10-20), indicating that cells were successfully stimu-
lated, initiated gene expression programmes to trigger cell proliferation and invoke an
immune response. This analysis provided insights into the dynamic cellular processes
in Tregs upon stimulation. For example, I observed that immune pathways, including
cytokine production were generally upregulated (cluster 4 and 8), while at the same time
they were downregulated (clusters 2 and 6), mostly driven by the interferon signalling
response (Figure 3.7 ).














0.00 0.25 0.50 0.75 1.00



































































































































































Figure 3.6: Differential gene expression analysis between resting and stimulated Tregs. A.
Gene expression levels for selected differentially expressed genes of resting and
stimulated Tregs. B. Heatmap of differentially expressed genes that follow a similar
co-expression dynamics and form 13 co-regulated gene clusters. On the x-axis are
the donors, on the y-axis is a random selection of a 10% of the genes present in each
cluster and the color corresponds to the quantile normalised gene expression value.
C. Distribution of gene expression dispersion estimates calculated per batch and
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Figure 3.7: Pathways enriched in differentially regulated clusters. Top three results of the path-
way enrichment analysis per each cluster of co-regulated genes using the Reactome
database. Numbers in brackets correspond to the genes contributing to the observed
enrichment.
The above analyses collapses sequence read counts to gene counts. I additionally
wanted to investigate to what extend Treg stimulation would have an impact on alterna-
tive transcripts. For that, I quantified the relative transcript ratios and found that the
majority of genes expressed more than one transcript (82.7%) (Figure 3.8 A). However,
most of the genes did not alter their relative transcript ratios, therefore I further fo-
cussed on a subset of genes that switched their primary transcript upon stimulation,
(Figure 3.8 B). Of the 9,727 genes with more than one transcript, 274 showed different
dominant splice isoforms in resting cells and in stimulated cells (Figure 3.8 C).
In order to uncover regulatory processes unrelated to the total changes in transcript
levels, I focussed on the genes that were not differentially expressed but switched splic-
ing isoforms between the two cell states. I identified five genes which encoded for TFs;
NFATC1, ELF4, RUNX1, HLF and YY1 (Figure 3.9 ), all of which showed alternative promoter
usage upon stimulation. I focussed on TFs because changes in parts of the gene body
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Figure 3.8: Five transcription factors have a different transcript dominant upon stimulation in
Tregs. A. Distribution of the number of transcripts per genes. B. Distribution of the
delta between the transcript ratio of the stimulated sample and the resting sample.
C. Pie chart illustration of the number of genes that encode for a single transcript,
that either have the same transcript being dominant in resting and stimulated cells,
or that have an alternative transcript being dominant and whether it is differentially
expressed or not.
which encode for functional domains can have direct implications in the downstream
processes they regulate. With the exception of RUNX1 and HLF, the other TFs in this
list have been associated with Treg function, even if the exact role of each alternative
transcript remains unknown. In resting Treg cells, the main NFATC1 transcripts expressed
were ENST00000318065 (10 coding exons) and ENST00000329101 (10 coding exons).
Conversely, upon stimulation the main transcript was ENST00000253506 (10 coding
exons), which uses an alternative upstream promoter (Figure 3.9 ). ELF4 main transcript
in resting cells was ENST00000335997 (8 coding exons), while in stimulated cells the
main transcript was ENST00000308167 (8 coding exons) (Figure 3.9 ). RUNX1 has many
isoforms, but the most highly expressed one in resting cells was ENST00000437180 (8
coding exons) and in stimulated cells it was the shorter transcript ENST00000344691
(6 coding exons), which lacks the first two exons of ENST00000437180. HLF had three
transcripts with detectable levels in Tregs, ENST00000226067 (4 coding exons) was
the main transcript in resting cells, while upon stimulation this switched to the other
two transcripts, ENST00000573945 (3 coding exons) and ENST00000575345 (3 coding
exons), which lacked the first exon. Finally, the main transcript for YY1 in resting cells
was ENST00000262238 (5 coding exons), which was also highly expressed in stimulated
cells, and additionally the expression of ENST00000554804 (4 coding exons) isoform
increased. ENST00000554804 uses an alternative promoter and lacks the 3’ UTR region
of the gene (Figure 3.9 ). Alternative transcripts with different exon composition could
explain differences in the genes function upon stimulation in Tregs. Indeed, the main
3.3 Results 87
YY1 transcript expressed by resting Tregs results in the coding protein P25490, while
ENST00000554804 results in the coding protein H0YJV7.
3.3.5 Integration of epigenetic and gene expression data points towards the
regulation of immune genes
I next sought to determine the chromatin changes that contribute towards the reg-
ulation of transcriptional programs in response to cell stimulation. First, to identify
chromatin regions that could control gene expression, I assessed if differential active
promoters and enhancers correlated with differential gene expression (Wang et al.,
2013b). Using a window of 3 kbp around the TSS I found that active promoters induced
upon stimulation were predictive of 16% of upregulated genes (p-value = 1.2x10-9) while
the downregulation of promoters predicted 9% of downregulated genes (p-value =
2.7x10-6). On the other hand, using a window of 100 kbp around the TSS I observed that
upregulated active enhancers were predictive of 27% of upregulated genes (p-value =
3.9x10-11), while downregulated active enhancers were predictive of 25% of downregu-
lated genes (p-value = 1.4x10-11) (Figure 3.10 A). Open chromatin regions and non-active
promoters were not predictive of changes in gene expression (p-value > 0.05). The
majority of genes (96%) were assigned a single differentially active promoter, with the
exception of a small set of 27 genes that had two or three promoters. However many
genes (37%) had more than one enhancer, highlighting the interplay between multiple
enhancers in complex gene regulatory processes (Figure 3.10 B). Amongst the genes
with four or more enhancers I identified interleukin receptors (IL1RN, IL23R, IL12RB2
and IL36RN) and TFs (REL, EGR2 and IRF8). These genes play an important role in cell
signalling and transcriptional responses, which could explain why multiple enhancer
interactions would regulate their expression. The median distance between any two
enhancers regulating the same gene was 20.4 kbp, indicating potential enhancer clus-
ters (Figure 3.10 C). Finally, I was interested to see whether any of the chromatin marks
were more informative than others in predicting gene expression changes. I found
that the different assays equally contributed to the predictability of gene expression
(Figure 3.10 D), highlighting the importance of performing them in tandem.
Next, I assessed if genes with predictive regulatory elements were enriched for any
pathways. I found that both genes with upregulated enhancers (763 genes) and pro-
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Figure 3.9: Transcription factor genes employing alternative promoters upon stimulation. A.
Transcript expression levels of resting and stimulated Tregs for selected transcription
factors that are not differentially expressed but show an alternative transcript being
dominant between the resting and stimulated conditions. B. RNA-seq read pile-ups
across the intron and exons of the genes in resting and stimulated cells, indicating
different usage of transcript isoforms.
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Figure 3.10: Differentially regulated active promoters and enhancers provide insights into
mechanisms of gene expression regulation upon stimulation. A. Predictive func-
tion of the differentially active promoters (AP) and differentially active enhancers
(AE) to regulate gene expression. B. Number of differential active promoters and en-
hancers predicted to regulate gene expression. C. Distance between the enhancers
for the genes with multiple predictive differentially active enhancers. D. Regulatory
elements predictive of gene expression changes split per chromatin mark that was
differentially regulated.
moters (383 genes) were related to the immune response (Figure 3.11 ). Conversely, no
enrichment was found for the downregulated genes with associated active elements.
The genes driving the enrichment in immune related pathways included key Treg genes
induced upon activation. For example, TNFSF9, a gene that encodes for the 4-1BB ligand
that binds the TNFRSF9 co-stimulatory molecule that is upregulated upon stimulation
in a FoxP3 dependent manner (Marson et al., 2007) (Figure 3.12 A) and LRRC32, a gene
that encodes for GARP, and is upregulated on the surface of activated Tregs (Wang
et al., 2009) (Figure 3.12 B). To validate if the observed gene expression changes were
recapitulated at the protein level, I performed flow cytometry analysis to measure
the protein expression of GARP. Tregs from ten donors were stimulated overnight with
anti-CD3/anti-CD28 beads and stained with a fluorophore labeled antibody against
GARP 16 hours after activation. Indeed, the upregulation of GARP upon stimulation was
also significant at the protein level (p-value < 10-5) (Figure 3.12 B).
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Figure 3.11: Pathway enrichment analysis for the upregulated genes that have assigned predic-
tive regulatory elements in the chromatin. The numbers correspond to the number
of genes contributing towards the observed enrichment.
Interestingly, both genes, TNFSF9 and LRRC32, were characterised by changes in the
levels of deposition of H3K4 trimethylation only, while the levels of H3K27 acetylation
and chromatin accessibility remained unchanged. This indicates a mechanism in which
the promoter is primed for activity by high levels of H3K27ac and the gene expression
is regulated by the modulation of H3K4me3 levels. An additional 37 genes followed
a similar expression regulation pattern (Table 3.2 ), including 8 TFs (e.g. IRF1, NFKBIA,
EGR1, TBX21, FOSL2 and TRAF4). Therefore some active promoters of genes that play an
important role in Treg functions, were upregulated upon activation of Tregs.
Finally, I looked at the enrichment of TF binding sites (TFBSs) in the differential active
promoters and enhancers with concordant effects with gene expression (Figure 3.13 A).
I identified six enriched motifs in upregulated active enhancers, including the SMAD
family of TFs, which are required for TGF-β signalling, an essential Treg cytokine (Fig-
ure 3.13 B). Downregulated active enhancers were enriched for four motives, including
FoxP3 (Figure 3.13 B), the hallmark TF for Tregs. A different set of TFs was enriched
in active promoters. Here, I identified five enriched motifs in upregulated promoters,
including IRF4 and RARA (Figure 3.13 B). The only enriched motif in downregulated
promoters was TP53 (Figure 3.13 B). Interestingly, upon stimulation I observed the enrich-
ment of TFs that are able to polarise cells towards different fates. The SMAD family of
TFs positively regulates the generation of Th17 cells from Tregs, RARA is known to inhibit




























































































































Figure 3.12: Expression of genes related to the immune response is modulated through active
promoters and enhancers differentially regulated upon stimulation. A. Gene ex-
pression and genome track sequence pile-ups for H3K27ac, H3K4me3 and ATAC
for TNFSF9. B. Gene expression and genome track sequence pile-ups for H3K27ac,
H3K4me3 and ATAC for LRRC32. Also shown is the FACS plot of expression of GARP in
resting and stimulated conventional and regulatory T cells.
responses (Zheng et al., 2009). This finding could implicate that upon stimulation Tregs
recruit different TFs to promote T cell activation and ultimately arrive to an immune
response resolution.
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Table 3.2: Upregulated genes that are only regulated at the level of H3K4me3.
Symbol Reg. Score Symbol Reg. Score Symbol Reg. Score
SESN2 0.067 TNFSF9 0.309 MAP2K3 0.081
AIM2 0.067 PPAN 0.413 C8orf33 0.12
LINC01353 0.094 PPP1R15A 0.024 CHRNA6 0.153
SH2D2A 0.092 DUSP2 0.138 PYCR1 0.368
NTRK1 0.156 FOSL2 0.08 SNHG15 0.078
NPM3 0.319 SNHG17 0.041 TRAF4 0.14
PPIF 0.117 CENPM 0.226 TRIP6 0.585
CCDC86 0.042 HMOX1 0.108 AKAP7 0.086
LRRC32 0.105 RRP9 0.287 C16orf91 0.221
IL23A 0.272 EGR1 0.132 CHSY1 0.035
LINC00944 0.062 IRF1 0.028 CDKN1A 0.08































































Figure 3.13: Transcription factor enrichment in differential active promoters and enhancers. A.
Transcription factor binding sites (TFBS) enriched in the differentially regulated active
enhancers (AE) and active promoters (AP) that were predictive of gene expression
changes. B. Position weight matrices (PWMs) for the enriched TFBS motifs.
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3.3.6 Differential splicing upon stimulation
Of 5,018 differential peaks there were 4,367 that were not assigned to regulate the
expression of a gene nearby. This could implicate a long range enhancer-promoter
interactions, not captured by the 3 kbp window applied in my analysis. Another explana-
tion could be that a proportion of these peaks are associated with alternative splicing
or promoter switching. Previous studies did not report concordant changes between
H3K4me3 and gene expression upon T cell stimulation (Barski et al., 2009; Ni et al., 2016).
However, using the combination of different chromatin marks I was able to establish
an association between histone modifications and gene expression levels. Therefore, I
hypothesise that similar effects could also be extended to differential splicing events.
I used LeafCutter (Li et al., 2018) to identify and quantify the relative excision ratios of
26,342 alternative introns. LeafCutter only maps reads across junctions, so an excision
ratio is estimated based on the relative number of reads spanning a specific junction in
relation to the total number of reads that fall within that cluster. I performed differential
intron excision analysis between resting and activated Treg cells and detected 6,861
differentially spliced clusters corresponding to 4,279 genes (FDR < 0.01). Only a quarter
of these genes had been detected as differentially expressed when considering total
gene counts, the majority (72%) of which were upregulated (Figure 3.14 A). For example,
276 TFs (35% of all the TFs present in the dataset) had at least one differentially spliced
cluster, of which only 67 were differentially expressed as a total gene count. This set
included TFs essential to Treg cell identity, such as FOXP3 (Figure 3.14 B) and IKZF2, which
encodes for Helios, as well as BACH2, which is important in the NF-κB signalling pathway
and PRDM1, which controls the expression of IL-10 (Martins et al., 2006). Therefore
splicing analysis can give new insights into Treg stimulation induced gene regulatory
processes that might be missed at the gene counts level.
Since the LeafCutter algorithm has been reported to annotate up to 37% of novel junc-
tions (Li et al., 2018), I expected to find previously unreported splicing events in Tregs. I
investigated whether any of the differentially spliced junctions identified were novel
based on the GENCODE intron database (Harrow et al., 2012). I annotated 34.5% of
junctions as cryptic (Figure 3.14 C), due to either a new 5’ splice site, a 3’ splice site,
two new splice sites or a new connecting junction. In order to assess the likelihood
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of the newly identified introns being functional I measured the conservation of their
splicing patterns across different species using the PhyloP score (Pollard et al., 2010). I
found that the annotated splice junctions along with the novel junctions had a PhyloP
score shifted towards higher conservation compared to a random selection of base
pairs (t-test p-value < 10-16, mean PhyloP 3 and 3.4 accordingly). Cryptic 5’ and 3’ splice
sites also had a shifted score towards high conservation (t-test p-value < 10-16), but
less than the annotated junctions (mean PhyloP 0.4 and 0.9 accordingly). The score of
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Figure 3.14: Treg stimulation induces alternative splicing events that are not captured by gene
counts analysis. A. Differential expression status of all genes compared to differ-
entially spliced genes. B. The hallmark Treg TF, FoxP3, displayed two differentially
spliced clusters in response to stimulation. C. The number of differently annotated
discovered junctions. D. PhyloP conservation score of the differentially spliced
annotated junctions.
After having built confidence in the reliability of the novel splice junctions, I investigated
whether any of the identified events could result from a novel TSS. In order to answer
this, I overlapped the introns with differentially up and down regulated active promoters.
An additional 18% of upregulated active promoters (corresponding to 592 regions) to
the 12% annotated previously overlapped with differentially spliced sites. The overlap
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was smaller in downregulated regions, with only 9% of peaks overlapping. The overlap
was equally distributed across the five different junction annotations (Figure 3.15 A),
where of the 6,861 differential clusters 536 overlapped with an active promoter. The
majority of the genes overlapped with more than one differentially active promoter,
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Figure 3.15: Differential splicing analysis combined with differential active promoters identi-
fies unannotated promoters. A. Proportion of splice junctions that overlap with
a differentially active promoter, stratified by the same direction of regulation. B.
Number of differentially active promoters per differentially spliced gene.
To examine this hypothesis, I focussed on the genes that had more than one peak
overlapping a differentially spliced site. I found 137 genes which had an intron cluster
that overlapped with more than one upregulated active promoter, of which 21 had at
least one non-annotated site identified through alternative splicing. For example, BACH2
was characterised by a hidden promoter near exon 5 which has not been previously
reported as a TSS (Figure 3.16 ). I manually curated all of the results into a confident list
of putative novel TSS discovered in activated Tregs (Table 3.3 ).
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Figure 3.16: BACH2 read pile ups across the different assays. BACH2 is an example of a differen-
tially spliced gene with a hidden promoter near exon 5.
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Table 3.3: Curated table of gene clusters with cryptic 5’ as identified with LeafCutter which
overlap with a differential active promoter.
Gene Chr Cluster start Cluster end Psi Peak start Peak end Reg.
THEM4 chr1 151895194 151907321 -0.035 151904370 151906291 down
RABGAP1L chr1 174982905 174989849 -0.061 174989781 174991559 up
DNMT3A chr2 25314161 25314239 -0.013 25312413 25314978 up
ACOX3 chr4 8416535 8435923 -0.003 8434792 8436758 up
RFC1 chr4 39351476 39353287 -0.032 39352048 39354813 up
GPRIN3 chr4 89250233 89292972 0.013 89287934 89291450 up
CAMK2D chr4 113661772 113677508 0.02 113677125 113677605 up
RP11-223C24.1 chr4 142556334 142583452 0.074 142556250 142558001 up
EXOC2 chr6 497489 498736 -0.025 496434 501111 up
BACH2 chr6 90008856 90079634 -0.017 90074556 90082215 up
PRKAR1B chr7 584568 585196 -0.053 582705 585353 up
PRKAR1B chr7 596304 601453 -0.068 600745 605710 up
MAD1L1 chr7 2014642 2066490 0.112 2065942 2066709 down
NCOA2 chr8 70141399 70141479 -0.703 70137278 70145939 up
NCOA2 chr8 70216764 70216997 -0.169 70216687 70217838 up
TTC39B chr9 15267948 15299350 0.037 15294520 15297400 up
TTC39B chr9 15267948 15299350 0.037 15298564 15300490 up
ETS1 chr11 128462576 128480191 0 128478615 128481236 up
ATP10A chr15 25781223 25861782 0.071 25849286 25851564 up
CFDP1 chr16 75305182 75391380 0.011 75380122 75381111 down
RAI1 chr17 17681793 17792933 -0.002 17781594 17784555 down
RAI1 chr17 17681793 17792933 -0.002 17792699 17793267 down
SIRPG chr20 1649408 1686332 -0.048 1681827 1687206 up
TIAM1 chr21 31195305 31195406 -0.351 31185659 31196858 up
RAC2 chr22 37226803 37241587 0 37237226 37239494 up
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3.4 Discussion
Regulatory T cells are necessary to maintain the immune system in balance, and both
changes in Treg cell numbers and Treg functional defects can result in autoimmunity
(Buckner, 2010). The importance of Tregs is greatly appreciated by the immunology
community and there is an abundance of studies characterising Tregs through FACS
(Roncador et al., 2005; Duhen et al., 2012). However, these studies rely on a limited
number of protein markers, and a more global approach to identify Treg specific genes
and transcriptional programs is needed. Previous studies suggest that there are large
changes in gene expression in response to stimulation, which together compose a
Treg specific signature. However these studies have either been carried out in mice
(Stubbington et al., 2015), using microarray technology (Pfoertner et al., 2006) or in a
limited sample size (Birzele et al., 2011; Bhairavabhotla et al., 2016). Understanding
the changes induced by stimulation at the transcriptional level and integrating this
with chromatin data is important to advance our understanding of how the immune
response is orchestrated, and how that might increase the risk of autoimmunity.
The lack of genomic resources for Tregs can be partly attributed to the fact that they
are scarce. Therefore, to study rare cell populations it is important to develop robust
genomic protocols that are sensitive enough to be applied to small amounts of cellular
material. In this chapter I presented a methodical comparison between an established
protocol for chromatin profiling, ChIP-seq, and its recentmodification, ChM-seq (Schmidl
et al., 2015). ChM has been successfully used on cell lines (Schmidl et al., 2015), which
are easier to handle than primary cells, and on innate lymphoid cells (Lim et al., 2017),
but the robustness of the protocol across other cell types remains to be shown. Here,
I demonstrated that ChM-seq can be robustly used for profiling primary Tregs, a cell
type that is rare and has low viability ex vivo. ChM-seq was faster to perform than
established ChIP-seq protocols, captured 100% of the peaks mapped with ChIP-seq
and achieved an overall higher significance for the same peaks. I therefore applied
ChM-seq in a larger scale genomic analysis to profile stimulation induced changes in
Treg regulatory landscape.
Through the integration of profiles from three different chromatin marks, H3K27ac
ChM-seq, H3K4me3 ChM-seq and ATAC-seq, I was able to gain valuable insights into the
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dynamic process underlying complex gene regulatory processes in Tregs and define
gene promoters and enhancers. The majority of histone changes upon stimulation were
induced at the level of acetylation of H3K27 and chromatin accessibility, while the gene
promoters, as marked by the tri-methylation of H3K4 remained unchanged. H3K4me3
is deposited at the 5’-end of a genes and is known to mark actively transcribed genes.
The strength of H3K4me3 signal at promoters is strongly correlated with the expression
of genes (Okitsu et al., 2010). By combining chromatin data with gene expression I was
able to demonstrate that changes in the chromatin landscape were predictive of the
expression of 1,706 genes. Of these, 35 genes were regulated at the level of H3K4me3
exclusively, without changing the status of H3K27ac. This implies the precise action of
methyltransferases independently of acetyltransferases, which to my knowledge has
yet to be reported in Tregs. Among the 35 genes was LRRC32, which encodes for GARP,
whose expression on the cell surface correlated with the increase in gene expression.
GARP has been suggested to be a specific marker for activated Tregs, with levels of GARP
expression correlating with the cells’ suppressive capacity (Wang et al., 2009). It would
therefore be interesting to study the remaining genes on this list in the context of Treg
biology to better understand their regulatory mechanism and function. In fact, many
of these are already known to be highly expressed in Tregs upon stimulation, such as
DUSP2 and FOSL2 (Birzele et al., 2011), while others have never been reported before,
such as MAP2K3 and TNFSF9. TNFSF9 encodes for the ligand of 4-1BB, which has been
extensively studied in Tregs (Marson et al., 2007). Recent data suggests that 4-1BB ligand
is expressed on T cells in order to prevent effector T cell development and maintain
a favourable Treg to Tcon ratio (Eun et al., 2015). Along with our data demonstrating
the upregulation of TNFSF9 and the formation of a new promoter upon stimulation,
this suggest that expression of 4-1BB ligand might be another mechanism employed by
Tregs to maintain the immune balance.
The confident definition of active promoters through the intersection of the chromatin
annotation layers also gave me the opportunity to examine unannotated genes TSS. I
used RNA-seq annotation-free approaches to quantify splicing events induced upon
stimulation. I overlapped the newly defined exon junctions with the differentially active
promoters to determine whether some of these could mark unknown transcripts. I
found 21 genes that had unannotated promoters spanning their gene body. These
included the transcription repressor BACH2 which promotes the differentiation of Tregs
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(Roychoudhuri et al., 2013) and has been implicated in immune-mediated diseases
such as coeliac disease and inflammatory bowel disease. Another gene with a putative
cryptic TSS is the DNA methyltransferase DNMT3A. DNMT3A is expressed at lower levels
in Tregs of patients with rheumatoid arthritis (RA) than healthy controls as measured
by qPCR (Kennedy et al., 2014), even if deletion of the gene in mice does not seem to
impair the expression of FOXP3 (Wang et al., 2013a). This discrepancy could be due to
the fact that RA patients express a different isoform of DNMT3A which might be missed
by conventional primers designed for the primary isoform. Experimental validation of
the expression of different transcripts and determining whether they are coding would
increase our understanding of Treg cell biology.
The clustering of genes by expression pattern across the two conditions provided in-
sights on the processes of gene regulation upon stimulation. The majority of genes
related to the immune response were upregulated upon stimulation. These included
previously identified Treg specific genes such as IL2RA, CTLA4, LRRC32, IL13, IL10 and
TNIP3 (Birzele et al., 2011) and non-Treg specific genes such as SCD and IL22. In addition,
I found that some genes previously believed to be specific to naive T cells, were also
upregulated in Tregs, such as FOS, CXCL11 and NR4A2. These discrepancies could come
from different Treg isolation protocols (use of commercially available kit instead of flow
cytometry sorting), different stimulation approaches (anti-CD3/anti-CD28 antibodies
instead of PMA/ionomycin) and differences in sample size. Integration of different
datasets and combined analysis could help determine the source of these differences
and instruct the design of future RNA-seq experiments.
By examining different isoforms in Tregs I was able to find a set of genes that employ
alternative promoters upon stimulation. Interestingly, amongst these genes I identified
five transcription factors (TFs), three of which have documented functions in T cells. For
example, ELF4 has been shown to facilitate FOXP3 expression in thymic Tregs (Rudra
et al., 2012) and to be downregulated upon activation in naive CD4+ cells (Yamada et al.,
2010). Alternative transcription regulation represents a potential regulatory method
for the expression levels of this gene. Previous studies on alternative transcription of
NFATC1 have mostly focused on the lack of the C-terminal domain, which is specific to
effector T cells and not Tregs (Vaeth and Feske, 2018). The long transcript of NFATC1 plays
an important role in Treg differentiation and function, where it can directly bind the
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CNS2 of the FOXP3 gene to maintain its stable expression (Li et al., 2014). However there
are no studies that show a specific function for the alternative promoter I identified here.
Finally, YY1 TF levels are lower in resting Tregs compared to other T helper cells whereby
it is essential for the regulation of Th2 cell fate (Hwang et al., 2013). YY1 overexpression
anti-correlates with the level of FoxP3, since YY1 inhibits SMAD3/4 binding at the FOXP3
locus, resulting in the loss of the cells’ suppressive capacity (Hwang et al., 2016). In
fact, in natural settings YY1 expression is increased in Treg cells under inflammatory
conditions. Here I observed a different isoform being upregulated upon stimulation,
which results in a different protein coding product, shedding light into the potential
regulation of this gene. If the alternative transcript of a TF lacks the DNA binding do-
main, this could have substantial effects on the downstream processes the TF regulates.
Further validation studies on the potentially different functions of the two YY1 isoforms
are needed to better understand Treg regulation.
This chapter provides a resource of gene regulatory events detected in Tregs upon
stimulation. It will take follow up studies to assess the extent to which these events are
specific to Tregs or whether they reflect more global changes in gene expression in T
cells upon stimulation.
102 3 Regulation of gene expression in regulatory T cells in response to cell stimulation
4Linking genetic effects of molecular
phenotypes of regulatory T cells to
immune disease associated variants
Collaboration note
The data acquisition was performed in collaboration with Natalia Kunowska, Gosia
Golda and Claire Cattermole, all of whom were Research Assistants in Gosia Trynka’s
lab. I did the RNA-seq data analysis and the integration with GWAS variants. Lara
Bossini-Castillo performed the ATAC-seq, H3K4me3 and H3K27ac ChM-seq data analysis,
and was involved in all discussions around this project. RNA-seq library construction
and sequencing was undertaken by the DNA Pipelines core facility at Sanger. I thank
Kaur Alasoo for the helpful discussions on the best QTL analysis approaches, Alice Mann
for sharing the GWAS summary statistics and David Roberts’ lab for providing us with
half of the processed lymphocyte cones.
4.1 Introduction
Genome-wide association studies (GWAS) have revealed hundreds of genetic variants
associated to common immune diseases, such as inflammatory bowel disease (IBD) and
rheumatoid arthritis (RA). The vast majority of disease associated variants reside out-
side gene coding regions, which means that their downstream effects remain unknown.
Furthermore, the majority of disease variants map to regions of strong linkage disequi-
librium (LD), which can include up to hundreds of highly correlated single nucleotide
polymorphisms (SNPs), making the causal variant statistically indistinguishable from
others (Spain and Barrett, 2015). Finally, the associated loci harbour multiple genes, and
without further experiments it is impossible to determine which gene is affected by the
associated variant. It is important to address these limitations, since linking associated
disease variants to target genes, pathways and cellular functions, is instrumental for
understanding disease processes and the development of new therapies.
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In order to link disease variants to target genes, an easily implemented approach is to
measure the genome-wide gene expression levels to identify genes whose expression is
correlated in a linear fashion with the allele frequency of the nearby variants, referred
to as expression quantitative trait loci (eQTLs). Statistical approaches have shown that
a small proportion of the total number of eQTLs ( 2%) is expected to colocalise with the
associated variants (Guo et al., 2015). Indeed, coeliac disease variants were found to
be enriched in peripheral blood mononuclear cells (PBMCs) eQTLs (Dubois et al., 2010;
Trynka et al., 2011), and eQTLs detected in CD4+ memory T cells were enriched for RA
and type-1 diabetes (T1D) variants (Hu et al., 2014).
However, in order to achieve reliable eQTL and subsequent colocalisation results, it
is important to carry out gene expression assays in an isolated cell type, since gene
expression is cell type specific. Different statistical approaches have been developed
to determine the most relevant cell types for the study of different complex diseases.
These studies leverage the fact that disease variants localise in the non-coding regions
of the genome, and assess their enrichment in epigenetic marks. Such approaches
identified that across different immune diseases the associated variants were enriched
in active chromatin marks and accessible chromatin sites of CD4+ T cells ( Maurano
et al., 2012; Trynka et al., 2015, 2013; Finucane et al., 2015). CD4+ T cells are a heteroge-
nous population of cells, with each subset characterised by a specialised function,
and genetic effects specific to a rare subset of cells would be missed when assaying
total CD4+ cells. For example, while an eQTL study in total CD4+ T cells from over 300
individuals found 166 genes colocalising with five immune traits, it was difficult to
deconvolute the role of the different genes in each T cell subset (Kasela et al., 2017). In
fact, previous studies showed that enrichment of disease variants was observed in rare
cell subpopulations, such as regulatory T cells (Trynka et al., 2013), which only constitute
5% of CD4+ cells. Tregs were more highly enriched than other CD4+ T cell types for
T1D and RA risk variants, which would imply that a proportion of the disease variants
modulate gene expression by affecting the function of enhancers and promoters that
are specific to Tregs. The observations made were based on genetic evidence, but the
role of Tregs in immune diseases is well documented in the immunology field (Buckner,
2010) and many differences from naive cells have been reported using comparative
RNA-seq approaches (Birzele et al., 2011; Bhairavabhotla et al., 2016).
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Although correlation of disease associated variants with gene expression through eQTL
studies is informative, most of the time it is insufficient to determine the exact causal
variant within a locus of statistically correlated polymorphisms. This challenge can be
addressed by carrying out RNA-seq in conjunction with assays that annotate the non-
coding portion of the genome, such as profiling histone modifications through ChIP-seq
or open chromatin regions with ATAC-seq. By performing QTL mapping across different
molecular layers one is able to refine the allelic effects propagation from chromatin to
gene expression. Additionally, assaying chromatin profiles gives the advantage that the
variants can be functionally prioritised by assessing their location in the regulome. A
variant within a peak will have a higher probability of being functional compared to
a variant outside of a peak. Colocalisation across multiple layers of gene expression
regulation would therefore provide a mechanism of action for a specific variant within
the locus, such as the disruption of a transcription factor binding site. Of course, such
approaches are expensive and if carried out would require a commensally large effort.
It has been estimated that approximately 30% of variants affecting gene expression
in CD4+ T cells act by affecting the chromatin conformation nearby a gene (Chen et al.,
2016; Gate et al., 2018).
In this chapter I assess the role of genetic variants associated with immune-mediated
diseases on gene expression (eQTLs) and transcript ratios (trQTLs) in naive and regula-
tory CD4+ T cells from 169 and 100 individuals, accordingly. I identify thousands of eQTLs
and trQTLs and find that they are largely independent from each other. By comparing
eQTLs and trQTLs between Tregs and naive CD4+ T cells, I pinpoint to Treg specific effects,
and find that 58% of the effects are shared between these two closely related cell types.
I colocalise eQTLs and trQTLs with GWAS in Tregs and naive T cells, and find that the
majority of colocalisation associations occur with immune-mediated diseases. While
the majority of colocalising signals were shared across the two cell types, there were
many that were Treg specific, implicating important differences in the biology of the
two cells. Finally, the same individuals from which I had Treg gene expression profile
were assayed for ATAC-seq, H3K4me3 ChM-seq and H3K27ac ChM-seq, allowing me to
map QTLs. By using the five different QTL maps I was able to refine 33 GWAS association
signals to prioritise functional variants for MAP3K8 and TNFRSF9/PARK7.
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4.2 Materials and Methods
4.2.1 Cell culture and sample collection
Lymphocyte cones were obtained with informed consent from donors at the NHS Blood
and Transplant, Cambridge (REC 15/NW/0282) and from the NHS Blood and Transplant,
Oxford (REC 15/NS/0060).
All donors were healthy adults of Caucasian origin. PBMCswere isolated using Lympholyte-
H (Cedarlane Labs, Burlington, Canada) density gradient centrifugation. CD4+ T cells
fraction of the PBMCs was obtained by negative selection using EasySep® Human CD4+ T
Cell Enrichment Kit (Cat. no. 19052, StemCell Technologies, Vancouver, Canada), following
the manufacturer’s instructions but using half the recommended volumes of the CD4+ T
Cell Enrichment Cocktail and the D Magnetic Particles. CD4+ cells were resuspended
in the FACS staining buffer (2 mM EDTA and 0.5% FCS in PBS) at 108 cells per ml. The
cells were stained with the following antibody cocktail: anti-CD4+-APC (30 µl/ml final
volume, clone OKT4, Cat. no. 317416, BioLegend, San Diego, U.S.), anti-CD127-FITC and
(30 µl/ml, clone eBioRDR5, Cat. no.11-1278-42, Thermo Fisher Scientific, Waltham, U. S.)
and anti-CD25-PE (80 µl/ml, clone M-A251, Cat. no. 356104, BioLegend) for at least 30
minutes at room temperature in the darkness. The cells were washed copiously with
FACS buffer and resuspended at 108 cells per ml in full medium (IMDM, 10% FCS) and
kept overnight at 4ºC. Before sorting, the cells were stained with DAPI, to discriminate
live and dead cells. The CD4+, CD25high, CD127neg population corresponding to Treg
lymphocytes was used for the downstream assays.
4.2.2 FACS staining
To define the proportions of memory and naive cells in the CD4+ population, an aliquot
of 106 cells CD4+ enriched cells were resuspended in 100 µl FACS buffer and stained with
a cocktail of anti-CD4+-APC and anti-CD127-FITC antibodies (3 µl each), anti-CD25-PE (8
µl) and anti-CD4+5RA-BV785 (4 µl, clone HI100, Cat. no. 304140, BioLegend), incubated
at room temperature in the dark for at least 30 minutes, washed copiously with FACS
buffer and analysed on BD Fortessa.
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To verify the FoxP3 expression in the sorted Treg populations, after the sorting the cells
were stained for expression of CD4+, CD25 and CD127 surface markers, and then stained
with anti-FOXP3-BV421 antibody (5 µl per 106 cells, clone 206D, BioLegend) using the
eBioscience™ Foxp3 / Transcription Factor Staining Buffer Set (Thermo Fisher Scientific),
according to the manufacturer’s instructions.
4.2.3 RNA-seq
For RNA-seq experiments, 0.5 x 106 sorted Treg cells were washed with ice-cold PBS and
resuspended in TRIzol (Thermo Fisher Scientific). After standard phenol/chloroform
isolation step, the total RNA contained in the upper, aqueous phase was further purified
with RNeasy Mini Kit (QIAgen, Hilden, Germany), according to the manufacturer’s instruc-
tions. The RNA libraries were constructed using KAPA RNA HyperPrep Kit (Roche, Basel,
Switzerland), following a standard automated protocol. The libraries were multiplexed
and sequenced at 75 bp paired-end on an Illumina HiSeq V4 to yield on average 57
million reads per sample.
4.2.4 ATAC-seq and ChM-seq
ATAC-seq was performed as described in Chapter 3 to yield on average 112 million reads
per sample. ChM-seq was performed as described in Chapter 2 and Chapter 3 to yield 70
million reads per samples for H3K27ac and 79 million reads per samples for H3K4em3.
4.2.5 Polymorphism genotyping and imputation
A total of 551,839 genetic markers were genotyped using the Infinium® CoreExome-24
v1.1 BeadChip by Illumina. After quality control per individual, the total genotyping rate
reached 0.99869. 243,820 variants passed several per polymorphism filtering steps (mi-
nor allele frequency (MAF) > 10%; SNP call rate > 95%, Hardy-Weinberg equilibrium (HWE)
p-value < 0.001). We then performed imputation using BEAGLE 4.1 software (Browning
et al., 2018) with a reference panel comprising the individuals included 1000 Genomes
Phase 3 and the UK10K projects (model scale parameter = 2). We applied stringent
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post-imputation quality filtering (Allelic R-Squared ≥ 0.8, HWE p-value < 0.001, MAF >
10% in the analysed cohort and in the reference panel) and 4,647,308 variants remained.
Of those, 512,320 were insertion-deletions and 608 were multiallelic polymorphisms.
European origin was confirmed by principal component analysis (PCA) including the
1000 Genomes project and UK10K project individuals. Identity by state was calculated
for all individuals and relatives and replicates were removed (pi hat > 0.2). Duplicate
donors were identified.
4.2.6 RNA-seq data processing
Reads were aligned to the GRCh38 human reference using STAR and quantified using
featureCounts and using Salmon, as described in Chapter 3. I used VerifyBamID v1.0.0
(Jun et al., 2012) to detect and correct sample swaps and cross-contamination across
the donors. I excluded short RNAs and pseudogenes from the analysis. I quantile
normalised the gene expression values using the CQN method (Hansen et al., 2012)
for downstream analysis. I collapsed the transcript expression levels to genes using
tximport and excluded short RNAs and pseudogenes from the analysis. I only kept
genes with mean expression greater than 1 transcript per million (TPM). This resulted
in 12,227 genes using the STAR alignment approach and 13,773 genes using the Salmon
approach.
In addition to collapsing the transcripts to genes, I used the Salmon transcript output
to calculate transcript ratios based on the total expression per gene. I determined
the transcript ratios of 125,879 transcripts corresponding to 14,885 genes. I used the
STAR+featureCounts output to determine the euclidean distance between all samples
in the dataset. Finally, I used Leafcutter (Li et al., 2018) to identify intron clusters and
determine alternatively spliced junctions within these. I used these measurements to
calculate the abundance ratios for the different junctions within a cluster. I determined
the junction ratios of 162,251 junctions corresponding to 39,265 clusters.
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4.2.7 Gene expression QTL mapping and analysis
Before carrying out a QTL study I removed the major histocompatibility complex locus
and the X and Y chromosomes of each sample. I used linear regression implemented
in the QTLtools (Delaneau et al., 2017) software to map cis eQTLs within a +/-500 kbp
window around the gene. I used the “–permute 10000” within a 100 kb window option
to obtain permutation p-values for each gene. For each mapping approach I used as
covariates the number of PCs that would lead me to explain down to 1% of the observed
variance, which was 16 PCs for STAR and Salmon, 19 PCs for transcript ratios and 37 PCs
for splice ratios. I picked the top most significantly associated variant for each gene and
used false discovery rate (FDR) correction to identify genes with at least one significant
eQTL at 5% FDR level. I processed in exactly the same way the naive CD4+ T cell dataset
after downloading it from the EGA archive using the study code EGAD00001002671. I
included 14 PCs for STAR alignment and 8 PCs for transcript ratios using Ensembl.
I identified genes that were eQTLs using one method or one cell type at 5% FDR and
used their lead variants in the other method or cell type to calculate the linkage dise-
quilibrium (LD) between the two variants.
I defined an eQTL as cell type specific when comparing naive and regulatory T cells
using three criteria: (i) the gene was expressed in one cell type only, (ii) the gene had
a significant eQTL effect in one cell type (FDR ≤ 0.05) and not in the other (FDR > 0.2)
and (iii) one cell-type’s eQTL SNP was unlinked from any of the eQTL SNPs reported in
the other cell type. I correlated the regression slopes of the top significant variant of
each cell type with the same gene-variant combination of the other cell type, even if
the gene-variant were not eQTLs. I defined genes with opposite effect if the absolute
regression coefficient was greater than 0.5 in both cell types. In trQTL, I defined cell type
specific effects using the same first two criteria, but the third one was: (iii) a different
transcript’s ratio was disturbed between the two cell types. I used g:Profiler (Reimand
et al., 2016) R package to identify the KEGG pathways enriched for cell type specific eQTL
and trQTL genes.
I used the fdensity function from the QTLtools package (Delaneau et al., 2017) to calcu-
late the enrichment of regulatory marks near lead eQTL and trQTL variants.
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4.2.8 Colocalisation with immune disease traits
I used coloc v2.3–1 (Giambartolomei et al., 2014) to test for colocalisation between QTLs
and GWAS hits listed in Table 4.1 . I ran coloc on a 400 kbp region centered on each
lead expression (e)QTL, transcript ratio (tr)QTL, chromatin accessibility (ca)QTL, activity
(act)QTL and promoter (prom)QTL variant that was less than 100 kbp away from a GWAS
variant with a nominal p-value< 10-5. I only kept the colocalisations between molecular
QTLs and GWAS that had more than 50 SNPs tested, and were therefore well powered,
and where the sum of the probabilities of having a significant signal in both studies
was over 0.8 (H3+H4 ≥ 0.8). I finally required the probability of the signal being due to
a single shared variant (H4) to represent 0.8 of the probability of having a significant
signal in both studies (H4/(H3+H4) ≥ 0.8). I calculated the R2 between all colocalising
lead immune GWAS variants to determine immune disease loci.
Table 4.1: GWAS summary statistics used in the colocalisation analysis.
Abb. Trait Reference Category
ALL Allergies Ferreira et al., 2017a Autoimmune
AST Asthma Demenais et al., 2018 Autoimmune
CD Crohn’s disease Lange et al., 2017 Autoimmune
CEL Celiac disease Trynka et al., 2011 Autoimmune
IBD Inflammatory bowel disease Lange et al., 2017 Autoimmune
MS Multiple sclerosis International Multiple
Sclerosis Genetics Con-
sortium (IMSGC) et al.,
2013
Autoimmune
PBC Primary biliary cirrhosis Cordell et al., 2015 Autoimmune
PS Psoriasis Tsoi et al., 2012 Autoimmune
RA Rheumatoid arthritis Okada et al., 2014 Autoimmune
SLE Systemic lupus erythromatosus Bentham et al., 2015 Autoimmune
T1D Type-1 diabetes Onengut-Gumuscu et al.,
2015
Autoimmune
UC Ulcerative colitis Lange et al., 2017 Autoimmune
MCH Mean corpuscular hemoglobin Astle et al., 2016 Metabolic
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CAD Coronary artery disease Nelson et al., 2017 Metabolic
LDL Low density lipoprotein Astle et al., 2016 Metabolic
T2D Type-2 diabetes Morris et al., 2012 Metabolic
AD Alzheimer’s disease (late onset) Lambert et al., 2013 Other
DEP Depression (broad) Howard et al., 2018 Psychiatric
INT Intelligence Sniekers et al., 2017 Psychiatric
SCZ Schizophrenia Schizophrenia Working





4.3.1 eQTL mapping and comparison of alignment methods
I collected 117 RNA samples from 100 genotyped donors of European ancestry over
the course of 10 months. I used two alignment methods to quantify gene expression
levels; the first one, STAR (Dobin et al., 2013), relied on a reference genome, while the
second approach, Salmon (Patro et al., 2017), used a pseudo-alignment algorithm which
is reference free. Additionally, the Salmon algorithm allowed me to quantify the tran-
script ratios (referred to as Ensembl) and the LeafCutter algorithm allowed to assess for
differential splicing events across all samples (referred to as leafcutter) (Li et al., 2018).
I first verified whether there were any sample swaps, and found a single swap between
two donors that was rectified. I examined how much of the gene expression variability
was explained by any of the recorded experimental procedures using the STAR align-
ments and featureCounts quantification, and found that there was a large batch effect,
based on when the blood samples were processed, explaining 37.7% of the variability.
Using PCA I determined that the first 16 PCs collectively explained down to 1% of the
variability. Since the Treg cohort was collected over the course of 10 months I wanted
to test if that would have an effect on the gene expression profiles. For that I used the
17 donors who were sampled at two independent time points. I observed that the Eu-
clidean distance between the gene profiles of two replicates was smaller than between
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Euclidean distance between two donors









Figure 4.1: Euclidean distance between all pairs of donors. Histogram of the Euclidean distance
between any two donors in the dataset. The red lines mark the location of the 17
donors who had blood drawn on two occasions.
two random samples (Kolmogorov-Smirnov test p-value = 1.33x10-6) (Figure 4.1 ).
I used a standard linear regression model to map QTLs (Delaneau et al., 2017) using
the gene expression and transcript ratios measurements, within a 500 kbp cis-window
around the gene, transcript or intron cluster. I included the first 16 PCs as covariates
for both quantification methods. I detected genetic effects on over 4,000 genes and
2,000 transcript ratios at 5% FDR (10,000 permutations; Figure 4.2 ). At the gene level I
observed 23% more eQTLs using STAR combined with featureCounts than using Salmon
quantification while at the transcript ratio level (trQTLs) there was no difference in the
number of trQTLs detected. After conditioning on the lead variant I found at least one
additional effect for 32%-48% of the genes, depending on the alignment method used.
In order to compare the different QTL mapping approaches I tested if the lead variants
for the same gene-sets (or transcript-sets) were concordant. Specifically, I took all lead
variants at 5% FDR from one method and compared them to the lead variants of the
same genes (or transcripts) from the second method. I then calculated the fraction of
lead variant pairs that were in high (R2 ≥ 0.8), medium (0.2 ≤ R2 < 0.8) or low LD (R2 <
0.2). At the gene level, a small proportion of genes that were eQTLs did not pass the
filtering thresholds using STAR, and were therefore annotated as specific (Figure 4.3 ).
Nevertheless, 46% of the eQTLs detected using either of the two mapping approaches
were in high LD with each other. For the remaining eQTL analysis I used the STAR
quantification since it led to a higher discovery of eQTLs, yet discarding the eQTLs for
the genes with low counts. At the transcript ratio level, 45% of Ensembl trQTLs were
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Figure 4.2: Number of Treg genes whose expression is under control of a common genetic vari-
ant. Number of gene eQTLs (A) and trQTLs (B) detected by four different mapping
and expression quantification approaches. The colour corresponds to the number of
independent variants influencing the expression of each gene.
concordant with the leafcutter trQTLs, while 37% of leafcutter QTLs were concordant
with Ensembl trQTLs. Since I discovered more trQTLs using the Ensembl annotation
and they resulted in higher concordance with leafcutter, I only used Ensembl for any
further trQTL analysis. Finally, I compared the concordance between eQTLs and trQTLs.
Interestingly, I observed that the two were largely independent of each other, with only
25% of eQTLs also affecting transcript ratios and 29% of trQTLs also being eQTLs. This
suggests that the majority of eQTL variants are independent of splicing, and that genetic
variants that affect transcript ratios might be undetected when collapsing read counts
to gene levels.
4.3.2 Cell type specificity of gene expression
Next, to estimate the proportion of eQTLs specific to Tregs, I compared eQTLs discovered
in Tregs with eQTLs called in CD4+ naive T cells. I chose this dataset because these
two cell types are closely related, the naive CD4+ T cell dataset is of similar size (169
individuals) to the Treg dataset and all the individuals are of British origin (Chen et al.,
2016). I assessed if the same set of genes was under genetic control in the two cell
types. To call an eQTL gene cell type specific I required FDR ≤ 0.05 in one cell type
and FDR > 0.2 in the second cell type. Using this criterion, I observed that the majority
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Figure 4.3: Concordance between the lead QTL variants detected by different methods. Sum of
genes with different LD scores between the top variants identified by two quantifica-
tion methods. The LD categories are: high LD: R2 ≥ 0.8; medium LD: 0.2 ≤ R2 < 0.8;
low LD: R2 < 0.2.
of Treg eQTL genes were shared with naive T cells (77.4%) (Figure 4.4 A). To further
understand if the genes that were called eQTLs in both cell types were regulated by the
same genetic variants, I calculated the strength of LD between all of the independent
associated genetic variants reported per gene between the two cell types. I only kept
the strongest LD score per gene for all downstream analysis. I found that amongst
the shared genes, the majority of the variants were in high LD with each other, but a
substantial proportion (33%) were caused by independent signals. Therefore, to define
a gene as a cell type specific eQTL I used the following three categories: (i) the gene
was expressed in one cell type only (2.9% of eQTLs), (ii) the gene had a significant eQTL
effect in one cell type (FDR ≤ 0.05) and not in the other (FDR > 0.2; 15.7% of eQTLs)
and (iii) the Treg eQTL SNP was unlinked from any of the eQTL SNPs in naive T cells
(23.9% of eQTLs). Amongst the second category I found many genes related to Treg
function, including CD28 co-stimulation receptor (FDR=2.38x10-8; regression slope=0.155)
and MAP3K8 which induces the NF-κB immune response (FDR=5.11x10-6; regression
slope=-0.272) (Figure 4.4 C). In total, I found 2,284 Treg specific genes and 4,419 naive
T cell specific genes. The higher number of naive eQTL genes can be partly explained
by the larger sample size resulting in a larger starting number of eQTLs. Interestingly,
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both naive and regulatory T cell specific eQTL genes were enriched in T cell receptor
signalling pathways (Figure 4.4 E; p-value naive = 4.1x10-3; p-value Treg = 4.9x10-3). These
genes can help us better understand the differences in biology between these two cell
types, since they are involved in essential T cell processes.
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p-value = 8.98x10-10  beta = -0.44p-value = 0.716   beta =0.03
p-value = 5.65x10-7  beta =0.55p-value = 0.663  beta =0.06
p-value = 7.35x10-12   beta =0.16p-value = 0.859   beta =0































































































































































































































































































































































Figure 4.4: Comparison of eQTLs and trQTLs called in CD4+ naive and regulatory T cells. Classi-
fication of cell type specific QTLs discovered in naive and regulatory T cells for eQTL
(A) and trQTL (B). Examples of Treg specific C. eQTLs and D. trQTLs. E. Results of the
pathway enrichment analysis for the cell type specific eQTLs and trQTLs using the
KEGG database.
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I repeated the same analysis using the trQTLs (Figure 4.4 B). While the overall pattern
looked similar to the eQTL analysis, I observed a lesser degree of overlap between
the two cells. Additionally, I found that when examining transcript ratios, even when
the same gene in naive and regulatory T cells was affected by a trQTL effect, in 42.7%
of cases it was a different transcript’s ratio that was disturbed by a genetic variant. I
defined Treg/naive T cell specific trQTLs using the same first two categories as with
the cell type specific eQTL genes, that is (i) the gene was expressed in one cell type
only and (ii) the gene was a significant trQTL in one cell type (FDR ≤ 0.05) and not
in the other (FDR > 0.2), which collectively represented 13.2% of trQTLs. In addition, I
included a third category (iii) that a different transcript’s ratio was disturbed between
naive and regulatory T cells. Amongst the Treg specific trQTLs there were many genes
related to the immune response, such as FOSL2, a component of the AP1 transcription
factor machinery (FDR=1.3x10-5; regression slope=-0.442) and TNFRSF9, which encodes
for the 4-1BB co-stimulatory ligand (FDR=2.8x10-3; regression slope=0.55) (Figure 4.4 D).















































Spearman cor = 0.793
5058/5371 eQTLs
Spearman cor = 0.811
Figure 4.5: Correlation between the regression slopes for the top eQTL variants discovered in
CD4+ naive and regulatory T cells. The regression slope of the top eQTL variant in
naive T cells plotted against the slope for the same variant-gene pair in Tregs (left
panel) and vice versa (right panel).
I observed that the sizes and the direction of the effects of the mapped eQTLs were
highly correlated between the two cell types (Figure 4.5 ; Spearman correlation 0.793
in naive and 0.811 in regulatory T cells). There were only twelve genes with opposite
directions and only five of these were eQTLs in both cell types; DST and PLEKHA7, which
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are adhesion junction plaque proteins, were also eQTLs in Tregs and GNLY, MME and
HIST1H4B were also eQTLs in naive T cells. None of these genes have a different function
in the two cell types. The number of eQTLs with opposite effects was therefore very
small, which is consistent with the close relation of these cell types.
4.3.3 Colocalisation of eQTLs and trQTLs with disease associated variants
I used a statistical colocalisation approach to determine whether any of the observed
eQTLs and trQTLs colocalised with immune disease associations (Giambartolomei et al.,
2014). Such colocalisation of disease and molecular signals would implicate the same
underlying causal variant and could provide insights in the molecular mechanisms for
some of the immune associated GWAS loci. I tested five hypothesis for colocalisation.
Hypothesis zero (H0) tests whether there is any association at all, H1 and H2 test whether
there is an association with just one or the other study, H3 tests whether the signal from
GWAS and QTL is due to two independent SNPs, and H4, that the association between
GWAS and QTL is due to one shared SNP. I used 0.5 as a probability threshold for H4 and
calculated the colocalisation power (sum of H3 and H4), on which I used a 0.8 threshold.
To report a significant colocalisation I used a 0.8 threshold of H4/power (Figure 4.6 ).
By doing so I ensured that I focused my downstream analysis on signals at loci with
colocalising associations predominantly driven by H4 (Guo et al., 2015).
Figure 4.6: Thresholds used for colocalisation between eQTLs and GWAS traits. A. Probability
of the signal being significant in both assays due to two independent causal SNPs
(H3) or the same SNP (H4). B. Power (H3+H4) versus the coloc score (H4/power). I
used a selection of six immune traits with a high number of associated SNPs for
illustration purposes.
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I observed tens of colocalisations between GWAS traits and eQTLs in both naive and
regulatory T cells (Figure 4.7 ). The highest number of colocalisations was achieved for
inflammatory bowel diseases (IBD), ulcerative colitis (UC) and Crohn’s disease (CD), but
also allergies (ALL), schizophrenia (SCZ) and rheumatoid arthritis (RA). I used metabolic
disorders as a control, because I would expect to observe less colocalising signals
between Tregs and metabolic traits compared to immune disorders. Indeed, the median
number of colocalising signals across the ten most enriched immune diseases was
ten, while it was only two for the ten most enriched metabolic traits. The number of
colocalisations correlated with the number of regions tested, and in consequence I
observed more colocalisations in naive T cells. Interestingly I observed a large number
of colocalisations with SCZ, which has a known immune component. I additionally
observed a substantial number of colocalisations with other psychiatric traits, such as
depression (DEP) and intelligence (INT), since psychiatric disorders are characterised
by a large degree of sharing across their loci (Cross-Disorder Group of the Psychiatric
Genomics Consortium, 2013). I observed a similar number of hits in trQTLs and in eQTLs,
despite testing approximately 25% fewer regions for trQTLs. This implicates that in
addition to regulating gene expression, a proportion of immune disease variants will
function through altering transcript ratios.
To examine whether among the colocalising signals there were some that were cell type
specific, I focussed on ten immune diseases. There was a clear separation between
the Treg colocalising signals, the naive colocalising signals and the colocalisations
shared between the two cell types. A proportion of signals that colocalised in Tregs was
accounted for by the Treg specific eQTL or trQTL (Figure 4.8 A). Those genes are thereby
referred to as Treg exclusive colocalisations. The colocalising signals shared across the
two cell types had similar regression slopes (R2 = 0.88 for eQTLs and R2 = 0.78 for trQTLs
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Figure 4.7: Number of colocalising QTL genes and GWAS loci in relation to the number of tested
QTL genes and the disease loci. A. Number of tested eQTL and trQTL genes (FDR ≤
0.05) per trait and number of genes colocalising in naive and regulatory T cells. B.
Number of all GWAS loci with p-value < 10-5 versus the number of colocalising GWAS
loci. AD: Alzheimer’s disease; ALL: allergic disease (asthma, hay fever and eczema);
AST: asthma; CAD: coronary artery disease; CD: Crohn’s disease; CEL: celiac disease;
DEP: Broad depression; IBD: inflammatory bowel disease; INT: intelligence; LDL: low
density lipoprotein; MCH: mean corpuscular hemoglobin; MS: multiple sclerosis; PBC:
primary biliary cirrhosis; PS: psoriasis; RA: rheumatoid arthritis; SCZ: schizophrenia;
SLE: systemic lupus erythematosus; T1D: type-1 diabetes; T2D: type-2 diabetes; UC:
ulcerative colitis.
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Figure 4.8: Shared and specific colocalising signals in naive and regulatory T cells. A. Coloc
values in naive cells and Tregs for eQTLs and trQTLs. Genes have been assigned a
color based on whether they colocalise in one or both cell types. Additionally, genes
that are eQTLs or trQTLs specifically in Tregs are labelled. B. Correlation between the
regression slopes of naive cells and Tregs for the same genes.
4.3.4 Coloc genes have higher probability of being loss of function intolerant
I wanted to further investigate if colocalising genes were truly biologically more relevant
to the studied diseases. If that would be the case I would expect them to be less tolerant
to loss of function mutations. I therefore assessed the identified eQTL and colocalising
genes in the context of protein-coding studies and human knock-out variants (Lek et al.,
2016). In this catalog each gene is assigned a probability of being loss of function intol-
erant (pLI) by counting the number of observed loss of functions alleles in 50 thousand
exomes and extrapolating that to the probability of a gene being intolerant to being
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knocked-out, therefore labelling it as essential. This means that a gene with an assigned
high score is likely to be indispensable to the cell’s core pathways. In their study the
authors reported that eQTL genes are more tolerant to loss of function mutations. When
assessing 10,747 genes that were expressed in Tregs and had calculated pLIs, I observed
that the median pLI was 0.087, which decreased to 0.039 when only considering genes
with eQTL effects in Tregs (Figure 4.9 A). This is concordant with the fact that genes with
eQTLs are more likely to withstand genetic variability. When restricting the analysis
to eQTL genes in immune GWAS loci, I observed a similarly low median pLI of 0.058.
However, for the eQTL genes that colocalised with immune disease signals the median
pLI increased to 0.2, indicating that disease colocalising Treg eQTL signals are enriched














































































































Figure 4.9: Probability of coloc genesbeing loss function intolerant (pLI). A.Distribution of prob-
ability of genes being loss function intolerant (pLI) grouped by whether (i) they are
expressed in the dataset (ii) they fall within GWAS loci, defined by the lead reported
variants and LD R2 ≥ 0.8. (iii) they are eQTLs in the dataset, (iv) they are eQTLs and
they fall in immune GWAS loci, and (v) they colocalise with immune GWAS signals. B.
Distribution of COLOC gene’s pLIs.
Using a combination of colocalisation of eQTL and immune disease GWAS signals and
restricting the list to the genes with pLI scores greater than the median, that is pLI >
0.2, I obtained a list of 33 genes with higher confidence of being truly disease relevant.
Interestingly, I observed that many colocalising genes involved in the signalling of the
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immune response (CD28, TNFRSF14 and MAP3K8) and essential transcription factors
(ELMO1, BACH2 and IKZF4) were characterised by a pLI higher than the median 0.2
(Figure 4.9 B). Furthermore, for loci where a GWAS signal colocalised with a variant
regulating the expression of more than one gene, this analysis allowed me to prioritise
the most relevant gene. For example, ORMDL3 and GSDMB both colocalised with a signal
from RA, T1D, ALL, UC, CD, IBD, asthma (AST) and systemic lupus erythematosus (SLE).
However, the pLI of ORMDL3 (0.7) was much higher than that of GSDMB (0.0), which
would indicate that ORMDL3 is more essential for the cell’s function, and therefore
variation in its expression might have a higher phenotypic impact. Of the 33 genes, 7
are likely to play a role in disease biology through specifically affecting Treg function,
since these were not eQTLs in naive cells (CD28, KDELR2, MAP3K8, IKZF4, STAT5A, ZNF652
and PIM3).
4.3.5 eQTLs are enriched in active chromatin marks
Amongst the mechanisms by which eQTLs and trQTLs might exert their effects are
alterations of transcription factor binding sites, leading to differential binding between
the two alleles, switching on/off alternative promoters and altering the interactions
between enhancers and promoters. These events are reflected in regulatory regions of
the genome mapped by histone modifications and chromatin accessibility. I therefore
tested if regulatory annotations were enriched in the vicinity of the eQTL and trQTL
variants. I measured the density of functional annotations in a one million bp window
around the lead associated variant reported for each eQTL or trQTL gene. I observed
that both eQTLs and trQTLs were enriched in ATAC-seq, H3K27ac, H3K4me1 and H3K4me3
ChM-seq defined peaks (Figure 4.10 ). On the other hand, they were depleted from
H3K27me3 ChM-seq peaks. Furthermore the observed enrichment was higher than in
non-QTL genes. Having confirmed that both eQTLs and trQTLs were enriched in active
regulatory regions, I proceeded to perform a QTL analysis using ATAC-seq, H3K27ac and
H3K4me3 ChM-seq annotation layers.
4.3.6 Coordinated influence of gene expression and regulatory QTLs on
GWAS loci
For the same individuals for whom I mapped eQTL and trQTLs I obtained QTL results
for H3K27ac ChM-seq (91 individuals), H3K4me3 ChM-seq (88 individuals) and ATAC-seq
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Figure 4.10: Density of functional genomic annotations aroundTregeQTLs and trQTLs. The num-
ber of peaks called for the different chromatin assays was counted in 1,000 bp bins
around 1,000 kbp of the positions of the top eQTL and trQTL for the significant
genes.
(73 individuals). There were 9,179 activity QTLs (actQTLs called from H3K27ac ChM-seq),
5,992 promoter QTLs (promQTLs called from H3K4me3 ChM-seq) and 1,253 chromatin
accessibility QTLs (caQTLs called from ATAC-seq) detected. Given that I observed that
immune disease variants colocalised with eQTL variants, and active regulatory regions
were enriched in proximity to eQTL and trQTL genes, I wanted to further investigate
if there were instances where the chromatin regulatory signals (regQTLs) would also
colocalise with disease variants. For that, I ran the colocalisation method, as previously
described, but instead of eQTL and trQTL summary statistics I used regQTLs with GWAS
signals. In immune diseases, I detected between 0 (psoriasis (PS)) and 48 (IBD) signals
colocalising with QTLs mapped for all three chromatin marks (Figure 4.11 A), and H3K27ac
showed the highest number of colocalising signals. In order to further quantify this, I
calculated the relationship between all the lead GWAS variants which colocalised with
the five QTL studies, and defined LD blocks based on R2 ≥ 0.5 (Figure 4.11 B).
I focussed on the GWAS variants that in addition to an eQTL or trQTL also colocalised
with a caQTL, promQTL or actQTL (colocalization between eQTLs and actQTLs shown
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Figure 4.11: Numbers of gene expression QTLs and regQTL colocalising with disease associated
loci. A. On the x-axis are the number of colocalising genes or peaks per assay and on
the y-axis are the different immune traits tested. Below the traits, in parenthesis are
the numbers of independent loci associated to the tested trait. The numbers at the
end of the bars correspond to the total number of features (genes or peaks) tested
for colocalisation. B. Number of colocalising loci determined by calculating the R2
between the lead GWAS variants for the different traits. They have been categorised
based on what type of assay they colocalised with.
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on Table 4.2 ). Loci that overlap with QTLs for different chromatin marks and gene
expression could be particularly informative for functional fine-mapping of disease loci
and could provide a potential explanation for the observed effect on the expression
of the gene. I found 47 lead GWAS SNPs which colocalised with regQTLs, the majority
overlapped with an actQTL (42/47). Amongst these genes there were eight genes that I
previously determined to be Treg exclusive colocalisations; CCL20, CLNK, CTSH, MAP3K8,
PIM3, SP140L, STAT5A and TNFRSF9. Using the GTEx database (GTEx Consortium, 2015),
I noticed that two genes, CTSH and SP140L, were ubiquitous eQTLs (Figure 4.12 ). I did
not further investigate whether these eQTL effects were caused by the same signal as
the one observed in Tregs. The remaining genes were eQTLs in a restricted number of
tissues, which would suggest that these genes are only functional in specific cell types
or tissues. For example, MAP3K8 was only affected in skin from sun exposed areas while
TNFRSF9 was only affected in the stomach (nominal p-value < 10-6).
Figure 4.12: eQTL effects in tissues assayed in GTEx for the immune disease loci with Treg ex-
clusive eQTLs and colocalisations with regQTLs. Included are only the eQTL signals
with p-value ≤ 10-6.
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Table 4.2: Treg eQTL colocalisations with actQTLs and immune disease GWAS. SNP ID: Lead
GWAS variant colocalising rsid; Trait: GWAS immune trait (ALL: allergic disease (asthma,
hay fever and eczema); AST: asthma; CD: Crohn’s disease; CEL: celiac disease; IBD:
inflammatory bowel disease; MS: multiple sclerosis; RA: rheumatoid arthritis; SLE:
systemic lupus erythematosus; T1D: type-1 diabetes; UC: ulcerative colitis); eQTL gene:
symbols of eQTL genes; actQTL peak co-ords: peak co-ordinates for actQTLs.
SNP ID Trait eQTL gene actQTL peak co-ords
rs697693 CD TNFRSF9 1:7921757-7945632
rs9658012 CEL TNFRSF9 1:7921757-7945632
rs10746475 IBD TNFRSF9 1:7921757-7945632
rs7523335 UC TNFRSF9 1:7921757-7945632
rs301802 ALL RERE 1:8361298-8433466
rs10826797 IBD MAP3K8 10:30432917-30439043
rs968567 RA FADS1, FADS2, FADS3, TMEM258 11:61831659-61836649
rs58688157 SLE IRF7 11:599606-617445
rs12148472 T1D CTSH 15:78941912-78945542
rs9934775 IBD BRD7, ADCY7 16:50262778-50371480
rs59716545 RA GSDMB, ORMDL3 17:39912458-39929022
rs12936409 CD, UC, IBD GSDMB, ORMDL3 17:39912458-39929022
rs8067378 AST GSDMB, ORMDL3 17:39912458-39929022
rs12453507 T1D GSDMB, ORMDL3 17:39912458-39929022
17:54863502 IBD DGKE 17:56866409-56871045
rs7207591 ALL STAT5A 17:42219755-42299818
rs4803937 CD PPP5C 19:46345737-46359367
rs11667255 UC PTGIR, GNG8, CALM3 19:46599219-46627182
rs10175070 UC CCL20 2:227804673-227819641
rs7563433 CD SP140 2:230323771-230338021
rs9989735 MS SP140L, SP140 2:230323771-230338021
rs4343432 CD ADCY3 2:24899368-24923784
rs76286777 IBD ADCY3 2:24870549-24891422
rs137845 UC PIM3 22:49975365-49977811
rs2581828 CD RP11-894J14.5 3:53095151-53133630
rs7660626 RA CLNK 4:10654765-10658912
Continued on next page
4.3 Results 127
Table 4.2 – Continued from previous page
SNP ID Trait eQTL gene actQTL peak co-ords
rs6894249 AST SLC22A5 5:132369046-132371617
6:90947340 CD BACH2 6:90264695-90268560
rs57585717 RA JAZF1 7:28168193-28183051
rs4722758 ALL JAZF1 7:28168193-28183051
rs917116 MS JAZF1 7:28120760-28131482
rs11981405 UC WBSCR27, CLDN4, ABHD11 7:73846994-73854377
I further investigated two of the Treg exclusive colocalising signals to gain a better
understanding of how the gene expression and regulation QTL analysis coalesce with
the GWAS signals. The approach of combining the colocalisation of GWAS variants with
different types of QTL analyses allowed me to prioritise genes and suggest functional
variants. An IBD GWAS signal, tagged by the top variant 10:30690376, colocalised with a
MAP3K8 eQTL signal and a 6.13 kbp peak marking the transcription start site of MAP3K8
actQTL signal (Figure 4.13 ). The whole locus was characterised by 5 genetic variants in
high LD (R2 ≥ 0.8) with the top IBD variant and 69 genetic variants in medium LD (R2
≥ 0.5) that were shared between the GWAS summary statistics and the Treg summary
statistics. Because not all of the variants from the Treg QTL studies were present in
the IBD GWAS summary statistics, I used the LD information, precomputed using the
hundred individuals of the Treg cohort, to determine the closest proxy SNPs. The eleven
variants that overlapped the actQTL (p-value < 0.001), formed two blocks whereby the
first block was in strong LD with the reported GWAS top variant (6 SNPs; LD 0.75) and
the second block was in medium LD (5 SNPs; LD 0.5). All the SNPs had p-value < 10-11 in
the IBD GWAS study. I tested whether any of the SNPs overlapped with H3K4me ChM and
ATAC peaks and found that two SNPs overlapped an ATAC peak. Of these only one had
p-value < 10-6 in both the eQTL (nominal p-value 2.25x10-8) and the actQTL (nominal
p-value 1.46x10-7) analysis, 10:30722908. This variant is common (MAF=0.354), and the
minor allele C is the protective allele (regression slope = 0.09). It results in decreased
levels of acetylation (regression slope = -0.19) and consequently decreased levels of
MAP3K8 expression (regression slope = -0.25).
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Another GWAS signal for IBD, UC, CD and CEL colocalised with an eQTL and a trQTL
affecting the expression of TNFRSF9, and a trQTL of PARK7, an adjacent gene encoded
on the opposite strand. Additionally, the signal colocalised with an actQTL marking the
promoter of TNFRSF9 and overlapping an H3K4me3 peak (Figure 4.14 ). There were five
SNPs in the actQTL peak that were significant in the IBD GWAS study (p-value < 5x10-8),
in the actQTL study (p-value < 0.0005) and the eQTL study (p-value < 0.001). One of the
five variants mapped onto the H3K4me3 peak, 1:7997183. This SNP is also in a target
region that interacts with the PARK7 promoter (bait) detected by promoter capture Hi-C
in CD34+ cells and the GM12878 cell line (Mifsud et al., 2015). The minor allele of this
SNP, A, was the risk allele (regression slope = 0.12) and resulted in decreased levels of
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Figure 4.13: Fine-mapping of a colocalisation signal between an IBD GWAS variant, a MAP3K8
eQTL and a MAP3K8 promoter actQTL. The three colocalising signals are plotted
using the same coordinates on the x-axis and the significance for the different
variants on the y-axis. Each variant is represented by a dot, colored based on the LD
relationship with the top GWAS variant 10:30690376. The lower panel is a focus on
the actQTL peak and eQTL gene, there are 11 prioritised SNPs. Of these one variant,
10:30722908 also overlapped with an ATAC peak and was therefore used to plot
the expression of the gene and the red pile-ups in the peak. The actQTL peak is
highlighted in red, while the remaining called peaks are in grey.
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Figure 4.14: Fine-mapping of a colocalisation signal between the IBD GWAS variants, a TNFRSF9
eQTL, a TNFRSF9 and PARK7 trQTLs and a TNFRSF9 enhancer actQTL. The three colo-
calising signals are plotted using the same coordinates on the x-axis and the signifi-
cance for the different variants on the y-axis. Each variant is represented by a dot,
colored based on the LD relationship with the top GWAS variant 1:8168261. The lower
panel is a zoom in on the actQTL peak and the eQTL gene, which prioritised five
SNPs. The actQTL peak is highlighted in red, while the remaining called peaks are in
grey. The promoter Hi-C interactions between the PARK7 promoter and regions of
TNFRSF9 are highlighted. The panel below shows the effect of the trQTLs on TNFRSF9
and PARK7. Of the five variants I prioritised a single variant, 1:7997183. I used the
alleles of this variant to plot the expression of TNFRSF9 and the read pile-ups of the
actQTL peak.
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4.3.7 regQTLs without gene expression QTLs are indicative of condition
specific effects
Importantly, in addition to the loci where I was able to link disease associated variants
to regQTLs and ultimately gene expression effects, I observed that the highest number
of colocalising signals was between the disease variants and actQTLs, without an af-
fected gene. I found that of the 191 LD blocks associated with immune diseases that
colocalised with any of the 5 Treg QTLs, 62 were supported by a gene expression effect,
while 96 were supported by a QTL in a regulatory mark, and only 33 were supported
by both chromatin mark and gene expression (Figure 4.11 B). Since H3K27ac mark is
known to be highly cell type specific, this could be indicative that while I assayed the
disease relevant cell type, the gene expression could only be manifested in a specific
cell state, e.g. upon cell stimulation. In order to assess whether this was the case,
I investigated how many of the actQTL peaks had a differentially regulated gene, as
identified in Chapter 3, within a 150 kbp window. Of the 78 actQTL loci, 34 contained at
least one upregulated gene and 32 contained at least one downregulated gene, with 15
of the loci containing both (Figure 4.15 A). Amongst the upregulated genes in actQTL loci
colocalising with immune GWAS, I found many immune relevant genes such as CTLA4,
PRDM1, LIF and LRRC32.
The actQTL enhancer in the proximity of LRRC32 has been shown to interact with the
promoter of LRRC32 in the GM12878 cell line and in primary endothelial precursor cells,
B cells, macrophages and monocytes (Javierre et al., 2016). This locus colocalises with
a GWAS signal from IBD, UC, CD, ALL and AST. In total, 28 SNPs overlapped with the
actQTL peak, located 57 kbp downstream of LRRC32, of which 10 were significant actQTLs
(p-value < 0.0003) (Figure 4.15 B). The lead IBD GWAS variant was located within the
peak, and it was an insertion, where the major allele G became GT and correlated with
an increase in IBD risk (regression slope = 0.149). Presence of the GT haplotype led
to decreased levels of acetylation (regression slope = -0.094) which would probably
correspond to decreased levels of LRRC32 upon stimulation.
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Figure 4.15: Regulatory QTLs without gene expression QTLs are indicative of context specificity.
A. Number of up and downregulated regulated genes per actQTL locus defined
by taking at 150kbp window around the start and end co-ordinates of the peak.
Highlighted are a few gene examples along with their pLIs. B. Fine-mapping of a
colocalisation signal between IBD GWAS variants and a LRRC32 enhancer actQTL. The
two colocalising signals are plotted using the same coordinates on the x-axis and the
significance for the different variants on the y-axis. Each variant is represented by a
dot, coloured based on the LD relationship with the top GWAS variant 11:76298625.
The lower panel is the actQTL peak highlighted in red, while the remaining called
peaks are in grey. The promoter Hi-C interactions between the LRRC32 promoter and
nearby enhancers are highlighted. I used the alleles of 11:76298625 to plot the read
pile-ups of the actQTL peak.
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4.4 Discussion
In this chapter I integrated eQTLs and trQTLs mapped in CD4+ naive and regulatory T
cells to reveal multiple effects on the regulation of expression of genes associated with
immune diseases. Despite the close nature of the two cell types, I observed hundreds
of cell type specific effects, many of which play an important role in T cell activation
pathways. Given the different roles of naive and regulatory T cells in regulating the
immune response, whereby the naive cells exert an effector function upon stimulation
by proliferating and secreting pro-inflammatory cytokines while the second returns
the system to homeostasis, these differences could be essential to better understand
CD4+ T cell biology. For example, I was able to recapitulate a CTLA4 eQTL effect that
was previously reported in whole CD4+ and CD8+ cells (Kasela et al., 2017) specifically
in naive T cells. On the other hand, the expression of the CD28 gene, which is 130 kbp
upstream of CTLA4, was an eQTL specifically in Tregs. CTLA4 is a hallmark Treg gene, and
is known for its inhibitory role in T cell mediated immune responses by outcompeting
CD28 for ligand binding (Read et al., 2000; Zheng et al., 2006). CD28 is the main co-
stimulatory receptor found on the surface of all T cells, and its engagement is essential
for a successful T cell activation event. Both of these genes sit within the 2q33.2 locus
which has been associated to CEL and RA (Trynka et al., 2011; Okada et al., 2014), but
the lead variants affecting their expression are not in LD (Raychaudhuri et al., 2009).
Interestingly, only the CD28 eQTL colocalised with a disease variant associated with CEL,
where the minor allele T (MAF=0.23) was the risk allele and resulted in decreased levels
of CD28 expression. In fact, while the majority of the observed colocalisations were
shared between the two cell types, there were many that were cell type exclusive. This
highlights the value of carrying out genomic analysis in isolated rare cell populations.
By performing expression QTL analysis in conjunction with transcript ratio QTL, I was
able to determine instances of colocalisation with immune traits in which the observed
variability in gene expression could be attributed to an affected transcript. However,
these only represented a minority (13/191) of eQTL genes colocalising with GWAS. In my
effort to understand how the remaining eQTL effects might arise, I observed that eQTL
signals were enriched in active chromatin regions (Gaffney et al., 2012; Pelikan et al.,
2018), thereby providing a potential gene expression regulation mechanism for their
action. I found that for 33/191 of cases the effect could be attributed to the disruption
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of a promoter, enhancer or accessible chromatin, as marked by H3K27ac, H3K4me3 and
ATAC-seq. This number is in the same range as previously reported for naive CD4+ T cells
(26%), neutrophils (18%) and monocytes (27%), using H3K27ac, H3K4me1 and DNA methy-
lation (Chen et al., 2016). I observed that in 96/191 of cases there was an epigenetic QTL
without an immediate effect on the expression of nearby gene. This might be indicative
of either long-range interactions which are missed by the current cis-QTL window or
that the effect would be manifested in a specific condition. Similar observations have
been previously noted for other cells, such as monocytes and induced pluripotent stem
cell derived macrophages (Fairfax et al., 2014; Alasoo et al., 2018). Therefore, while the
promoters and enhancers are primed for expression, they require an additional stimulus
to have an effect on the expression of the gene. In fact, it has been reported that 53% of
eQTLs are stimulation specific in monocytes, which is in the same range of the regQTLs
reported here without a gene (Fairfax et al., 2014). For example, while no CTLA4 eQTL
colocalisation was observed in naive cells, an actQTL peak colocalised with a lead GWAS
variant, 2:204738919, that has been associated with T1D and has been suggested to affect
the gene expression levels of CTLA4 via the disruption of an enhancer (Chen et al., 2016;
Westra et al., 2018). Amongst the regQTLs that colocalised with immune disease variants,
I also identified an actQTL nearby LRRC32 which colocalised with variants associated
with IBD, allergy and asthma (Lange et al., 2017; Ferreira et al., 2017a; Demenais et al.,
2018). LRRC32 encodes for GARP protein, which binds the latent form of TGF-β and its
blockade results in loss of Treg suppressive capacity (Konopacki et al., 2015). LRRC32
gene expression and protein levels are upregulated upon stimulation (Marson et al.,
2007), therefore, it is likely that the disease variants in the enhancer could affect the
gene expression of LRRC32 upon stimulation.
Finally, as an example of successful functional fine-mapping I presented two loci,
TNFRSF9/PARK7 and MAP3K8, where I observed colocalisation of disease associated
variants with gene expression QTLs that were further supported by chromatin regulatory
QTLs. TNFRSF9 gene expression and protein levels (4-1BB or CD137) increase specifically
in activated Tregs and not conventional T cells (Marson et al., 2007; Nagar et al., 2010).
The expression of CD137 has been reported to correlate with a Treg phenotype by display-
ing increased suppressor function on effector T cell proliferation (Schoenbrunn et al.,
2012), increased FoxP3 expression and epigenetic Treg identity through the demethy-
lation of FOXP3 and CTLA4 amongst other Treg genes (Nowak et al., 2018). Therefore, a
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QTL that would lead to decreased TNFRSF9 expression might lead to a decrease in Treg
suppressor capacity. PARK7 also has a documented role in Treg development, where
one study demonstrated that PARK7 knockout mice had dysfunctional induced Tregs,
with regards to their proliferative ability, while natural Tregs remained normal (Singh
et al., 2015).
While the correlation between the expression of TNFRSF9 and Treg phenotype are well
established (Schoenbrunn et al., 2012), the effect of MAP3K8 expression in Treg remains
a matter of controversy. MAP3K8 encodes for a serine/threonine kinase, referred to
as Tpl-2 or COT, which plays an important function in the processing and signal trans-
duction of the inflammatory cytokine TNF-α (Dumitru et al., 2000). Both a positive and
a negative regulation of FoxP3 have been suggested for Tpl-2. One study that used a
mouse strain prone to develop intestinal adenoma found that Tpl-2 ablation resulted
in increased inflammation-induced intestinal tumorigenesis, which correlated with
decreased levels of IL-10 and Treg generation (Serebrennikova et al., 2012). On the other
hand, a screen using a luciferase-based reporter system to identify which of 192 kinases
could modulate the DNA binding activity of FoxP3 highlighted Tpl-2 as an inducer of
Treg instability (Guo et al., 2014).
This chapter provides the first QTL study of Tregs, a rare cell type with an increasingly
important role in therapeutic settings. Some of the genes identified and discussed here
are already investigated as potential new drug targets. This study could therefore serve
a valuable resource for suggesting additional targets for future studies in the context
of immune-mediated diseases.




Parts of the discussion in this chapter have been published as “Immunogenomic ap-
proaches to understand the function of immune disease variants” (Glinos et al., 2017).
Many sections of the manuscript have been directly copied into this chapter.
The overarching theme of my research over the past three years has been understanding
the gene expression regulation of CD4+ cells. Starting from a fundamental immuno-
logical question, the differential requirement of co-stimulation in naive and memory
T cells, I set out to identify groups of genes that displayed increased sensitivity to a
specific stimulus. I then applied what I had learned in Tregs, but this time I focussed on
the mechanisms of gene expression regulation by assessing the effects of stimulation
across different gene regulatory layers, as well as their interplay. Finally, I reached
a population-scale problem, and set out to study the impact of genetic variation on
molecular traits in Tregs. I focussed on the overlap of the molecular genetic effects to
gain an understanding of the disturbed immunological pathways and their impact on
the development of immune-mediated diseases.
5.1 Mapping QTL effects in rare immune cell types
Over the past few years there have been a number of studies investigating the corre-
lation of quantitative immunogenomic phenotypes with disease associated loci (Nica
et al., 2010; Westra et al., 2013). These approaches have allowed to prioritise causal
variants (Hormozdiari et al., 2016), explained a proportion of the missing heritability
(Gamazon et al., 2018) and suggested disrupted gene pathways and cellular functions.
Although the majority of individual allelic effects have a minuscule effect on the overall
phenotype, such as a specific disease or height, the effects can be higher on the molec-
ular or cellular levels. Hence, some of the current efforts are focused on identifying
the critical disease cell types in which the associated variants are functional.[0.5cm]
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A challenge in GWAS functional follow up studies is that often the causal cell types
are unknown. Typically, for immune-mediated diseases, cell types can be identified
through immunology studies, where a limited set of specific cell markers, both intra- and
extracellular, used to characterise different cell populations between disease cases and
healthy control subjects. An alternative method that is independent from a predefined
set of markers, is single cell RNA sequencing (scRNA-seq). This approach can identify
previously unknown heterogeneity in a sample based on gene expression measured
at the individual cell level. There are now major international efforts that aim to use
scRNA-seq to characterise all human cells, the Human Cell Atlas (Regev and Others,
2016). This resource will provide the most comprehensive annotation of gene expression
in the human body which, when integrated with GWAS variants, has the potential to
improve our understanding of immune-mediated diseases by carrying single cell QTL
studies (Wills et al., 2013; Wijst et al., 2018). Since scRNA-seq outputs gene expression
measurements per cell, this approach will allow to group different cells together and
carry eQTL analsyses, thereby improve on understanding cell type specific effects.
In Chapter 4 I carried out a QTL study using a rare cell type, regulatory T cells, which only
represent 1-2% of total lymphocytes and need to be isolated using reliable cell markers
and cell sorting. Tregs, as well as other isolated cell populations, are difficult to culture
in vitro, rendering the identification of condition specific effects problematic. In addi-
tion, in order to reach sufficient statistical power to detect eQTL effects, it is important
to obtain blood from a high enough number of individuals. This is not only a laborious
task, but also increases the number of variables included in the repetition of blood
drawing and processing. Novel systems that allow cell culture and stimulation of cells
by limiting the batch effect as well as the establishment of standardised differentiation
protocols are necessary for future studies investigating rare cell types. Such approaches
are currently being developed by international consortia, such as the Milieu Interieur,
who by standardizing the blood culture of healthy volunteers and using flow cytometry
analysis have successfully deconvoluted complex immune response signatures and
provided valuable insights into the natural variation of immune cells (Urrutia et al.,
2016; Patin et al., 2018). Furthermore, as I showed in Chapter 3, the development of
reliable genomic protocols that work with low cell numbers is essential when scaling-up
to large cohorts (Buenrostro et al., 2013; Schmidl et al., 2015).
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The establishment of these standards might facilitate the expansion of QTL studies
in patient consortia. These efforts have so far been limited due to the difficulty in
discerning the etiology of a disease from the consequences. Furthermore, it is often not
possible to find patients in the early stages of the disease that have not been subjected
to a drug treatment, an effect that is not well understood. Clinical trials are promising
cohorts to study the effects of a drug on gene expression, and the interaction between
genotypes and drug effect. There are already a few studies that veer towards this direc-
tion. One study investigated the effect of an anti-IL-6 drug in SLE patients (Davenport
et al., 2018) and another study looked at the genomic determinants of variation in sepsis
patients (Davenport et al., 2016).
5.2 Predicting gene expression in CD4+ T cells
Gene expression regulation is complex and arises from the tight interplay of histone
modifications, transcription factor binding and post-transcriptional processes such as
small RNAs inhibiting translation. In Chapter 3 I assessed changes in gene expression,
transcript ratios, splicing junctions, H3K4me3, H3K27ac and ATAC measurements induced
by stimulation in Treg cells. I observed that many of the individual transcript ratios
affected by the presence of a stimulus, as well as the differentially spliced introns, were
not observed when only examining whole gene counts. This is concordant with past
research which showed that 60% of genes express different alternative spliced isoforms
in T cells (Ergun et al., 2013). While I did not examine alternative transcription events
initiated by CD28 in Chapter 2, this could be an interesting analysis to carry. Past re-
search has shown that changes in alternative transcription events are mostly mediated
through co-stimulation (Butte et al., 2012), with CD28 signalling directly affecting the
levels of the splicing regulator hnRNPLL. The role of histone marks in the regulation of
alternative transcription is not well understood, but it has been shown that alternative
promoter usage is marked by a change in the levels of H3K4me3 (Luco et al., 2010), but
it is important to find a way of reliably validating these findings using spatiotemproal
approaches approaches such as RNA fluorescent in-situ hybridization or data driven
approaches such as shotgun proteomics (Hu et al., 2015b).
It is also especially interesting to study transcript ratios, in addition to gene expression
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measurements, in the context of diseases. In Chapter 4 I observed that eQTLs and
trQTLs were largely independent of each other, a finding that has also been shown
in past studies (Lappalainen et al., 2013; Alasoo et al., 2018). The colocalisation anal-
ysis indicated that trQTLs and eQTLs had a similar enrichment in GWAS loci, despite
testing less genes in trQTLs, which has also been previously shown (Li et al., 2016c).
When examining patient studies, significant differences in alternative isoforms were
detected in multiple sclerosis patients that harboured a SNP in exon 4 of the PTPRC gene
that encodes for CD45 (Jacobsen et al., 2000) and a switch of the primary alternative
transcript used in human islets in response to cytokines (Eizirik et al., 2012). Together
these findings highlight the importance of studying alternative transcription events in
complex diseases.
The relationship between gene expression and chromatin marks is well documented
(Roadmap Epigenomics Consortium et al., 2015). I was able to annotate many genes to
differentially active enhancers or promoters in naive, memory and regulatory T cells. I
only annotated differentially active elements, however the degree to which different
histone marks change upon stimulation is not as well studied as gene expression. This
is because histone marks currently lack a reference against which peaks can be called
and the combinatorial presence of different modifications within the same locus is
not well understood. The establishment of computational protocols would help in the
standardisation of these analyses and in the integration of different datasets. The
concordance between histone marks and gene expression was reinforced in Chapter 4,
where I observed that a third of GWAS colocalising eQTLs could be explained by changes
in regQTLs. However, the opposite was not true, and many regQTLs were not assigned
an affected gene. By using the differential gene expression analysis from Chapter 3, I
was able to deduce a subset of genes that might only be eQTLs upon stimulation. Given
the high costs of sequencing, the labour invested in isolating cell types and the wide
range of possible stimuli, this provides a potential framework for the identification of a
few optimal conditions to carry condition specific eQTL analyses.
QTL effects have in fact mostly been annotated in the context of expression assays,
however, a proportion of GWAS variants may not act through gene regulation measured
by bulk gene expression assays, calling for the assessment of QTL effects using differ-
ent assays for gene expression regulation. In Chapter 4 I carried out gene expression
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profiling in parallel with multiple assays to understand gene expression regulation. A
promising technology is chromatin interaction analysis performed using Hi-C (Belton
et al., 2012) and coupled with chromatin immunoprecipitation (Mumbach et al., 2017).
This approach has recently been applied on CD4+ T cells, and the authors observed that
the majority of H3K27ac peaks do not necessarily interact with the closest gene. This
was the case of the LRRC32 gene that I observed to be regulated by an enhancer located
downstream. Furthermore, this method provides a direct mechanism for a genetic
variant to act, which might not be obvious when assaying H3K27ac alone. Therefore,
results from chromatin conformation assays can be used to help functionally fine map
disease associated variants.
5.3 Regulation of co-stimulatory pathways in immune diseases
A recurrent theme across this thesis has been the role of co-stimulation in the initi-
ation of the immune response, and how its perturbation can contribute towards the
predisposition to immune diseases. The main co-stimulator is CD28, which assists T
cell receptors in the conduction of a successful activation event. CD28 is encoded on
the same locus as its main competitor, CTLA-4, which has higher affinity for the same
ligands. While CD28 is constitutively expressed on the surface of T cells, CTLA-4 is only
expressed upon stimulation, outstripping the activating ligands from the surface of
other cells, and allowing the T cell to regain equilibrium. Interestingly, in Chapter 4 I
observed that both of these genes are under genetic control. CD28 was an eQTL in Tregs
and CTLA4 was an eQTLS in naive T cells. This is especially intriguing in the context
of my findings in Chapter 2, that memory T cells are more sensitive to the levels of
CD28 cross-linking, and the fact that Tregs have many characteristics of memory T cells.
This could provide an explanation as to why the CD28 eQTL is specific to Tregs; since
these are these cells are sensitive to its level. Naive T cells on the other hand mostly
depend on TCR signalling. As a future experiment, it would be important to carry out
proliferation assays in cells isolated from homozygous carriers for each allele affecting
the levels of CD28 and CTLA4 in order to confirm this hypothesis.
The experimental setting devised in Chapter 2 could be used to assess the impact of
genetic variability in co-stimulation sensitivity. This would be especially important
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for the design of future therapies that rely on targeting co-stimulatory pathways. The
central role of co-stimulation in T cell function has indeed rendered it an attractive
target for drug development. Strategies using CD28 and CTLA-4 blockade in animal
models have achieved success, paving the way to a number of clinical trials and safe
drugs (Ford et al., 2014; Lo et al., 2015). The most notable example is abatacept, a soluble
CTLA4-binding domain linked to an Ig region that binds the ligands CD80 and CD86, used
for the treatment of rheumatoid arthritis (RA) (Genovese et al., 2005). There are currently
more than 60 active clinical trials using CTLA4Ig drugs for treating a range of immune
diseases (clinicaltrials.gov). However, targeting CTLA-4 has mainly been successful in
immune diseases characterised by an increased Th1 response, probably due to the
fact that these cells display increased sensitivity to CD28 blockade (Ford et al., 2014).
This highlights the need to increase our understanding of alternative co-stimulatory
pathways in a cell type specific context.
It is not only the balance between CD28 and CTLA-4 signalling that determines the
activation status of a cell, there are many other co-stimulatory molecules that con-
tribute towards tipping the balance towards a specific response. While I performed the
titration experiments by initiating the CD28 pathways, it would be interesting to apply
the same framework using a range of stimulants in order to deconvolute the effect
of each co-stimulus from the one of TCR presence. However, if performed across all
stimulants and titrations, it would be difficult to reach a sufficiently high number of cells
per individual and to carry out the assays in parallel. In order to address the first issue,
a better measurement might be scRNA-seq, which would also indicate commitment
to specific cell fates. In order to address the second problem, a scheme to prioritise
co-stimulants might be necessary. In Chapter 4 I observed that the gene expression
of more than twenty co-stimulatory molecules and receptors were eQTLs in naive and
regulatory T cells. Among them was CD40, which is the target for a number of current
drugs being developed to attenuate a self-reactive immune response (Ford et al., 2014).
Other genes in this list would therefore also present interesting targets for clinical trials
with patients that are stratified by genotype. Among the co-stimulatory molecules that
were eQTLs in Tregs there were both TNFRSF9 (encodes for 4-1BB) and its ligand TNFSF9
(encodes for 4-1BBL). 4-1BB signalling has been shown to be CD28-independent in con-
ventional T cells cells and is able to induce cell division and proliferation (DeBenedette
et al., 1997; Cannons et al., 2001). 4-1BBL can expand Tregs ex vivo (Elpek et al., 2007) but
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also induce resistance to Treg-mediated suppression in conventional T cells (Robertson
et al., 2008). There is therefore evidence to support that 4-1BB blockade might be an
interesting target for future clinical studies.
5.4 Bridging immunology with genomics - time for proteomics?
However, it remains unclear to what degree the observed correlations between genotype
and a quantitative genomic phenotype result in alterations of protein levels. I demon-
strated in Chapter 2 a poor replicability of CD28 sensitive genes defined by RNA-seq at
the protein level. Furthermore, recent evidence suggests that less than 10% of all mRNA
variants could be validated at the protein level, using 29 healthy tissues (Wang et al.,
2019). This research was conducted as part of the Human Protein Atlas Project, which
aims to map all of the human proteins in cells, tissues and organs using a combination
of imaging, mass spectrometry-based proteomics and transcriptomic approaches. If
performed across hundreds of individuals this will prove an important resource to
carry out protein QTL (pQTL) studies. There are already a number of studies looking at
cytokine levels in combination with gene expression (Li et al., 2016b; Ahola-Olli et al.,
2017; Bakker et al., 2018) and two pQTL studies, one in human LCLs (Battle et al., 2015)
and one in mice (Chick et al., 2016). Bakker and colleagues reaffirmed the importance
of context specificity when assessing protein levels, even more so than when looking at
RNA. To obviate the need for an exhaustive stimulus assessment for a cytokine QTL study,
one can use differential gene expression analysis to prioritise a few conditions that are
more likely to result in drastic changes upon stimulation. These approaches will help to
understand how immune variants translate to dysfunctional protein products and shed
light on the unexplored post-translational mechanisms involved in immune-mediated
diseases, which have been suggested to be more important than the RNA levels (Battle
et al., 2015). This can be achieved by assessing the phosphoproteome of immune cells,
since phosphorylation is especially important in signalling cascades of CD4+ T cells.
Even when a correlation between the relative allele frequency and the level of a protein
is established, it is important to place the affected protein levels within a network. The
immune system is a highly dynamic network, with complex interactions taking place
between the different cell types and states. It has been demonstrated using protein
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protein interaction (PPI) assays that proteins encoded by genes in regions associated to
RA and Crohn’s disease form a network more closely connected compared to a random
set of proteins (Rossin et al., 2011). As such, it is becoming increasingly appreciated that
disease pathology associated with immune diseases is induced by the disruption of the
whole network. Therefore, an interesting future study would be to define PPI networks
based on the list of colocalising genes identified in Chapter 4 using purified Tregs for
which a reliable bait can be designed.
Mass cytometry has indicated that there is more heterogeneity than previously thought
in PBMCs and in different regions of the gut (Unen et al., 2016), which would imply
novel undocumented interactions between the different cellular subsets. For example,
Rieckmann and colleagues performed an extensive characterization of the proteome
and secretome of 28 human immune cell types (Rieckmann et al., 2017) and discovered
new signalling events between cells, such as a signalling event induced by IL-34 in CD4+
T cells. Therefore, even if a specific cell type is more relevant for the study of genetic
variation, this does not mean that other cell types within the affected tissue would not
display differences when compared to healthy tissues. This is why the proportion of
different immune subpopulations vary depending on the type of inflammatory diseases
(Unen et al., 2016), and while this can be a disease phenotype, it can also be a direct
result of a genetic variant. Elucidating mechanistic details of network disruption in
autoimmune diseases will contribute towards understanding how hundreds of genetic
variants affect different cellular processes and lead to a disease.
5.5 Concluding remarks
GWAS have discovered hundreds of associations with complex immune diseases, yet
deciphering the causal variants and molecular mechanisms which give rise to disease
has proven to be challenging. Through the accumulation of genetic, functional and
immunological data, a picture of how CD4+ T cell regulation is disrupted in immune
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